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Abstract 
 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of 
Kaposi’s sarcoma (KS). Like all herpesviruses, KSHV has a bi-phasic life cycle, 
with a dormant latent phase and a productive lytic phase. The switch from viral 
latency to lytic replication is mediated by the replication and transcription activator 
protein (RTA). RTA activates KSHV lytic gene expression via direct and indirect 
binding to lytic promoters. Moreover, it functions as an E3 ubiquitin ligase, actively 
degrading repressor proteins, such as Hey1, maintaining the virus in the latent 
state. 
The first aim of this study was to determine if RTA functions as a SUMOylation 
targeted ubiquitin ligase (STUbL), which recognises poly-SUMOylated targets via 
SUMO interacting motifs (SIMs). Results presented herein demonstrate that the 
Hey1 repressor protein is SUMO2 modified. Furthermore, mutation of SIM domains 
within RTA resulted in attenuation of RTA-mediated degradation of Hey1 and lytic 
reactivation. However, SIM mutation also severely reduced RTA-mediated 
transactivation. These results suggest that RTA may have STUbL activity but 
additional work is required to reconcile the effect of SIM mutation upon 
transcriptional activity.  
The second aim of this investigation was to identify novel points of interaction 
between RTA and the host cell. In chapter 4, SILAC-based quantitative proteomics 
identified hundreds of proteins which demonstrated a significant change in 
abundance upon RTA expression. Abundance of the cellular protein ARID3B was 
found to increase over 7-fold in the nuclear fraction. Furthermore, ARID3B was 
shown to re-localise to viral replication centres upon lytic reactivation. In chapter 5 
SILAC-based immunoprecipitations were performed to identify novel RTA 
interaction partners. The cellular co-activator RBM14 was found to be enriched in 
two independent SILAC data sets and subsequent investigation demonstrated that 
RBM14 localisation was altered upon RTA expression. These novel observations 
highlight the potential significance of cellular factors in KSHV infection. Further 
investigation is required to fully characterise the role of these proteins in viral 
reactivation.  
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Histidine Hs H 
Phenylalanine Phe F 
Tryptophan Trp W 
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1 Introduction 
 
1.1 Herpesviridae 
The Herpesviridae are a family of large enveloped viruses with double-
stranded DNA genomes ranging between 124–230kb (Gray et al., 2001; 
Davison et al., 2003). Herpesvirus particles consist of a genome-containing 
core, encased in an icosahedral capsid, approximately 125nm in diameter. 
This capsid is surrounded by an amorphous tegument layer, contained within 
a lipid envelope, which is studded with viral glycoproteins. Herpesvirus 
infections are found across a wide range of species, with over 130 
herpesviruses having been identified to date. Of the currently recognised 
herpesviruses, eight infect humans as their primary host; herpes simplex 
virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human cytomegalovirus 
(HCMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), human 
herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7) and Kaposi’s sarcoma 
associated herpesvirus (KSHV). These human herpesviruses are spread 
over the three defined Herpesviridae subfamilies, displaying varying host cell  
tropism and disease presentation (Knipe, 2001). 
 
1.1.1 Classification 
The family Herpesviridae is contained within the order Herpesvirales in 
addition to the Alloherpesviridae and Malacoherpesviridae families (Davison 
et al., 2009). The Herpesviridae comprises of all herpesvirus species 
infecting mammals, birds and reptiles whereas the Alloherpesviridae 
contains those which infect fish and amphibians and the 
Malacoherpesviridae consists of just two bivalve infecting species (Savin et 
al., 2010; Davison et al., 2005). The Herpesviridae is further divided into 
three subfamilies, the Alpha-, Beta- and Gamma- herpesvirinae, each 
containing multiple genera. These classifications, which were originally 
defined on the basis of biological features, have been strengthened with the 
advent of genome sequencing. 
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The Alphaherpesvirinae comprises of five genera including Varicellovirus 
(containing VSV) and Simplexvirus (containing HSV). Viruses within these 
genera have a variable host range, a short reproductive cycle and spread 
rapidly in cell culture. Infected cells are effectively destroyed by lytic 
replication and latent infections are primarily established in the sensory 
ganglia. In contrast, Betaherpesvirinae have a restricted host range, a 
lengthy reproductive cycle and are slow to proliferate in culture. Host cells 
become swollen upon productive infection and latent infections can be 
established in the kidneys, lymphoreticullar cells, secretory glands and other 
tissues. There are four genera within the Betaherpesvirinae, with the 
Cytomegalovirus (containing HCMV) and Roseolovirus (containing HHV-6 
and HHV-7) genera encompassing human herpesviruses. The 
Gammaherpesvirinae comprises of four genera including Lymphocryptovirus 
(containing EBV) and Rhadinovirus (containing KSHV). Latent 
gammaherpesviruses are often found in lymphoid tissue with viruses 
generally demonstrating specificity for either T or B lymphocytes. Figure 1.1 
shows the phylogenetic relationship between 40 herpesvirus species, 
including the eight human herpesviruses, across the three subfamilies  
(King, 2011; Roizman et al., 1981).  
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Figure 1.1 Phylogenetic tree for the Herpesviridae. 
A phylogenetic tree was constructed using the amino acid sequences from six 
genes of 40 herpesvirus species. Human herpesviruses are highlighted with a red 
star (Grose, 2012). 
 
1.1.2 Virion architecture 
All currently known herpesviruses share the same structural design, with 
each mature virion comprising a core, capsid, tegument and surrounding 
envelope (figure 1.2). The core contains the viral genomic DNA in the form of 
a torus (Furlong et al., 1972) and is encased within an icosahedral capsid. 
The capsid has a triangulation number T=16 and consists of 150 hexameric 
and 12 pentameric capsomeres (Wildy et al., 1960). The tegument occupies 
the space between the capsid and the envelope, containing approximately 
40% of the herpesvirus virion protein mass (Gibson, 1996). The tegument is 
largely unstructured however the innermost part of the tegument may also 
exhibit icosahedral symmetry (Zhou et al., 1999) due to the interaction of a 
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large tegument protein with the pentons of the capsid. Finally the envelope is 
a lipid bilayer derived from a host cell membrane,  containing at least a 
dozen different viral glycoproteins involved in viral entry (Mettenleiter et al., 
2009). 
 
Tegument
Glycoproteins
Envelope
Core
Capsid
 
Figure 1.2 The Herpesvirus virion. 
A schematic representation of the compartments of a mature herpesvirus virion.  
 
The overall protein composition of herpesvirus particles has also been 
studied by mass spectrometry analysis of purified virions. These 
investigations have been carried out for HCMV, EBV, KSHV, HSV-1, rhesus 
monkey rhadinovirus (RRV), and murine gammaherpesvirus 68 (MHV-68) 
(Maxwell and Frappier, 2007; Loret et al., 2008), identifying both viral and 
host protein constituents. For example, HCMV proteomic data identified 71 
viral proteins and 70 host proteins including cytoskeletal components and 
translational control factors (Varnum et al., 2004).  Some of the most 
commonly found cellular proteins in herpesvirus virions included β-tubulin, 
annexin, actin, ezrin/moesin, hsp70 and  hsp90 (Maxwell and Frappier, 
2007). However, it is yet to be determined if there is any functional role for 
these proteins in viral infection. Furthermore, virions have been shown to 
contain non-coding and coding RNA molecules from both the virus and host 
(Bresnahan and Shenk, 2000). These transcripts have been suggested to be 
packaged in either a non-selective manner, proportional to their abundance 
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in the cell (Terhune et al., 2004) but also in a selective manner, potentially 
through association with viral RNA binding proteins (Cliffe et al., 2009; 
Bresnahan and Shenk, 2000). 
 
1.1.3 Genome structure 
Herpesvirus genomes encode between 70 and 200 genes, approximating to 
around one gene every 1.5-2kb of DNA (McGeoch et al., 2006). Typically 
each gene has its own promoter region upstream of a TATA box, with a 
downstream transcription initiation site and open reading frame (ORF). The 
resulting transcripts are rarely spliced but have polyadenylation sites which 
are often shared by consecutive genes, producing overlapping 3’ co-terminal 
transcripts (McGeoch et al., 1985). Herpesvirus genomes show significant 
variation in nucleotide composition, ranging from 32 to 75% G+C content in 
different species. Notably the genomes of most Gammaherpesvirinae are 
deficient in CpG dinucleotides, which is thought to be a consequence of 
maintaining  latency in a dividing host cell population. Suppression of CpG 
dinucleotides  minimises mutation  of the viral genome occurring  through 
spontaneous deamination of 5-methylcytosine (Honess et al., 1989). 
Herpesvirus genomes also contain non-coding regions from which non-
coding RNAs, including microRNAs and latency-associated transcripts, are 
produced (Knipe, 2001). 
 
In addition to the unique sequences found within herpesvirus genomes, they 
characteristically contain regions of direct or inverted repeats. These repeat 
regions can be used to classify herpesvirus genome structures into six major 
groups as shown in figure 1.3 (Knipe, 2001). The class A genomes consist of 
a unique region flanked by a direct repeat sequences, this is similar to the  
class B genomes, however here the repeat regions consist of tandemly 
repeated 0.8–2.3 kbp sequences of variable copy number. The class B 
structure characterizes most Gammaherpesvirinae in the Rhadinovirus 
genus, including KSHV (Russo et al., 1996), whereas class A structures, are 
found across the Herpesvirales . The class C structure is typified by the EBV 
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genome which, like class B genomes, has tandemly repeated flanking 
regions but also an unrelated set of internal repeats (Given and Kieff, 1979). 
 
 
Figure 1.3 The six classes of herpesvirus genome structures. 
A schematic representation of the six herpesvirus genome structures A-F. The solid 
lines represent unique sequences, boxes indicate repeat regions and arrows 
indicate repeat orientation (a; repeat sequence; U; unique region, TR; terminal 
repeat, IR; internal repeat with S and L subscript indicating short or long) (Davison, 
2007). 
 
Class D genomes are characteristic of Alphaherpesvirinae in the 
Varicellovirus genus (Rixon and Benporat, 1979; Dumas et al., 1981). These 
structures contain two unique regions (UL and US), each flanked by inverted 
repeats (TRL/IRL and TRS/IRS). Class E structures are similar to class D but 
are more complex in that the TRL/IRL is much larger and genomes have a 
terminally redundant a sequence of several hundred bp. HSV-1 was the first 
virus to be characterised in this class (Sheldrick and Berthelot, 1975). Class 
F is exemplified by the betaherpesvirus THV and contains neither inverted 
nor direct repeats (Koch et al., 1985). The complexity of repeat regions 
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within some of these structures can give rise to functionally equivalent 
genomic isomers (Jenkins and Roizman, 1986). This is due to inversion of a 
unique segment, allowing it to be present in two orientations in the mature 
virion. For example, inversion within the class E structures produces four 
equimolar genome isomers (Davison, 2007). The three Herpesviridae 
subfamilies have been shown to share a common set of 43 core genes 
which are essential for lytic replication (McGeoch, 1999). These core genes 
are in the central genomic region and the arrangement of which is typically 
conserved within each subfamily. Furthermore non-coding sequences for the 
origin of lytic replication and genome cleavage and packaging are conserved 
(Spaete and Mocarski, 1985).  
    
1.1.4 Life cycle 
All herpesviruses have a biphasic life cycle, with a productive lytic phase and 
a dormant latent phase. Herpesvirus infection is initiated by fusion of the cell 
membrane with the viral envelope, via interactions between cellular 
receptors and viral glycoproteins. All herpesviruses have three conserved 
glycoproteins gB, gH, and gL, plus additional non-conserved proteins which 
bind to a range of cellular receptors such as heparan sulphate (Heldwein 
and Krummenacher, 2008). Once membrane fusion has taken place the 
capsid is transported along microtubules to the nuclear membrane via 
interaction with molecular motors such as dynein (Sodeik et al., 1997). The 
viral genome is then released into the nucleus through the nuclear pores 
(Ojala et al., 2000), where it becomes circularised and  lytic replication takes 
place. A coordinated temporal cascade of gene expression is initiated with 
immediate early (IE), delayed early (DE) and late genes being sequentially 
transcribed. Transcription of the IE genes does not require de novo protein 
synthesis and produces factors which regulate both viral and cellular gene 
expression (Takada and Ono, 1989). The DE transcripts then give rise to all 
the proteins required for viral DNA synthesis, which takes place in 
specialised sub-nuclear replication compartments (Quinlan et al., 1984). All 
herpesviruses encode a wide range of enzymes required for stimulation of 
DNA synthesis. Late gene expression produces proteins required for the 
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mature virion, including capsid proteins which are assembled to allow 
packaging of newly replicated DNA. The capsid then matures through 
several stages of envelopment. Initially the capsid is enveloped moving 
through the inner nuclear membrane into the perinuclear space before being 
de-enveloped moving though the outer membrane (Skepper et al., 2001). 
Re-envelopment takes place in the cytoplasm at endosomal membranes to 
produce mature progeny virions which are released by exocytosis (Mocarski, 
2007) (figure 1.4). However, the site of final envelopment has been a source 
of debate, with a recent study implicating a role for endocytic tubules rather 
than the commonly accepted trans-Golgi network (Hollinshead et al., 2012).  
 
As herpesviruses can establish life-long persistent infections in the host,  not 
all infections lead to productive replication. In this instance once the viral 
DNA enters the nucleus it forms a circularised episome which expresses 
only a small subset of genes. Entrance into latency is cell type specific for 
each herpesvirus and can be established in non-dividing or dividing cell 
populations. For example HSV and VZV remain latent in non-dividing 
neuronal cells, whereas EBV and KSHV establish latency in B-cells and thus 
require mechanisms for episomal maintenance. The latency associated 
transcripts are required for immune avoidance and episomal maintenance in 
replicating cells. Furthermore, they can play a role in repression of lytic 
replication, such as the HSV-1 encoded miRNAs which inhibit expression of 
IE genes (Umbach et al., 2008). These dormant genomes retain the 
potential to enter lytic replication upon an appropriate cellular stimulus 
(Penkert and Kalejta, 2011). 
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Figure 1.4 The herpesvirus life cycle. 
(a) Viral envelope glycoproteins interact with cellular receptors to mediate 
membrane fusion and cell entry. The virion is then transported to the nuclear 
membrane where viral DNA moves into the nucleus through nuclear pores. (b) A 
cascade of temporally regulated gene expression takes place with sequential 
transcription of immediate early (IE), delayed early (DE) and late genes. The IE 
genes facilitate the first round of transcription before (c) DE gene products allow the 
viral DNA to be replicated. (d) The genome is packaged into capsids formed from 
the late gene products and the nucleocapsid moves through the nuclear membrane 
via a process of envelopment and de-envelopment. The nucleocapsid then acquires 
the remaining virion constituents, being re-enveloped and exiting the cell by 
exocytosis (Coen and Schaffer, 2003). 
 
1.2 Gammaherpesvirinae 
The Gammaherpesvirinae contains four genera; Lymphocryptovirus, 
Rhadinovirus, Macavirus and Percavirus, with Lymphocryptovirus and 
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Rhadinovirus containing the two human pathogens EBV and KSHV, 
respectively (McGeoch et al., 2006). The gammaherpesviruses were first 
classified by their tropism for lymphocytes and have a similar genetic 
architecture, with a central conserved gene block, interspersed unique ORFs 
and capped by variable numbers of direct repeat sequences (figure 1.5) 
(Simas and Efstathiou, 1998).  Gammaherpesviruses can also induce 
lymphoproliferation and are associated with both lymphoid and non-lymphoid 
cell tumours.  
 
 
a) HVS
b) MHV-68
c) KSHV
d) EBV
 
 
 
Figure 1.5 Genetic organisation of the  gammaherpesviruses. 
The genomes of (a) herpesvirus saimiri (HVS), (b) murine gammaherpesvirus 68 
(MHV-68), (c) Kaposi’s sarcoma associated herpesvirus (KSHV) and (d) Epstein-
Barr virus (EBV) are shown. The conserved gene blocks I-IV are indicated and the 
ORF labels within these boxes relate to the HVS numbering system. Interspersed 
between these gene blocks are ORFs that are mostly unique to each individual 
virus and contain several homologues to cellular genes. Rhadinovirus genes with 
no homologues in HVS are numbered separately and with the following prefixes: K, 
KSHV-specific ORFs; M, MHV-68-specific ORFs; S, HVS-specific ORFs (Simas 
and Efstathiou, 1998).   
 
The gammaherpesviruses establish a latent state in lymphoid cells with 
specificity for B- or T-lymphocytes. Although gammaherpesviruses show 
most variation in the latent period of their life cycle, they must all have 
mechanisms to ensure a stable balance of latent vs. lytic replication. 
Furthermore, they must be able to maintain the viral genome in a dividing 
cell population and favourably modulate the host cell environment, for 
example in immune evasion and suppression of apoptosis (Speck and 
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Ganem, 2010). KSHV and EBV provide a useful tool for studying latency as, 
unlike the other human herpesviruses, it can be established in vitro 
(Longnecker and Neipel, 2007). Entry into the lytic replication cycle is 
triggered by expression of the highly conserved IE transcriptional activator 
RTA (Zalani et al., 1996; Sun et al., 1998; Wu et al., 2000). However in EBV, 
a second lytic switch protein, ZTA, is also required. Although the signalling 
mechanisms responsible for reactivation in vivo are not well defined, 
investigations from EBV, KSHV, and MHV-68 suggest plasma cell 
differentiation as a potential common trigger of gammaherpesvirus 
reactivation (Bhende et al., 2007; Liang et al., 2009; Wilson et al., 2007). 
 
1.2.1 Human Lymphocryptovirus EBV 
Epstein-Barr virus is a ubiquitous infection with almost 90% of the population 
being infected in childhood or adolescence. In most cases primary infection 
with EBV is asymptomatic but can occasionally present as infectious 
mononucleosis, causing fatigue and flu-like symptoms. EBV was also the 
first human tumour virus to discovered, identified from primary cell cultures 
of Burkitt’s Lymphoma (Epstein et al., 1964). EBV has since been 
recognised as an etiologic factor in multiple types of cancer arising in 
lymphocytes and epithelial cells. These malignancies include three types of 
B-cell associated lymphoma; Burkitt's lymphoma, Hodgkin's lymphoma 
(Levine et al., 1971) and lymphomas in immunosuppressed individuals 
(AIDS and post-transplant) and two carcinomas resulting from epithelial 
infection; Nasopharyngeal carcinoma (Pathmanathan et al., 1995) and 
gastric carcinoma (Shibata and Weiss, 1992). Although EBV primarily infects 
B-cells, rare infection of T-cells and NK cells also confers a high risk of 
associated lymphomas (Jones et al., 1988). Some of these neoplasia have 
very clear patterns of incidence such as Nasopharyngeal carcinoma in China 
and South-east Asia (Yu and Yuan, 2002). As these malignancies are found 
in specific geographic and ethnic populations this suggests a significant role 
for environmental, genetic, and immune co-factors in the development of 
these cancers. 
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1.2.1.1 Life cycle 
EBV is orally transmitted and upon transfer to a new host it infects B-cells, 
infiltrating the upper respiratory tract mucosa (Thorley-Lawson, 2005). EBV 
entry is mediated by the interaction between the virally encoded glycoprotein 
gp350/220 and cellular receptor CD21 (Nemerow et al., 1987).  Once the 
viral genome enters the nucleus the default pathway is to enter latency. In 
vitro infection of primary B-cells often results in immortalisation and 
generation of lymphoblastoid cell lines (LCLs). Investigation of latency in 
these LCLs identified the consistent expression of six nuclear antigens 
(Epstein-Barr nuclear antigens; EBNA-1, -2, -3a, -3c, -3b, and -LP) and three 
membrane antigens (latency-associated membrane proteins, LMP-1, -2a, 
and -2b) (Rickinson, 1996). Upon initial infection transcription is initiated from 
a viral promoter, Wp, driving production of EBNA-2 and EBNA-LP. The 
products of Wp transcription, in conjunction with RBP-jκ, then act to activate 
the second Cp promoter, just upstream of Wp (Henkel et al., 1994). This 
enables expression of the remaining EBNAs, in addition to EBNA-2 and 
EBNA-LP. The EBNA-1 gene product also feeds back to upregulate 
transcription from Cp and thus the virus moves from transcriptional 
regulation by host factors to viral proteins (Speck and Ganem, 2010).  
 
EBV latency in vivo is complex, with several latent programmes of gene 
expression having been identified. These patterns of EBV latency are a 
result of superb adaptation to the host B-cell maturation. During the natural 
immune response, antigen recognition by naïve B-cells causes B-cell 
activation and migration into the follicle to form a germinal centre (Thorley-
Lawson, 2005). This is  accompanied with B-cell proliferation and 
competitive selection for antigen specific B-cells. The resulting B-
lymphocytes then enter the peripheral circulation as memory B-cells. After 
initial infection, EBV enters the latency III growth programme as described 
above for in vitro infection. These latent products stimulate B-cell activation 
as if the infected cell is responding to an antigen. Once the B-cell enters the 
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follicle, the latency programme switches to latency type II, expressing only 
EBNA1, LMP1 and LMP2. These LMPs drive the B-cell through the germinal 
centre environment, giving rise to EBV positive memory B-cells (Gires et al., 
1997; Caldwell et al., 1998). Latent EBV can persist within memory B-cells 
by further limiting its transcriptional profile (Babcock et al., 1998). In non-
dividing peripheral B-cells no viral transcripts are produced, termed latency 
type 0. However, upon B-cell division EBV transitions to type I latency, with 
the expression of a single transcript, EBNA1, which is required for EBV 
genome maintenance (Hochberg et al., 2004). EBNA-1 is thought to bind to 
the oriP region of the viral genome, tethering it to metaphase chromosomes. 
This is thought to be mediated by binding between an AT-hook region of 
EBNA-1 and AT-rich DNA sequences (Sears et al., 2004). 
 
To maintain a reservoir of latently infected cells and enhance transmission to 
a new host, lytic replication must also occur. Differentiation of infected 
memory B-cells into antibody secreting plasma cells can trigger virus 
reactivation and migration of plasma cells to the oropharyngeal mucosa, 
facilitating viral transmission (see section 1.2.1.2). Furthermore, epithelial 
cells are permissive for EBV lytic replication and thus the epithelial cells in 
the nasopharynx represents a site of EBV amplification (Pegtel et al., 2004). 
Figure 1.6 depicts the full EBV life cycle in the context of B-cell development. 
In addition, EBV associated malignancies are linked with the different latency 
programmes as indicated in figure 1.6.  
 
- 15 - 
 
Figure 1.6 The EBV life cycle. 
EBV is transmitted in saliva and infects B-cells in the oropharyngeal mucosa. 
The virus then enters latency and stimulates B-cell activation to gain access to 
the memory B-cell pool. Here the genome is maintained with minimal viral 
gene expression. Periodic reactivation from activated memory B-cells 
facilitates transmission to a new host. (Abbreviations: BL, Burkitt's lymphoma, 
EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; HL, Hodgkin 
lymphoma; LMP, latent membrane protein; NHL, non-Hodgkin lymphoma) 
(Bollard et al., 2012). 
 
1.2.1.2 Lytic reactivation 
EBV reactivation is mediated by the expression of two immediate early 
transcripts; ZTA and RTA. ZTA is encoded by the BZLF1 gene and is a bZIP 
transcription factor with homology to c-jun and c-fos. ZTA binds as a 
homodimer to AP-1 like sites, known as ZTA responsive elements (ZRE) 
(Lieberman et al., 1990). Interestingly ZTA also preferentially activates CpG 
methylated promoters, most likely to evade the inhibitory effects of viral 
genome methylation (Bhende et al., 2004). RTA is encoded by the BRLF1 
gene and is a transcriptional activator with an amino-terminal DNA binding 
domain and a carboxy-terminal transcriptional activation domain. RTA binds 
to DNA indirectly via cellular factors and directly binding to RTA responsive 
elements (RREs) with a consensus sequence of GNCCN9GGNG (Gruffat 
and Sergeant, 1994). ZTA and RTA act cooperatively to activate EBV lytic 
gene expression, however ZTA appears to be more efficient at disrupting 
latency in certain cell lines (Ragoczy and Miller, 1999). This is in contrast to 
the Rhadinoviruses, where the single gene product RTA is sufficient for lytic 
induction (Lukac et al., 1998). Once these IE genes are expressed they 
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further activate their own and one another’s promoters to greatly enhance 
the initial lytic stimulus (Flemington et al., 1991; Ragoczy et al., 1998). This 
then triggers a temporal cascade of gene expression culminating in 
production of mature virions (Kenney, 2007). 
 
In cell culture multiple agents can be used to induce lytic replication, 
including 12-0-tetradecanoyl phorbol-13-acetate (TPA) and sodium butyrate. 
TPA acts via activation of protein kinase C (PKC) whereas sodium butyrate 
increases levels of activating histone acetylation on IE promoters (Zur 
Hausen et al., 1978; Jenkins et al., 2000). However engagement of the B-
cell receptor using IgG or IgM antibodies is the most physiologically relevant 
in vitro stimulus (Takada and Ono, 1989). This system has been used to 
dissect the potential signalling mechanisms involved in reactivation as 
illustrated in figure 1.7. BCR stimulation leads to activation of 
phosphotidylinositol 3-kinase (PI3K), Ras-family GTPases, and 
phospholipase C gamma-2 (PLC) signalling. This is followed by activation of 
additional downstream pathways, including PKC, calcium-dependent factors 
calcineurin and calcium/calmodulin-dependent kinase type IV (CAMK-IV), 
and stress MAP kinases (p38 and c-jun N-terminal kinase (JNK)) (Kenney, 
2007). 
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Figure 1.7 Pathways leading to EBV reactivation in the host cell.  
Signal transduction pathways that are activated by TPA treatment of cells or by 
BCR engagement are shown. Promoter motifs in the RTA and ZTA promoters 
(Rp and Zp) that are activated by the signalling pathways are indicated, as well 
as the transcription factors that bind to these motifs. Activation through the 
BCR is inhibited by the EBV LMP -2 protein (Kenney, 2007).  
 
 
Differentiation of latently infected B-cells into antibody secreting plasma cells 
has been shown to be a genuine in vivo signal to promote lytic reactivation 
(Laichalk and Thorley-Lawson, 2005). This differentiation process is 
controlled by a regulatory circuit of transcription factors, including Bcl-6, 
Blimp1, Pax5 and Xbp1 (figure 1.8). Upon antigen stimulation of a memory 
B-cell the bcl-6 repressor is downregulated, leading to increased levels of a 
master regulator Blimp1. Blimp1 inhibits B-cell specific gene transcription 
and indirectly promotes expression of Xbp1 through inhibition of the Pax5 
repressor protein (Shaffer et al., 2002). Xbp1 plays an essential role in the 
differentiation process (Reimold et al., 2001), linked to its role in the unfolded 
protein response (UPR). Under cellular stress the UPR is activated by Bip1 
binding to misfolded proteins and releasing ATF6 and IRE1α binding 
partners into the cytoplasm. ATF6 and IRE1α function to upregulate and 
differentially splice Xbp1 into its active form Xbp1s (Yoshida et al., 2001). 
Xbp1s facilitates the necessary morphological changes for plasma cell fate 
by enabling the secretion of immunoglobulin, upregulating chaperone 
proteins and inducing the degradation machinery. In the context of EBV 
infection, Xbp1 causes ZTA transactivation via binding to its consensus motif 
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within the BZLF1 promoter (Sun and Thorley-Lawson, 2007). Thus EBV 
harnesses the B-cell terminal differentiation pathway via XBP1s as a 
physiological signal to begin viral replication in a favourable cellular 
environment. 
 
 
Figure 1.8 B-cell differentiation into plasma cells. 
B-cell differentiation is controlled by a regulatory circuit of transcription factors 
including Bcl-6, Blimp1, Pax5 and Xbp1. Bcl-6 and Pax5 promote proliferation 
and maintenance of the B-cell fate, whereas Blimp1 and Xbp1 promote 
morphological changes required for plasma cell function. Upon antigen 
stimulation of a memory B-cell the Bcl-6 repressor is downregulated, relieving 
repression of Blimp1. Blimp1 inhibits the expression of B-cell specific genes both 
directly and indirectly through repression of the Pax5 transcription factor. 
Reduction in Pax5 levels leads to an increase in Xbp1 activity which promotes 
expansion of the secretory apparatus (Shaffer et al., 2002).  
 
1.2.2 Murine Rhadinovirus MHV-68 
Murine gamma-herpesvirus 68 (MHV-68) was originally isolated from the 
bank vole in Slovakia (Clethrionomys glariolus) and is an endemic pathogen 
in its natural host wood mice (Apodemus sylvaticus) (Blaskovic et al., 1980; 
Blasdell et al., 2003; Ehlers et al., 2007). The MHV-68 genome consists of a 
118kbp unique region, flanked by several 1.2kb terminal repeats (Efstathiou 
et al., 1990). A common feature of gamma-herpesvirus infection is 
lymphoproliferation and infection of BALB/c mice has been shown to cause 
lymphoid and non-lymphoid lymphomas in 10% of cases (Sunilchandra et 
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al., 1994). The complete MHV-68 genome has been cloned into bacterial 
artificial chromosomes and, unlike EBV and KSHV, MHV-68 can replicate 
robustly in permissive cell lines to generate high titres of progeny virions 
(Adler et al., 2000). This, in addition to an extensive knowledge of mouse 
genetics, makes MHV-68 infection of laboratory mice an appealing model 
system for gammaherpesvirus infection (Simas and Efstathiou, 1998). 
 
1.2.2.1 Life cycle 
Primary infection of MHV-68 occurs via the respiratory tract, with replication 
taking place in alveolar epithelial and mononuclear cells. The inflammatory 
response causes accumulation of infiltrates in the lungs, including 
macrophages, monocytes, CD4+ and CD8+ T-cells, leading to bronchiolitis 
and interstitial pneumonia (Sunilchandra et al., 1992a). From the lungs MHV-
68 enters the mediastinal lymph node (MLN) where it primarily infects B-cells 
in addition to dendritic cells and macrophages (Nash et al., 2001). Viral entry 
is mediated by gp70 and the conserved gH/gL complex binding to heparan 
sulphate on the lymphocyte surface (Gillet et al., 2009). From the MLN B-
cells spread to the spleen and other lymph compartments accompanied by 
CD4+ T-cell dependent B-cell proliferation and resulting splenomegaly 
(Usherwood et al., 1996).  
 
Following clearance of primary lytic infection in the lung and resolution of 
splenomegaly, MHV-68 persists as a long-term latent infection in B-cells 
(Sunilchandra et al., 1992b). Both conserved and MHV-68 specific genes are 
expressed during the establishment and maintenance of latency, for 
example ORF73 is a homologue of the KSHV LANA-1 and is involved in the 
maintenance of the MHV-68 episome during latency (Moorman et al., 2003). 
The MHV-68 specific vtRNAs can be detected in the spleen in the absence 
of viral DNA and are thus used as a  marker for latency, although their exact 
role is unknown (Bowden et al., 1997). 
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1.2.2.2 Lytic reactivation 
MHV-68 lytic replication is activated by expression of the virally encoded 
RTA protein. RTA is a transcriptional activator, up-regulating viral genes 
during reactivation and de novo infection (Wu et al., 2000; Wu et al., 2001b). 
Consistent with this, recombinant MHV-68 strains containing constitutively 
active RTA are locked into obligate lytic replication (Rickabaugh et al., 2004). 
The MHV-68 and KSHV RTA proteins are highly conserved and KSHV RTA  
can reactivate latent MHV-68 to produce infectious virions in cell culture 
(Rickabaugh et al., 2005). Although mechanisms of in vivo reactivation are 
poorly understood, chemical stimulation has been demonstrated to induce 
MHV-68 reactivation. Induction of B-cell lines using TPA and ex vivo 
stimulation of splenocytes using anti-IgG-IgM and anti-CD40 activates lytic 
replication (Moser et al., 2005).  It is likely that these agents converge on 
common down-stream effectors, which could to be linked to the mechanisms 
of in vivo lytic activation. Furthermore, epigenetic modifications have been 
shown to play an important role in the regulation of RTA expression. The 
histone deacetylase (HDAC) inhibitor Trichostatin A has been demonstrated 
to remove HDAC3 from the RTA promoter, enabling histone acetylation and 
promoting RTA expression (Yang et al., 2009b).  
 
The mechanism by which RTA activates downstream viral gene expression 
has been studied extensively for KSHV. Here RTA is known to up-regulate 
viral gene expression via both direct binding to promoter RTA response 
elements (RRE) and indirect binding through cellular transcription factors 
(section 1.3.2)(Deng et al., 2007). Although the mechanisms of MHV-68 RTA 
transactivation are less well characterised, RTA has been shown to bind to 
the promoters of ORF72, ORF57 and ORF18 (Pavlova et al., 2005; Allen et 
al., 2007; Hong et al., 2011). The activation of ORF18 was attributed to a 
27bp RRE located in the left origin of replication, however the mechanism of 
ORF72 and ORF57 binding has not been fully elucidated. 
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Several in vivo stimuli have been suggested to reactivate MHV-68 including 
TLR activation and B-cell maturation. Toll-like receptors (TLRs) are 
important components of innate immunity which recognise pathogen 
associated molecular patterns (PAMPs) and activate the adaptive immune 
response (Werling and Jungi, 2003). Lipopolysaccharide (LPS) and CpG 
DNA can be used to activate TLRs in experimental systems and were 
demonstrated to induce B-cell activation and MHV-68 reactivation in infected 
mice, resulting in heightened levels of virus replication in the lungs (Gargano 
et al., 2009). It is suggested that periodic pathogen exposure may contribute 
to intermittent virus reactivation and thus the homeostatic maintenance of 
chronic gammaherpesvirus infection. The MHV-68 M2 gene is also involved 
in reactivation (Herskowitz et al., 2005) and the absence of a functional M2 
gene results in a severe defect in virus reactivation from splenic B cells, 
which correlates with the absence of virus-infected plasma cells. The M2 
protein leads to upregulation of Blimp-1 and XBP1s transcripts, which drives 
plasma cell differentiation in a B lymphoma cell line (figure1.8) (Liang et al., 
2009). The virally encoded product M2 may therefore stimulate reactivation 
through manipulation of plasma cell differentiation to produce a reactivation 
competent environment. This supports a model whereby sporadic lytic 
replication in the plasma cell compartment supports long-term MHV-68 
latency.   
 
1.2.3 Human Rhadinovirus KSHV 
Kaposi's sarcoma (KS) is an angioproliferative tumour of endothelial origin, 
first described in 1872 by Moritz Kaposi, as an indolent disease affecting 
elderly males of Mediterranean descent. The causative infectious agent was 
not investigated until the 1980’s when there was a rapid rise in KS incidence, 
in association with the AIDS epidemic. In 1994 viral DNA was discovered in 
KS biopsies using representational difference analysis and was classified as 
belonging to a human gammaherpesvirus, termed Kaposi’s sarcoma 
associated herpesvirus (KSHV) (Chang et al., 1994). The KSHV genome 
has since been characterised as ranging from 165 to 170Kb, with 
approximately 140kb core DNA flanked by GC-rich terminal repeats of 
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varying length (Russo et al., 1996). In addition to the conserved herpesvirus 
genes, KSHV contains 15 KSHV specific ORFs (K1-15). The KSHV genome 
also contains numerous non-coding RNAs including 12 microRNAs and a 
larger polyadenylated and exclusively nuclear (PAN) transcript (Sun et al., 
1996; Cai et al., 2005). In contrast to other human herpesviruses, such as 
EBV, KSHV is not a ubiquitous infection. KSHV seroprevelance ranges from 
under 10% in Europe, Asia and the US to over 50% in sub-Saharan Africa 
(figure 1.9) (Uldrick and Whitby, 2011). 
 
Figure 1.9 Global KSHV seroprevalence. 
KSHV seroprevelance ranges from under 10% in the US, Europe and Asia to 
between 20 and 30% in Mediterranean countries and reaches over 50% in sub-
Saharan Africa (Mesri et al., 2010) 
 
1.2.3.1 KSHV associated malignancies 
There are four clinical subtypes of KS; classical, endemic, AIDS associated 
and iatrogenic, with differing severities of clinical presentation. The first 
described case of KS involved the classic subtype, being prevalent in 
Mediterranean men over 50 years of age (Friedmanbirnbaum et al., 1990). 
This form of KS is the least severe, with little involvement of the lymph nodes 
and internal organs. Endemic KS is found in regions of central and eastern 
Africa and can be either indolent or aggressive (Kasolo et al., 1997). KS is 
the most common malignancy associated with AIDs, with significant 
mortality. KS related to HIV infection is the most aggressive form of the 
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disease with the most lymph and visceral involvement. Finally iatrogenic KS 
develops in patients who are on immunosuppressive therapy to prevent 
transplant rejection. Although this form of KS is often resolved by restoration 
of immune function, this can increase the risk of allograft rejection (Duman et 
al., 2002).  
 
Despite the differences in clinical presentation, all forms of KS have identical 
histological features and KSHV infection is a prerequisite of disease 
development. KS tumours are typified by the characteristic spindle cell (KS 
cell), in addition to prominent inflammatory infiltrates and leaky vasculature 
(Boshoff et al., 1995; Ensoli et al., 2001).  However, KS does not appear to 
represent a classical neoplasia, with polyclonal tumours and spindle cells 
being heavily dependent upon exogenous growth factors. Unlike truly 
transformed cells, explanted KS cells will not induce tumours in nude mice or 
grow in vitro without additional growth factors (Salahuddin et al., 1988). As 
such, it is suggested that KS tumorigenesis represents an inflammatory-
driven oncogenic process, underscoring the importance of paracrine growth 
signals. It should also be noted that strong cofactors influence the 
development of KS, as KSHV itself is not sufficient for disease development. 
The most obvious of these factors is immunosuppression, linked to 
iatrogenic and AIDS-related KS. However, there are likely to be other 
contributing genetic and environmental factors (Brown et al., 2006).   
 
In addition to KS, KSHV is also associated with primary effusion lymphoma 
(PEL) (Cesarman et al., 1995) and multicentric Castleman disease (MCD) 
(Soulier et al., 1995). PEL presents as a lymphomatous effusion tumour 
contained within body cavities such as the peritoneum, pleurum, and 
pericardium (Komanduri et al., 1996). It is an aggressive malignancy with a 
median patient survival time of 6 months (Boulanger et al., 2005), arising 
from a clonally expanded transformed B-cell. MCD can also be an 
aggressive malignancy associated with high fatality. It is thought interleukin 6 
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(IL-6) overexpression strongly contributes to pathogenesis, in KSHV-related 
cases this is likely to be in part a result of the virally encoded IL-6 
homologue, vIL-6 (Parravicini et al., 1997). As MCD results from expansion 
of a polyclonal B-cell population (Du et al., 2001), it is considered a non-
neoplastic reactive lymphadenopathy.  
 
Current treatments for KSHV related malignancies are strongly based 
around traditional chemotherapy or HAART for AIDS related cases. 
However, very few therapeutics are aimed specifically at virally manipulated 
signalling pathways, which have the potential to be more efficacious than 
general treatment regimens (Wen and Damania, 2010). KSHV latent 
transcripts such as LANA, vFLIP and v-cyclin contribute to cancer 
development through enhancing the survival and proliferation of the infected 
cells. Although lytic infection does not have a direct role in immortalisation or 
transformation, evidence indicates that it is essential for KS tumorigenesis. 
This is illustrated by the fact that anti-herpesviral drugs such as gancyclovir 
can inhibit KS progression (Mocroft et al., 1996). It is postulated while latent 
genes drive neoplastic transformation, this is augmented by paracrine 
secretion of growth and angiogenic factors from a small population of lytically 
infected cells (Mesri et al., 2010). Figure 1.10 demonstrates viral and cellular 
signalling pathways with potential involvement in promoting a tumour-
favourable microenvironment. 
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Figure 1.10 Proposed mechanism of KSHV induced sarcoma. 
(a) Early lytic genes such as vGPCR, K1, vIL-6 and K15 (shown in red), 
manipulate cellular signalling pathways, promoting the expression and secretion 
of inflammatory, angiogenic and proliferative factors (including platelet-derived 
growth factor-β (PDGFB), vascular endothelial growth factor (VEGF), 
angiopoietin 2 (ANGPT2), IL-6 and IL-8). (b) Secreted factors from lytic cells 
activate receptors on latently infected cells through a paracrine mechanism. This 
enhances the pro-oncogenic activities of KSHV latent genes, such as vFLIP, 
vcyclin and latency-associated nuclear antigen (LANA), in addition to the KSHV-
encoded microRNAs in neoplastic progression. (Abbreviations;β-cat, β-catenin; 
CDK, cyclin-dependent kinase; GSK3β, glycogen synthase kinase 3β; HIF, 
hypoxia-inducible factor; IAPs, inhibitor of apoptosis proteins; NF-κB, nuclear 
factor-κB; PKC, protein kinase C; PLC, phospholipase C; ROS, reactive oxygen 
species) (Mesri et al., 2010). 
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1.2.3.2 Life cycle 
KSHV is principally transmitted through saliva and infects a subset of 
tonsillar IgMλ-expressing B cells, before establishing latency (Hassman et 
al., 2011). Primary infection is generally asymptomatic in immunocompetent 
individuals but can induce flu-like symptoms in the immunocompromised 
(Oksenhendler et al., 1998). KSHV cell entry is initiated by attachment of 
viral glycoproteins gpK8.1, gB, gH and ORF4 to surface heparan sulphate. 
This is followed by interaction of gB with several cellular integrins to induce 
virion entry (Chandran, 2010). The KSHV genome is then maintained as a 
chromatinised episome, transcribing a minimal set of latency associated 
transcripts.  
 
The latent locus was recognised to encode four ORFs; LANA, v-FLIP, v-
cyclin and the kaposin family. LANA, v-FLIP and v-cyclin transcripts are 
initiated from a single promoter, the major latent locus, producing co-terminal 
mRNA by differential splicing (Dittmer et al., 1998). The Kaposin locus is 
driven from a separate transcriptional unit which also generates 12 pre-
miRNAs and a bicistronic RNA for v-cyclin and v-FLIP (Pearce et al., 2005). 
LANA is required for the replication and persistence of viral episomes 
(section 1.2.3.4) and represses expression of the lytic transactivator protein, 
RTA (Lan et al., 2005). Furthermore it has roles in p53 inhibition (Friborg et 
al., 1999), impairment of Rb function (Radkov et al., 2000) and promotion of 
S-phase entry (Fujimuro et al., 2003).  V-cyclin is a viral homolog of cellular 
cyclin D which activates cdk6, however its function in the context of infection 
is not well understood (Chang et al., 1996). The v-FLIP latent protein 
potently activates NF-κB which both inhibits apoptosis and stabilises latency 
through antagonising lytic activation (Chaudhary et al., 1999; Guasparri et 
al., 2004). These major latent transcripts are necessary for KSHV 
persistence, however the subsequent manipulation of host processes 
contributes to the development of KSHV associated neoplasia. 
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Latent episomes retain the capacity for lytic reactivation upon an appropriate 
inducing stimulus. This leads to the production of three IE proteins RTA, K-
bZIP and ORF45. RTA is responsible for the lytic switch while K-bZIP has 
both activatory and inhibitory roles in transactivation (Ellison et al., 2009). 
ORF45 is involved in suppression of the interferon response (Zhu et al., 
2002). As with EBV and MHV-68, B-cell differentiation has been shown to 
induce lytic replication, providing a physiologically relevant setting for viral 
transmission (section 1.2.3.3). The progeny virions can also lytically infect 
oral epithelial cells which contribute the driving cells in KS progression 
(Johnson et al., 2005). 
 
1.2.3.3 Lytic reactivation 
Latent genomes retain the ability to enter the lytic cycle which is induced by 
the expression of the viral RTA transcript. However, a key question in KSHV 
biology is what are the physiological triggers of RTA expression. Several 
chemical inducers have been demonstrated to reactivate latent genomes 
and have been used to identify downstream effectors which converge upon 
the ORF50 promoter (section 1.3.1). Slower progress has been made in 
identifying true in vivo reactivating stimuli, but several factors including 
hypoxia, B-cell differentiation and the immune response have been 
implicated in this process. As classic KS is commonly found in extremities 
that are poorly oxygenated, it was hypothesised that hypoxia could play a 
role in reactivation. Consequently it was found that exposure of the KSHV 
latently infected human B cell lymphoma cell line (BCBL-1) to low oxygen 
levels could induce lytic replication (Davis et al., 2001).  Under normoxic 
conditions the hypoxia-inducible factor 1α (HIF-1α) is degraded, however 
upon hypoxia this degradation is blocked leading to HIF-1α accumulation 
(Huang et al., 1998). HIF-1α then interacts with HIF-1β which binds as a 
dimer to hypoxia-responsive elements (HREs) within target promoters (Jiang 
et al., 1996). The virally encoded LANA protein was found to associate with 
HIF-1α and bind to several HREs within the RTA promoter (Cai et al., 2006). 
Thus, LANA and HIF-1α act cooperatively to induce RTA expression under 
hypoxic conditions.  
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The immune response has also been suggested to play a role in KSHV 
reactivation. Similar to MHV-68, activation of the innate immunity 
components, toll-like receptors (TLRs), has been implicated in reactivation. 
As TLRs recognise pathogen unique patterns, secondary infection of B-cells 
may contribute to sporadic lytic induction. Agonists to TLR7 and 8 
reactivated latent KSHV, in contrast to TLR4 activation, suggestive of 
pathway specificity (Gregory et al., 2009). Moreover secondary infection with 
a genuine activator of TLR7/8, vesicular stomatitis virus, could induce lytic 
replication in PEL cells. Certain inflammatory cytokines which are highly 
expressed in KS tumours can also promote lytic replication. For example, 
IFN-γ can induce reactivation in BCBL-1 cells however IFN-α has inhibitory 
effects (Chang et al., 2000). The role of these factors and their interplay 
requires further investigation. Interestingly, reactive oxygen species (ROS) 
have been implicated in mediating hypoxia and inflammatory induced 
reactivation (Ye et al., 2011). Removal of the ROS, hydrogen peroxide 
(H202), inhibited KSHV lytic replication induced by hypoxia and pro-
inflammatory cytokines. Moreover, exogenous H202 increased levels of lytic 
proteins in a dose-dependent manner.  
 
Finally, B-cell terminal differentiation has also been linked to lytic reactivation 
of gammaherpesviruses, including KSHV, EBV and MHV-68 (Wilson et al., 
2007; Laichalk and Thorley-Lawson, 2005; Liang et al., 2009).  
Differentiation of B-cells into antibody secreting plasma cells is a crucial 
component of the adaptive immune system. Additionally it provides a 
physiological stimulus relevant for KSHV transmission. Specifically, antigen 
stimulation and subsequent terminal differentiation of B-cells in the oral 
mucosa would facilitate viral shedding into saliva, promoting horizontal 
transmission. The effector of this reactivation mechanism is the transcription 
factor Xbp1. B-cell stimulation down-regulates the Bcl-6 repressor, leading to 
upregulation of Blimp1 and Xbp1 plasma cell differentiation factors (figure 
1.8) (Shaffer et al., 2002). Xbp1 subsequently promotes expansion of the 
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secretory apparatus through the UPR (Yoshida et al., 2001). The highly 
active spliced form of Xbp1 (Xbp1s) was demonstrated to activate the 
ORF50 promoter and induce lytic reactivation (Wilson et al., 2007; Yu et al., 
2007).  The Xbp1s binding site was mapped to an ACGT core element within 
the ORF50 promoter region, which was previously identified as a weak HRE 
(Dalton-Griffin et al., 2009). Interestingly, hypoxia was also demonstrated to 
increase levels of Xbp1s, suggesting a role for both HIF-1α and Xbp1s in 
hypoxic reactivation. Thus, Xbp1s links B-cell terminal differentiation to lytic 
reactivation. 
 
1.2.3.4 Genome replication 
Replication of the KSHV genome occurs in both the lytic and latent life cycle 
phases through alternative mechanisms. During lytic reactivation, levels of 
KSHV DNA increase in the order of 100 fold producing high titres of progeny 
virions (Lukac and Yuan, 2007). Conversely, latent replication for genome 
maintenance occurs only once per cell division in concert with host DNA 
replication. Moreover, during lytic reactivation replication is initiated at the 
ori-Lyt and progresses via a rolling-circle mechanism whereas latent 
replication proceeds bidirectionally from the ori-P (Lieberman et al., 2007). 
The process of replication during latency has yet to be clearly elucidated, 
however it is known to be mediated by the virally encoded LANA protein. 
The LANA C-terminus binds both KSHV DNA and the host chromatin 
components Histones 2A-2B and MeCP2, facilitating episomal maintenance 
throughout cell division (Barbera et al., 2006; Matsumura et al., 2010). Two 
LANA binding sites (LBS1 and LBS2) were mapped to the terminal repeat 
region of the KSHV genome, neighbouring a known replication element 
(Garber et al., 2002). As LANA itself does not have any replication activity it 
must recruit host replication factors, as demonstrated for the licencing factor 
ORC2 and topoisomerase IIβ (Stedman et al., 2004; Purushothaman et al., 
2012). 
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Lytic replication is initiated from two origins ori-Lyt-L and ori-Lyt-R, positioned 
between K4.2 and K5 and K12 and ORF71, respectively (AuCoin et al., 
2002). These origins are composed of a virtually identical 1.1kb core and 
600bp GC-rich repeats. The core region consists of an RRE, eight C/EBP 
binding motifs and an AT rich palindromic sequence, which are all necessary 
for origin function (Wang et al., 2004c). RTA and K-bZIP are viral origin 
binding proteins essential to the formation of a replication initiation complex 
upon the ori-Lyt. K-bZIP associates with DNA via its interaction with C/EBP, 
whereas RTA binds directly to its RRE.  RTA has been shown to associate 
with six core replication proteins, which are conserved across the 
herpesviruses (Wang et al., 2006). These replication proteins include a 
single-stranded DNA binding protein, a DNA polymerase, a polymerase 
processivity factor, and a trivalent helicase-primase complex. This complex 
forms large globular replication compartments within the host nuclei, 
associated with sites of DNA synthesis (figure 1.11) (Wu et al., 2001a). 
Other non-essential proteins have been shown to enhance lytic replication 
such as the virally encoded thymidine kinase. Several host cell factors have 
also been implicated in aiding lytic replication through association with the 
ori-Lyt and replication compartments, including topoisomerases and 
poly(ADP-ribose) polymerase I (PARP-1) (Wang et al., 2008).  
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Figure 1.11 The ori-Lyt replication complex. 
The IE proteins RTA and K-bZIP (K8) bind to the six core proteins to form a pre-
replication complex. This complex then binds to ori-Lyt DNA via interactions 
between CEBPα and K-bZIP, and RTA and its responsive element to facilitate 
replication (Wang et al., 2006). 
 
1.3 KSHV RTA 
The RTA protein, encoded by the ORF50 gene, is the master lytic switch 
protein of KSHV. Expression of RTA is both necessary and sufficient for lytic 
induction (Sun et al., 1998; Lukac et al., 1998). It achieves this through its 
roles as a transcriptional activator and an E3 ubiquitin ligase. RTA shows 
immediate early kinetics, being expressed within four hours of chemical 
induction of latent cell lines and resistant to cycloheximide treatment upon 
de novo infection (Sun et al., 1999). The protein itself is 691aa with a 
predicted molecular mass of 73.7kDa, however this differs from its apparent 
size of 110kDa observed by Western blotting. This is due to RTA being 
highly post-translationally modified, with the C-terminal domain being serine 
and threonine rich, providing potential phosphorylation sites (Lukac et al., 
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1999). RTA contains several functional domains related to its role as a 
transcriptional activator. These include a N-terminal DNA binding domain 
and a C-terminal activation domain. The activation domain is highly acidic 
and contains four hydrophobic activation domains (AD1-4). Additionally, RTA 
encodes a proline-rich central region thought to be involved in RTA 
dimerization and two nuclear localisation signals (NLS) (West and Wood, 
2003) (figure 1.12). Moreover, RTA contains a non-canonical Cys plus His 
catalytic domain responsible for its E3 ubiquitin ligase activity (Yu et al., 
2005). 
 
Figure 1.12 The functional domains of KSHV RTA protein. 
Schematic showing the position of RTA functional domains. (Abbreviations, 
NLS; nuclear localisation signal, AD; activation domain) (West and Wood, 
2003). 
 
1.3.1 Expression of RTA 
Transcription of the ORF50 region generates multiple transcripts, including a 
major 3.6Kb product, composed of five exons. This transcript is tricistronic, 
encoding ORF50, K8 (K-bZIP) and K8.1 transcripts. The ORF50 gene itself 
is composed of two exons separated by one intron and splicing results in the 
primary RTA transcript (West and Wood, 2003). The ORF49 gene product is 
also encoded within this region in the antisense orientation, within the 
ORF50 intron. Two other transcripts, T3.0 and T1.2, were identified as 
antisense to the ORF50 coding region (figure 1.13). Recently T3.0 was 
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demonstrated to play a role in RTA stabilisation while a role for T1.2 has yet 
to be described (Jaber and Yuan, 2013). As described in section 1.2.3.3, 
several physiological stimuli have been demonstrated to reactivate KSHV 
from latency. For this entry into the lytic cycle, transcription from the ORF50 
genomic region must first be initiated. Therefore, expression of RTA is 
stringently controlled to ensure tight maintenance of latency with periodic 
rounds of productive replication. The activity of the RTA promoter is thus 
regulated by a variety of cellular and viral activators and repressors, as well 
as chromatin conformation.  
 
Figure 1.13 The KSHV ORF50 locus. 
Schematic of the ORF50 genome region and the resulting alternatively spliced 
transcripts (West and Wood, 2003). 
 
1.3.1.1 Negative regulation of RTA 
DNA methylation and histone modification have vital roles in gene regulation 
through modulation of chromatin structure. The transcriptional state of the 
KSHV genome is heavily dependent upon such epigenetic modifications. 
DNA methylation causes gene silencing by preventing binding of 
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transcription factors to promoters, or by recruitment of methyl-CpG-binding 
domain proteins (MBDs), which in turn recruit histone deacetylases (Clouaire 
and Stancheva, 2008). Bisulfite sequencing demonstrated that the ORF50 
promoter is heavily methylated in latently infected BCBL-1 cells. Treatment 
of these cells with the DNA methyltransferase inhibitor, 5-AzaC, can induce 
lytic reactivation, demonstrating the importance of promoter methylation 
status. Moreover this is reflected by in vivo pathogenic progression, as 
samples from KSHV carriers show heavy methylation of the ORF50 
promoter, which is greatly reduced in tissue biopsies from individuals with 
KS, PEL and MCD (Chen et al., 2001).  
 
In contrast, histone acetylation is an activating epigenetic mark, which 
promotes an open chromatin conformation. This modification is controlled by 
the antagonistic action of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). Treatment of latent cell lines with HDAC inhibitors, 
such as sodium butyrate and valproic acid, can reactivate KSHV from 
latency (Lu et al., 2003; Shaw et al., 2000). HDACs 1, 5 and 7 have been 
shown to associate with the RTA promoter in latently infected cells, 
promoting a closed chromatin conformation, with a nucleosome stably 
positioned over the RTA transcriptional start site (Lu et al., 2003). 
Interestingly, a recent genome wide study of KSHV epigenetic modifications 
has demonstrated the presence of bivalent chromatin modifications on the 
ORF50 promoter (Toth et al., 2010). During latency the repressive 
H3K27me3 histone mark is accompanied by the activating H3K4me3 
modification. This provides a poised state of repression allowing a rapid 
response to reactivation with increasing levels of H3K4me3 and decreasing 
H3K27me3. 
 
Latent viral proteins also play a role in directly repressing the ORF50 
promoter. LANA represses basal levels of RTA expression and RTA-
mediated auto-activation. LANA interacts with the cellular transcription factor 
Rbp-jκ and binds to the ORF50 promoter (Lan et al., 2005). RTA auto-
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activation is dependent upon the interaction between itself and Rbp-jκ (Liang 
et al., 2002). Thus LANA represses RTA activation through competing for 
Rbp-jκ binding, in addition to recruiting additional co-repressors. The latent 
miRNA cluster also has a role in maintaining latency, notably miR-K9 and 
miR-K4-5p. The miR-K9 transcript directly targets a sequence in the 3’ UTR 
of RTA and inactivation of this miRNA leads to a 2-3 fold increase in 
spontaneous lytic reactivation (Bellare and Ganem, 2009). The major 
purpose of miR-K9 is likely to prevent stochastic variations in basal RTA 
transcription triggering inappropriate entry into the lytic cycle. Moreover, miR-
K4-5p contributes to latency via targeting the Rb-like protein 2 (Rbl2) to 
increase expression of DNA methyltransferases DNMT1, -3a and -3b (Lu et 
al., 2010).  
 
The NF-κB pathway has also been shown to have a role in repression of 
KSHV lytic replication. In PEL cell lines, inhibition of NF-κB signalling 
enhances lytic gene expression whereas overexpression impairs lytic gene 
expression (Brown et al., 2003). However, contradictory to this, NF-κB can 
be strongly activated in cells undergoing lytic replication and in cell lines 
such as HFF, in which blockade of NF-κB activation fails to increase 
reactivation (Grossmann and Ganem, 2008). The latent vFLIP protein has 
been demonstrated to inhibit lytic replication by suppressing the AP-1 
pathway in an NF-κB dependent manner (Ye et al., 2008). As such, 
upregulation of the ORF50 promoter and RTA transactivation is affected, as 
AP-1 is involved in lytic reactivation. The role of NF-κB in KSHV regulation is 
therefore strongly context dependant. For example, as AP-1 can be 
activated by several mechanisms, the NF-κB pathway may not always 
provide sufficient suppression.  Finally the Notch responsive cellular 
transcription factor, Hey1, has been shown to repress the RTA promoter 
(Yada et al., 2006). Hey1 belongs to the Hey family of bHLH transcriptional 
repressors, which have various roles in Notch signalling (Fischer and 
Gessler, 2007).  
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1.3.1.2 Positive regulation of RTA 
Chemicals such as TPA and sodium butyrate can induce reactivation in cell 
culture models. TPA treatment activates the stress map kinases, p38, JNK 
and MEK in a PKC dependent manner (Xie et al., 2008). These signals 
converge upon AP-1, a transcriptional activating complex which binds 
specific DNA sequences through a leucine zipper mechanism. AP-1 binds to 
a consensus sequence within the ORF50 promoter leading to its activation 
(Wang et al., 2004a). Sodium butyrate is a HDAC inhibitor and its ability to 
upregulate RTA expression has been mapped to a Sp1/Sp3 element. This is 
accompanied with recruitment of Ini1/Snf5, a member of the SWI/SNF family 
of chromatin remodelling enzymes, to the promoter region (Lu et al., 2003). 
These agents provide insights into the mechanism by which epigenetic 
modifications and signalling events induce RTA transcription. 
 
To ensure coherent entry into the lytic cycle upon an inducing stimulus, RTA 
also auto-activates its own promoter providing a robust positive feedback 
loop. This auto-activation also requires additional cellular factors Oct-1 
(Sakakibara et al., 2001), Sp1/Sp3 (Chen et al., 2001), C/EBPα (Wang et al., 
2003b) and Rbp-jκ (Liang and Ganem, 2003). The interaction of RTA and 
Rbp-jκ is important for RTA transactivation function and auto-activation is 
severely reduced in Rbp-jκ null cells (Liang and Ganem, 2003). Finally a 
small viral peptide, vSP-1, encoded by the T3.0 transcript has been shown to 
promote lytic entry through RTA stabilisation (Jaber and Yuan, 2013). This 
peptide, which is encoded antisense to ORF50 locus, interacts with RTA and 
prevents its degradation by the ubiquitin-proteasome pathway. Similar to 
RTA auto-activation this helps to ensure robust entry into the lytic cycle, 
promoting maintenance of RTA at the protein level.   
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1.3.2 RTA-mediated transactivation mechanisms 
RTA is known to transactivate a wide range of KSHV IE and DE promoters. 
It achieves this through direct binding to responsive promoters in addition to 
indirect binding via co-activator proteins.  
 
1.3.2.1 Direct promoter binding of RTA 
RTA has been shown to activate several KSHV promoters by direct DNA 
binding to RTA response elements (RREs). These include PAN, Kaposin 
and vIL6 in decreasing order of binding affinity. PAN is a non-coding 
polyadenylated RNA molecule which is the most abundantly expressed 
transcript in KSHV lytic infection (Sun et al., 1996). RTA activates the PAN 
promoter 7000 fold upon reactivation though an interaction with a 25bp PAN 
RRE, which was identified through analysis of progressive promoter deletion 
mutants (Chang et al., 2002; Song et al., 2001). Regions of homology were 
used to identify a similar 25bp RRE located in the kaposin promoter, with two 
stretches of 16bp and 5bp being exact matches (Chang et al., 2002). A 26bp 
RRE was also identified within the vIL6 promoter, however this region shows 
no homology to the PAN or Kaposin elements (Deng et al., 2002).  Despite 
the disparity displayed by these promoters, attempts have been made to 
identify an RTA consensus binding sequence. Liao et al hypothesised that 
the formation of oligomeric RTA allowed multiple contacts with stretches of 
periodic AT repeats in the conformation (A/T)3N7(A/T)3N7(A/T)3N7 (Liao et al., 
2003). A further study used a chromatin immunoprecipitation assay coupled 
with a KSHV whole-genome tiling microarray (ChIP-on-chip) approach, to 
identify 19 RTA binding sites in the KSHV genome including novel targets of 
ORFK4.1, ORF16, ORF45, the miRNA cluster, ORF74 and ORFK15. 
Comparison of the identified binding regions produced the consensus 
binding motif TTCCAGGAT(N)(0-16)TTCCTGGGA, a palindromic element 
with two tandem repeats (Chen et al., 2009). However, the majority of the 
identified RREs contained only part of this motif. This suggests some 
degeneracy in RTA sequence recognition, as well as strong involvement of 
other factors in gene activation. 
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1.3.2.2 Indirect promoter binding of RTA 
Direct DNA binding by RTA is not sufficient to transactivate all of its target 
promoters. Alternatively, RTA co-operates with many cellular transcription 
factors, including Rbp-jκ (Liang et al., 2002), C/EBPα (Wang et al., 2003a), 
and AP-1(Wang et al., 2004a) to facilitate lytic gene expression. Rbp-jκ is a 
transcriptional regulator which binds to DNA in a sequence specific manner 
and recruits repressor complexes. Upon activation of the Notch membrane 
protein it is cleaved to release the notch intracellular domain (NICD) which 
translocates to the nucleus. Here NICD outcompetes repressor complexes 
for Rbp-jκ binding and subsequently activates the associated promoters 
(Fischer and Gessler, 2007). RTA hijacks this cellular signalling pathway by 
mimicking the role of NICD, binding to the central region of Rbp-jκ to replace 
bound repressors and activate target promoters (Liang et al., 2002). Rbp-jκ 
binding sites are found in multiple RTA responsive promoters, including 
ORF74 (Liang and Ganem, 2004), ORF57, K-bZIP, ORF50 and SSB (Liang 
et al., 2002), and are essential for RTA transactivation. The importance of 
this interaction is illustrated by a Rbp-jκ knockout cell line which is unable to 
support lytic reactivation (Liang and Ganem, 2003).  
 
RTA also directly interacts with CCAAT/enhancer-binding protein-α 
(C/EBPα), a member of the leucine family of transcription factors. This co-
operative interaction promotes transcription of K-bZIP (Wang et al., 2003a), 
ORF57, ORF50 and PAN (Wang et al., 2003b). Additionally RTA and 
C/EBPα co-operate to activate the C/EBPα promoter, forming a positive 
autoregulatory loop (Wang et al., 2003b). Moreover, cJun and cFos are 
components of the AP-1 transcriptional activator complex which interact with 
each other and RTA. This complex facilitates RTA mediated transactivation 
of the K-bZIP, ORF57 and ORF50 promoters (Wang et al., 2004c). 
Furthermore RTA expression can induce expression of cJun, providing 
another positive feedback mechanism.  
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Once activating factors have bound to target promoters, RTA directly recruits 
chromatin remodelling complexes, such as CBP/p300 (Gwack et al., 2001) 
and SWI/SNF (Gwack et al., 2003a), to promote an open chromatin 
conformation. The CBP/p300 proteins are transcriptional activators with 
intrinsic HAT activity and the SWI/SNF complex is an ATP dependent 
remodelling complex (Clapier and Cairns, 2009). RTA also recruits the 
TRAP-mediator complex (Gwack et al., 2003a) which acts as an interface 
between the general transcription machinery and sequence-specific 
transcription factors (Malik and Roeder, 2010). RTA was demonstrated to 
interact directly with the TRAP230 subunit of TRAP/Mediator, the Brg1 
subunit of SWI/SNF and CBP. Genetic ablation of these interactions 
prevented lytic reactivation, indicating the necessity for chromatin 
remodelling in RTA transactivation. 
 
Some cellular factors mediate repression of RTA transactivation including 
interferon regulatory factor 7 (IRF7) (Wang et al., 2005)  and K-RBP (Yang 
et al., 2009a). IRF7 is a component of the innate antiviral response and 
binds to the ORF57 promoter in the latent genome. The IRF7 binding site 
overlaps the RRE within the ORF57 promoter and therefore prevents RTA 
transactivation by competitive binding (Wang et al., 2005). K-RBP is a 
KRAB-containing zinc finger protein which binds to DNA sequences with a 
high GC content via its zinc finger domain (Yang et al., 2009a). In this 
fashion it binds to the ORF57 promoter and suppresses RTA binding and 
promoter activation. Post-translational modification of RTA by cellular factors 
can also have an inhibitory effect on RTA activity. The poly(ADP-ribose) 
polymerase-(PARP)-1 and human homologue of kinase from chicken (KFC) 
cellular proteins interact with the serine–threonine (ST)-rich region of RTA 
(Gwack et al., 2003b). The phosphorylation and poly-ADP-ribosylation of this 
ST region decreases RTA transcriptional activity. Furthermore, lytic 
replication was also enhanced upon inhibition of RTA’s interaction with these 
modifying enzymes.   
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KSHV encoded factors can also modulate the transactivation ability of RTA.  
ORF57 is a KSHV DE gene product which functions in mRNA biogenesis 
(Jackson et al., 2012). ORF57 synergises with RTA in a promoter- and cell 
line-specific manner to enhance transactivation (Kirshner et al., 2000). This 
is thought to be in a post-translational manner, however the mechanism of 
this enhancement is unknown. K-bZIP is another KSHV IE protein which can 
have both positive and negative roles in lytic reactivation. A genome wide 
study investigated the effect of RTA or K-bZIP on 83 KSHV promoters. From 
this analysis 34 viral promoters were found to be activated by RTA and 21 by 
K-bZIP. Of the 34 RTA responsive promoters, three were repressed in the 
presence of both RTA and K-bZIP. These promoters are responsible for 
expression of ORF57, K15 and K-bZIP itself (Ellison et al., 2009). Stable 
expression of K-bZIP in BCBL-1 cells is also sufficient to inhibit TPA-induced 
lytic replication (Izumiya et al., 2003).  K-bZIP therefore has a multifunctional 
role in lytic induction acting as a transcriptional activator and repressor of 
RTA transactivation. 
 
1.3.3 Ubiquitin ligase activity of RTA 
Many viruses encode proteins that inhibit the interferon (IFN)-mediated 
antiviral response, a process activated by cellular interferon regulatory 
factors (IRFs). IRF3 and IRF7 transcription factors stimulate production of 
IFNα and IFNβ, which are required for expression of IFN-stimulated genes  
(Taniguchi et al., 2001). Upon herpesvirus cell entry antiviral responses are 
induced, however lytic gene products have evolved to counteract this 
process. For example, the KSHV encoded ORF45 inhibits IRF7 activation by 
preventing its phosphorylation (Liang et al., 2012). Moreover the ubiquitin 
ligase activity of RTA was first discovered due to its ability to inhibit IRF7 (Yu 
et al., 2005). Interaction between RTA and IRF7 abrogated transcription of 
IFNα/β by a proteasome dependent mechanism. RTA was demonstrated to 
poly-ubiquitinate itself and IRF7, consistent with RTA possessing E3 
ubiquitin ligase activity. The catalytic function of RTA was mapped to three 
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key residues Cys131, Cys141, and His145, mutation of which specifically 
ablated auto-ubiquitination and IRF7 degradation (Yu et al., 2005). However, 
this Cys plus His-rich domain shows no significant homology to other 
identified E3 ligase motifs. In addition to the anti-viral effects of IRF-7, it has 
also been shown to repress the KSHV ORF57 promoter of latent genomes 
(Wang et al., 2005). Therefore, the RTA mediated degradation of IRF7 has a 
dual function; firstly it aids disruption of the antiviral response during 
reactivation. Secondly it promotes transactivation by removal of repressive 
complexes from responsive promoters.  
 
Additional substrates for RTA’s E3 ubiquitin ligase activity have since been 
identified, namely the transcriptional repressors Hey1 (Gould et al., 2009) 
and K-RBP (Yang et al., 2008). Hey1 belongs to a conserved family of basic 
helix-loop-helix (bHLH) transcriptional repressor proteins. Hey1, plus the 
related genes Hey2 and HeyL, function in development and are induced by 
the Notch signalling pathway (Fischer and Gessler, 2007). Hey proteins can 
form repressive complexes on target promoters via recruitment of the 
nuclear receptor corepressors, mSin3A and HDACs (Iso et al., 2001). The 
KSHV ORF50 promoter itself is repressed due to the binding of Hey1 and 
mSin3A (Gould et al., 2009; Yada et al., 2006). RTA was shown to 
ubiquitinate Hey1, targeting it for proteasomal degradation. This Hey1 
degradation was sufficient to abolish Hey1 repressive complexes from its 
promoter (figure 1.14). K-RBP is a transcriptional regulator belonging to the 
Kruppel-associated box (KRAB) containing zinc finger protein family and 
represses transactivation of several KSHV promoters. Similarly to Hey1, 
RTA promotes ubiquitin conjugation and proteasomal degradation of K-RBP 
in a Cys plus His dependent manner (Yang et al., 2008). 
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Figure 1.14 The role of Hey1 in KSHV reactivation. 
During latency repressive complexes such Hey1-mSin3A inhibit expression of RTA. 
B-cell maturation leads to the production of Xbp-1s, which is sufficient to induce low 
levels of RTA transcription. RTA-mediated degradation of Hey1 leads to disruption 
of repressive complexes and thus full activation of the RTA promoter (Gould et al., 
2009).    
 
RTA has been shown to reduce levels of LANA, K-bZIP and Toll-interleukin-
1 receptor domain-containing adaptor-inducing β-interferon (TRIF), and this 
downregulation can be prevented by treatment with the MG132 proteasome 
inhibitor (Ahmad et al., 2011; Yang et al., 2008). This suggests that these 
proteins are degraded by the ubiquitin-proteasome pathway however a role 
for RTAs E3 ligase activity has not been characterised. Furthermore, RTA 
reduces levels of NF-κB by a proteasome-independent pathway (Yang et al., 
2008). All of these examples of RTA-mediated downregulation involve 
proteins which repress RTA transactivation function (IRF7, Hey1, K-RBP, 
LANA, K-bZIP and NF-κB) or promote the innate immune response (IRF7 
and TRIF). As the ability of RTA to induce degradation is required for 
reactivation, this suggests the E3 ligase function of RTA is required to initiate 
lytic replication in the presence of transcriptional repressors. This regulation 
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mechanism means that levels of RTA must be sufficient to efficiently 
degrade repressor complexes to allow transactivation and exit from latency. 
 
1.4 Post-translational modifications 
Post-translational modification (PTM) of proteins permits expansion of the 
functional diversity of the proteome. PTMs include covalent attachment of a 
chemical group or proteolytic cleavage of a protein, regulated by transferase 
and protease enzymes, respectively. To date more than 400 discrete types 
of modifications and more than 90 000 individual PTMs have been identified 
through biochemical and biophysical analysis (Lothrop et al., 2013). Some of 
the most intensively studied of these modifications include phosphorylation, 
ubiquitination, methylation, glycosylation, acetylation, lipidation and 
SUMOylation. These modifications can function individually or in 
combination to alter the localisation, activity or protein-protein interactions of 
a given substrate. In some instances, such as phosphorylation, the chemical 
group directly affects the target protein by changing its surface charge. 
However, PTMs are frequently translated to a given biological function via 
recognition by modular domains within effector proteins. For example 
acetylation and methylation are recognised by bromo- and chromo- domains, 
respectively (Ulrich and Walden, 2010).The complexity of such a system 
means that our ability to identify PTMs currently outstrips our knowledge of 
their diverse cellular functions.   
 
1.4.1 Ubiquitination 
The post translational ubiquitin modifier is a 76 amino acid protein, 
conserved from yeast to humans. Ubiquitin modification is involved in a 
myriad of cellular processes, the best characterised of which is targeting of 
proteins for proteasomal degradation. However ubiquitin attachment also 
plays a role in DNA repair, transcriptional regulation and lysosomal targeting 
(Metzger et al., 2012). Ubiquitination is catalysed by the successive action of 
three components, the ubiquitin activating (E1), ubiquitin conjugating (E2), 
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and ubiquitin ligating (E3) enzymes. The ubiquitin moiety is first joined, via a 
thioester bond, to an E1 Cys residue in an ATP dependant reaction. This 
activated ubiquitin can then be transferred to the active site cysteine of an 
E2 enzyme. Finally ubiquitin is transferred to the ε-amino group of the 
acceptor lysine, via an isopeptide bond, in an E3 dependant reaction 
(Husnjak and Dikic, 2012). Ubiquitin modifications can occur singly at one 
(monoubiquitination) or several sites (multi-monoubiquitination). Moreover, 
chains of ubiquitin can be formed through successive conjugation reactions 
targeting any of the seven internal lysine residues (Lys6, Lys11, Lys27, 
Lys29, Lys33, Lys48, or Lys63) (Ikeda and Dikic, 2008) or terminal 
methionine (Kirisako et al., 2006) within ubiquitin itself (polyubiquitiation). 
The different types of ubiquitin modifications can then induce alternative 
functional outcomes. Ubiquitination is a reversible process and 
deubiquitinating enzymes (DUBs) can remove modifications from target 
substrates. Figure 1.15 summarises the ubiquitin conjugation reaction and 
possible resulting ubiquitin conformations. 
 
The human genome encodes two E1 ubiquitin activating enzymes, Uba1 and 
Uba6 (Jin et al., 2007), and approximately 40 E2 conjugating enzymes. 
However much of the specificity of the ubiquitin system is encoded by the E3 
ligases, with over 600 estimated E3s encoded within the mammalian 
genome (Li et al., 2008). There are two major classes of E3 ligases, HECT 
and RING finger type, with different structures and enzymatic mechanisms 
as discussed below. 
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Figure 1.15 Ubiquitin conjugation pathway and outcomes. 
a) Conjugation of ubiquitin to a target substrate through the successive activity 
of ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-ligating 
enzyme (E3). HECT E3 activity involves generation of an E3 ubiquitin 
intermediate whereas RING E3s do not. Removal of ubiquitin is catalysed by 
deubiquitinating enzymes (DUBs). b) Ubiquitination can result in 
monoubiquitination, multiple monoubiquitination or polyubiquitination. 
Attachment to alternative ubiquitin residues can produce homotypic or mixed 
linkage chains with differing functional consequences (Husnjak and Dikic, 2012).  
 
HECT E3 ligases 
There are approximately 30 HECT (Homologous to E6-AP Carboxy 
Terminus) E3 ligases encoded in the human genome, consisting of a C-
terminal HECT domain and a substrate specific N-terminal domain. During 
ubiquitin conjugation a HECT-ubiquitin intermediate is formed, with a 
thioester linkage of a ubiquitin moiety to the HECT active site cysteine 
(Scheffner et al., 1995). The 350 amino acid HECT region consists of two 
domains, an N-lobe responsible for E2 binding and a C-lobe containing the 
active site (Huang et al., 1999). These lobes are joined by a flexible hinge 
region to facilitate transfer of ubiquitin (Verdecia et al., 2003). 
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RING finger E3 ligases 
The remainder of the E3 ligases belong to the RING (Really Interesting New 
Gene) and RING-related families. In contrast to the HECT domain proteins, 
RING ligases do not form a ubiquitin modified intermediate. Alternatively 
RING E3s provide a scaffold to facilitate direct transfer from E2 to the 
substrate. The canonical RING finger is a Zn
2+ 
coordinating domain, with 
multiple precisely spaced His and Cys residues (Lorick et al., 1999). Figure 
1.16 illustrates the RING structure with the two zinc ions held in a cross-
brace arrangement.  Several variations upon the typical ring finger also exist 
such as the U-box domain family (Aravind and Koonin, 2000). In the U-box 
domain, conserved charged and polar residues have replaced the zinc 
binding sites, maintaining structure and function via hydrogen bonding 
networks. These RING ligases can function as monomers, dimers or as part 
of a complex (Deshaies and Joazeiro, 2009).   
 
 
 
Figure 1.16 The RING finger domain. 
Schematic of the RING finger motif containing cysteine and histidine residues 
and co-ordinated zinc ions in a cross-brace structure (Deshaies and Joazeiro, 
2009).  
 
Conjugation of ubiquitin to a target substrate can have many outcomes, 
however fundamentally it provides an additional binding platform which can 
alter the interaction profile of a protein. Ubiquitin modifications are 
recognised by specific ubiquitin binding domains within an interacting 
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protein. At present over a dozen ubiquitin binding domains (UBDs) have 
been described (Dikic et al., 2009). In some cases a UBD can recognise a 
specific type of polyubiquitin linkage, however many UBD interactions are 
context-dependant. The families of UBDs are structurally diverse however 
they all interact with ubiquitin in a non-covalent manner. Often it is the 
interaction of ubiquitinated substrates with UBD containing effectors that 
transmits a ubiquitin signal, resulting in a functional consequence. Discussed 
below are examples of the  proteolytic and non-proteolytic functions of 
ubiquitin conjugation. 
 
1.4.1.1 Proteolytic functions 
The best characterised role of ubiquitination is marking of substrates for 
degradation by the 26S proteasome. Lys48-linked chains were initially 
implicated in proteasomal targeting (Chau et al., 1989), however Lys11-, 
Lys29-, and Lys63-linked chains have also been shown to contribute to 
protein degradation (Komander and Rape, 2012). Shuttle factors such as 
Rad23 and Dsk2 interact with ubiquitinated proteins via a UBD and deliver 
them to the proteasome (Elsasser and Finley, 2005). The 26S proteasome is 
a 2.5 MDa complex consisting of a 20S core particle and a 19S regulatory 
particle. The shuttle factors and ubiquitinated cargo dock upon the 19S 
subunit which mediates protein unfolding, ubiquitin recovery and transfer to 
the 20S subunit. The 20S core then mediates the progressive degradation of 
unwound proteins which are fed through the central channel (Chitra et al., 
2012). Lysosomal degradation of plasma membrane proteins is also 
regulated through monoubiquitination or Lys63-linked chains. ESCRT 
complexes bind to ubiquitinated membrane proteins via a UBD, an 
interaction which is enhanced by recognition of associated lipid membranes 
(Raiborg and Stenmark, 2009).  
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1.4.1.2 Non-proteolytic functions  
Ubiquitin conjugation also plays a role in non-proteolytic processes, which 
are often related to monoubiquitination or the formation of Lys63 linked 
chains.  These functions are a result of ubiquitin mediated changes in 
protein interactions or localisation. Monoubiquitination of the processivity 
factor PCNA in response to DNA damage promotes the interaction with Y 
family polymerases (Moldovan et al., 2007). These polymerases are 
specialised to prevent collapsing of stalled replication forks. This interaction 
is mediated by combinatorial binding to PCNA and ubiquitin through the 
polymerase PIP box and UBDs, respectively (Bienko et al., 2005). Lys63 
chain formation also impacts upon protein interactions as demonstrated by 
modification of the ribosomal protein L28 (Spence et al., 2000). This 
attachment enhances translation through polysome stabilisation. Multi-
monoubiquination has been demonstrated to affect the localisation of p53 (Li 
et al., 2003). These modifications are likely to prevent the export machinery 
from accessing p53 nuclear export signals. The examples of proteolytic and 
non-proteolytic functions discussed here highlight that both the ubiquitin 
topology and molecular context play a role in functional outcomes. 
Combinatorial detection of the ubiquitin moieties and factors such as 
substrate domains or lipid membranes facilitates changes in intra- or inter- 
molecular binding (Komander and Rape, 2012). 
 
 
1.4.2 Viral manipulation of the ubiquitin system 
The flexibility of ubiquitin in regulating protein function and its role in 
countless cellular processes makes manipulation of this system an 
appealing target for viruses. Viruses have evolved to influence the ubiquitin 
system through encoding their own ubiquitin components, interaction with 
cellular ubiquitin components and enhancing ubiquitination events. Through 
these mechanisms viruses have developed strategies to manipulate 
apoptosis, the cell cycle, antiviral pathways and membrane trafficking. 
Examples of these strategies are discussed below . 
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1.4.2.1 Virally encoded ubiquitin machinery 
As E3 ligases provide specificity to direct the ubiquitination machinery, it is 
unsurprising that there are numerous examples of virally encoded E3 
ubiquitin ligases. Almost all identified viral E3s are of the RING class with no 
known examples belonging to the HECT family. The HSV-1 infected cell 
protein 0 (ICP0) is an IE gene product which has intrinsic E3 ligase activity 
and an identified RING domain (Boutell et al., 2002). ICP0 induces 
ubiquitination of PML nuclear body components (Everett et al., 2006), and 
p53 (Boutell and Everett, 2003) leading to proteasomal degradation and 
enhancement of virus replication. This is supported by the fact that ICP0 null  
mutant viruses replicate less efficiently and demonstrate higher levels of 
interferon-stimulated gene expression (Harle et al., 2002).  
 
The RING-CH family of E3 ligases are defined by a C4HC3 Cys-His ring 
configuration not previously recognised in RING E3 ligases (Ohmura-
Hoshino et al., 2006). These enzymes promote immune evasion and all 
downregulate levels of MHCI. These RING-CH proteins are membrane 
integrated and facilitate ubiquitin dependant downregulation of receptors 
through a clathrin mediated pathway to an endolysosomal compartment 
(Duncan et al., 2006). KSHV K3 and K5 belong to this family which 
ubiquitinate MHCI, promoting internalisation and lysosomal degradation 
(Coscoy et al., 2001). The KSHV RTA protein represents a non-canonical E3 
ligase (section 1.3.3). RTA E3 ligase activity is ascribed to a catalytic Cys 
plus His-rich region with no homology to known E3 ligases. This activity 
contributes to viral reactivation and immune evasion (Yu et al., 2005).  
 
Multiple viruses have also been shown to encode DUBs, including the HSV-1 
UL36 protein (Kattenhorn et al., 2005). UL36 is conserved across the three 
herpesviral families and encodes a large tegument protein which is cleaved 
to the catalytically active fragment UL36
usp
.  Herpesviruses lacking an active 
UL36
usp 
are less pathogenic in vivo, however its role in the viral life cycle has 
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not been elucidated (Jarosinski et al., 2007). A DUB has also been identified 
in KSHV, ORF64 which can de-ubiquitinate K48 and K63 linked chains 
(Gonzalez et al., 2009) and appears to play a role in lytic replication.  Finally, 
baculoviruses also provide an example of a virally encoded ubiquitin 
molecule (Reilly and Guarino, 1996). This is the most distantly related 
ubiquitin to that of animals identified and therefore may participate in only a 
subset of ubiquitin regulated processes.  
 
1.4.2.2 Viral interactions with cellular ubiquitin machinery 
In addition to encoding their own ubiquitin modifying enzymes, viruses also 
manipulate host ubiquitination factors through interaction with viral proteins. 
One frequent strategy is the use of viral E3 adaptor proteins, which interact 
with cellular E3 ligases to direct their function. The prototypical example is 
the E6 oncoprotein of Human papillomavirus (HPV) 16 and 18. E6 directly 
interacts with the HECT type ubiquitin ligase E6AP and induces degradation 
of p53 (Scheffner et al., 1990).  This function contributes to the oncogenic 
potential of these HPV strains by inhibiting apoptosis upon uncontrolled 
cellular proliferation. The cullin-RING E3 ligases are also subject to 
manipulation by numerous viral proteins, such as the HIV-1 encoded protein 
Vif. The host cell apolipoprotein B editing complex (APOBEC) acts as an 
anti-retroviral factor which causes cytidine to uracil mutations during HIV-1 
reverse transcription. This results in hypermutation and a block in viral 
replication (Mangeat et al., 2003).  The Vif adaptor protein recruits the Cul5 
elongin B/C-Rbx SCF ligase and promotes polyubiquitination and 
proteasomal degradation of APOBEC3G (Yu et al., 2003). Manipulation of 
this cullin-RING ligase therefore represents an important anti-viral evasion 
strategy.  
 
1.4.2.3 Ubiquitin dependant viral processes 
Ubiquitin has been demonstrated to play a role in viral egress of retroviruses. 
Upon completion of replication, viruses utilise the host membrane trafficking 
system to bud off from the plasma membrane. This process is equivalent to 
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the formation of multivesicular bodies, whereby monoubiquitinated cargo 
proteins bind to a complex of the Tsg101 and ESCRT (Katzmann et al., 
2001). The retroviral Gag protein late domain contains a PTAP motif which 
can directly recruit Tsg101 and ESCRT (VerPlank et al., 2001). This enables 
vesicle formation enhanced by the ubiquitination of Gag. In HIV-1, the 
Nedd4 E3 ligase was shown to exert a ubiquitin-dependent effect through 
the viral Gag protein involving ubiquitination of components of the ESCRT-1 
complex, including TSG101 (Chung et al., 2008). This modification activates 
ESCRT-I to function in the release of enveloped viruses from the plasma 
membrane.  
 
1.4.3 Sumoylation 
SUMO is a small ubiquitin like modifier of 12kDa of which there are four 
paralogues in humans (SUMO1-4). SUMO2 and SUMO3 are 97% identical 
and can form poly-SUMO chains on target proteins. SUMO1 shares 50% 
identity with SUMO2/3 and unlike SUMO2/3 cannot form poly-SUMO 
molecules but can act as a chain terminator (Tatham et al., 2001; Matic et 
al., 2008). It remains unclear whether SUMO4 has any cellular function, or 
represents a pseudogene (Owerbach et al., 2005). The SUMOylation 
conjugation reaction has parallels with ubiquitination, utilising an E1 
activating enzyme, an E2 conjugating enzyme and an E3 ligase. A SUMO 
molecule is first processed to its mature form by the action of SUMO-specific 
proteases (SENPs) which reveals a Gly-Gly motif, mediating attachment to 
downstream molecules. The E1 SUMO-activating enzyme 1 and 2 
heterodimer (SAE1-SAE2) then proceeds to activate the SUMO molecule, 
becoming covalently linked through a catalytic Cys residue. The E2 enzyme 
Ubc9 then transfers the SUMO to a target Lys residue, via a SUMO-Ubc9 
intermediate. Although this process does not require a SUMO E3 ligase in 
vitro, in vivo E3 enzymes are likely to provide targeting specificity to the 
SUMOylation reaction. The SUMOylation reaction is a highly dynamic and 
reversible process, with SENP proteases acting to remove SUMO moieties 
from target proteins (figure 1.17) (Wilkinson and Henley, 2010). 
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Characterisation of known SUMOylated proteins has revealed a consensus 
sequence for SUMO acceptance, which appears to be present in about 75% 
of identified SUMOylation sites (Xu et al., 2008). This site, with the sequence 
ΨKxE (in which Ψ is an aliphatic branched amino acid and x is any amino 
acid), has no parallels to the ubiquitin conjugation system, where no 
consensus target has been characterised (Rodriguez et al., 2001). 
 
 
Figure 1.17 The SUMOylation pathway. 
(1) SENPs process SUMO precursors to reveal a C-terminal Gly-Gly motif 
before the mature molecule is covalently linked to the SAE1-SAE2 activating 
enzyme (2). (3) SUMO is then transferred to the catalytic Cysteine residue of 
Ubc9. (4) A SUMO E3 ligase provides a scaffold to facilitate conjugation of 
SUMO onto the target protein from Ubc9 (5) SENPs deconjugate SUMO from 
substrate to release free SUMO (Everett et al., 2013). 
 
Unlike the ubiquitination pathway, where there are at least 20 identified E2 
enzymes, there is only one E2 enzyme responsible for SUMO conjugation. 
Therefore the flexibility and specificity of the SUMO system is likely to be 
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coded in its E3 ligase and SUMO protease enzymes. In humans, the main 
group of identified E3 SUMO ligases belong to the PIAS family which 
consists of five members. The PIAS proteins contain a SP-RING catalytic 
domain similar to the RING class of E3 ubiquitin ligases (Hochstrasser, 
2001). Two other SUMO E3 ligases have been identified which do not 
contain a RING motif, Polycomb2 (Pc2) (Kagey et al., 2003) and Ran-
binding protein 2 (RanB2) (Pichler et al., 2002). However it is likely that there 
are numerous undiscovered E3 enzymes. One of the characteristics of 
SUMO governed processes is that only a small pool of target proteins need 
be modified to produce a significant effect (Hay, 2005). The SENP proteases 
therefore play an important function in removal and recycling of covalently 
attached SUMO moieties. In humans there are seven SENPs which can be 
divided into three groups based upon specificity, structure and localisation 
(Yeh, 2009). SENP1 and SENP2 can recognise SUMO1-3, whereas SENP3 
and SENP5 target SUMO2/3 and are localised to the nucleolus. SENP6 and 
SENP7 have an additional loop in their catalytic domain and favour 
deconjugation of poly-SUMO2/3.  
 
The functional consequences of SUMOylation are wide ranging affecting 
stability, localisation or activity of a given protein. At the molecular level 
SUMOylation can be thought of having three non-mutually exclusive effects. 
SUMO modification may inhibit protein-protein interactions by blocking 
interaction sites. Conversely, it may facilitate additional protein-protein 
interactions by providing a novel binding surface. Furthermore SUMOylation 
may directly affect the function of a protein by inducing conformational 
alterations (Wilkinson and Henley, 2010). Two of the most thoroughly 
investigated areas of SUMO biology focus on its role in DNA repair and 
transcriptional regulation (which is predominantly repression). SUMOylation 
has several roles in DNA repair, including modulation of the enzyme 
thymidine DNA glycosylase (TDG), which provides an example of a SUMO-
induced conformational change. TDG is a base excision repair enzyme 
responsible for removal of G:U and G:T mismatches. SUMO1 modification of 
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TDG facilitates a non-covalent intra-molecular reaction with a SUMO1 
binding site. This causes a structural change, which reduces DNA-protein 
affinity and permits disassociation of TDG from the DNA (Hardeland et al., 
2002; Baba et al., 2005).  
 
SUMO dependant protein-protein interactions are often mediated by the 
presence of a SUMOylation interaction motif (SIM). This domain is 
analogous to the numerous identified UBD (ubiquitin binding domains) and 
SIM containing effectors translate specific SUMO modifications to biological 
outcomes. SIM domains have the consensus sequence (V/I/L)-X-(V/I/L)-
(V/I/L) (where V; valine, L; leucine, I; isoleucine) often neighbouring acidic or 
phosphorylated residues (Song et al., 2004). These non-covalent SUMO-
SIM interactions have been shown to play an important role in transcriptional 
silencing. One common mechanism is the recruitment of chromatin 
remodelling enzymes to SUMOylated transcription factors, promoting 
establishment of a heterochromatic state (Garcia-Dominguez and Reyes, 
2009). CREB-binding protein (CBP) functions as a transcriptional co-
activator for several transcription factors and CBP SUMO1 modification acts 
to repress this activity. The transcriptional co-repressor Daxx interacts 
specifically with SUMO1 modified CBP via its internal SIM domain. This 
leads to recruitment of HDAC2 and transcriptional silencing (Kuo et al., 
2005; Lin et al., 2006). This exemplifies how SUMO attachment can cause a 
switch in transcriptional co-regulators from activating to inhibitory states. 
 
1.4.4 Viral manipulation of SUMOylation system 
The consequences of protein SUMOylation are not easily predictable, as 
SUMO conjugation acts to alter inter- and/or intra- molecular interactions of a 
given substrate. This can alter localisation, activity, binding or stability of a 
modified protein, thus SUMOylation can be involved in countless cellular 
process. The diverse consequences and flexibility of this system has 
therefore been exploited by many pathogens. Viruses have been shown to 
interact with cellular components of the SUMO conjugation machinery as 
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well as encoding viral homologues. Moreover, many viral proteins are 
themselves SUMOylated or interfere with SUMO dependent cellular 
processes. Discussed below are examples of how DNA viruses have 
exploited each stage of SUMO modification and figure 1.18 summarises all 
viral proteins known to presently interact with the SUMO machinery 
(Wimmer et al., 2012).  
 
1.4.4.1 Viral interaction with cellular SUMO machinery  
To date there is only one example of viral modulation of the SAE1-SAE2 
enzyme from the avian adenovirus, chicken embryo lethal orphan (CELO). 
Gam-1, which is functionally similar to the human adenovirus (E1B-19K) 
protein, induces the loss of PML-NBs and causes a general deregulation of 
the SUMO pathway. This is achieved through proteasomal reduction of both 
E1 and E2, proteins as well as prevention of the E1-SUMO thioester-
intermediate (Boggio et al., 2004). Other viral proteins have been shown to 
interact with cellular Ubc9 and E3 ligases to promote their own SUMOylation. 
The EBV RTA protein binds to Ubc9, PIASxalpha and PIASxbeta and is 
SUMOylated at three specific lysine residues (Chang et al., 2004; Liu et al., 
2006). Similarly the HCMV IE2 transcriptional regulator is SUMO modified at 
two lysine residues and interacts with Ubc9 and PIAS1. These interactions 
increase SUMO modification and transcriptional activity of IE2 (Lee et al., 
2003; Ahn et al., 2001). 
 
1.4.4.2 Virally encoded SUMO machinery 
There are two currently recognised virally encoded SUMO E3 ligases, 
including the KSHV K-bZIP protein. K-bZIP associates with Ubc9 and 
SUMO-2/3 in a SIM dependant manner to catalyse auto-SUMOylation and 
SUMOylation of two of its interaction partners, p53 and Rb. SUMOylation of 
p53 leads to its activation and K-bZIP was demonstrated to be recruited to 
several p53 chromatin sites in a SIM-dependent manner (Chang et al., 
2010). The human adenovirus serotype 5 (HAdV5) E1B-55K protein also has 
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intrinsic SUMO E3 ligase function. Like K-bZIP it SUMOylates p53 but 
promotes its inactivation through localisation to PML-NBs (Pennella et al., 
2010).  
 
Although there are no biochemical examples of viral proteins with SENP 
activity, some potential examples can be inferred from structural comparison. 
The proteases of African swine fever virus, adenovirus and poxvirus contain 
a catalytic triad domain, distantly related to the SENP active site motif. They 
have therefore been defined as a class of cysteine proteases which include 
SENPs (Wimmer et al., 2012).  
 
1.4.4.3 SUMOylated viral proteins 
Numerous viral proteins have been shown to be subject to SUMOylation with 
various functional consequences. The EBV lytic switch protein ZTA is 
modified at residue K12 by SUMO1, SUMO2 and SUMO3 (Hagemeier et al., 
2010). This modification reduces ZTA transactivation capacity, potentially 
through recruitment of cellular HDACs (Murata et al., 2010). SUMOylation 
may therefore be involved in regulating the EBV life cycle by promoting entry 
into latency. SUMOylation can also regulate protein stability, covalent 
modification of human papillomavirus minor capsid protein  L2, preferentially 
by SUMO2/3, stabilises the capsid protein. However this modification also 
reduces the binding affinity of L2 to the L1 capsid protein (Marusic et al., 
2010). 
 
1.4.4.4 Viral interference with SUMO-dependent cellular pathways 
Several viruses have been shown to disrupt the formation of PML nuclear 
bodies, which are sites of SUMO enrichment. These PML bodies have 
multiple cellular constituents including PML, SP100 and SUMO1-3. PML 
structures have roles in apoptosis, regulation of gene expression and anti-
viral defence mechanisms (Everett et al., 2013). The HSV-1 protein ICP0 is 
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an E3 ubiquitin ligase which targets proteins for proteasomal degradation. 
ICP0 has been shown to induce degradation of Sp100, PML and SUMO-
PML to quash PML induced antiviral responses (Everett et al., 2006). As 
ICP0 interacts with SUMO and contains numerous putative SIMs it 
potentially represents a viral SUMOylation targeted ubiquitin ligase (STUbL) 
(Boutell et al., 2011). Thus ICP0 may repress PML antiviral responses 
through reduction of its SUMOylated components. The VZV homologue of 
ICP0, ORF61, disrupts PML in a degradation independent manner. However 
ORF61 also binds SUMO and PML disruption requires its internal SIMs 
(Wang et al., 2011).  
 
 
Figure 1.18 Viral manipulation of host SUMOylation. 
A schematic showing the known points of interaction between viruses and the 
cellular SUMOylation machinery (Wimmer et al., 2012).  
 
1.4.5 Crosstalk between SUMO and ubiquitin systems 
Ubiquitin and the ubiquitin-like protein SUMO are covalent post translational 
modifications which are independently involved in countless cellular 
processes. However functional interrelations of these two modifications are 
now being characterised, notably in response to DNA damage. These 
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relationships include modification of the same target residue, SUMO 
dependent ubiquitination and the successive modification of distinct but 
functionally linked substrates. The classic example of modification of the 
same target residue to regulate protein function is that of proliferating cell 
nuclear antigen (PCNA). PCNA is a cofactor of DNA polymerases which 
encircles DNA, functioning as a sliding clamp. Although PCNA has no 
intrinsic enzymatic activity, it acts a binding hub for proteins involved in cell 
cycle control, DNA repair and chromatin assembly (Moldovan et al., 2007). 
Post-translational modification of the K164 residue of PCNA is necessary for 
dealing with DNA damage, allowing bypass of replication-blocking lesions. 
Monoubiquitination recruits translesion synthesis DNA polymerases 
promoting error-prone DNA repair, whereas polyubiquitination supports DNA 
repair by activating an error-free damage avoidance pathway (Hoege et al., 
2002). During S-phase the K164 residue can also be subject to SUMO 
modification which, like monoubiquitination, promotes recruitment of the 
error prone DNA polymerase. However, this occurs via interaction with the 
Srs2 helicase which restricts inappropriate recombination events during 
replication (Papouli et al., 2005). In this way mutually exclusive SUMO and 
ubiquitin modifications can occur on the same residue to promote 
recruitment of different accessory factors. 
 
Ubiquitin modifications are known to play an important role in the repair of 
DNA double strand breaks (DSBs). Upon initiation of DNA repair the 
checkpoint kinase ataxia telangiectasia mutated (ATM) protein 
phosphorylates H2AX and mediator of DNA-damage checkpoint 1 (MDC1). 
This promotes recruitment of the E3 ubiquitin ligase RNF8, which in turn 
ubiquitinates several chromatin associated proteins and H2AX. This 
engages an additional E3 ubiquitin ligase RNF168 which catalyses further 
ubiquitination events, ultimately recruiting the BRCA1 ubiquitin ligase, which 
is essential in promoting the homologous recombination repair pathway 
(Ulrich, 2012). More recent findings have elucidated a cooperative role for 
SUMOylation at DSB repair foci. The E3 SUMO ligase enzymes PIAS1 and 
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PIAS4 promote SUMO modification of several components including 
BRCA1, enhancing their recruitment to DNA repair foci (Galanty et al., 
2009).  
 
The discovery of SUMOylation targeted ubiquitin ligases (STUbLs) 
demonstrated a link between SUMO modification and ubiquitin dependant 
proteasomal degradation. STUbL proteins contain both an E3 ubiquitin 
ligase domain to conjugate ubiquitin and multiple SIMs to mediate 
recognition of a SUMO modified substrate. The first example of a STUbL 
was identified in S. cerevisiae as the Slx5-Slx8 heterodimer, containing two 
SIMs and a RING domain (Xie et al., 2007; Uzunova et al., 2007). Slx5-Slx8 
was found to selectively bind high molecular weight SUMO conjugates and 
play a role in maintaining genomic stability. STUbL activity was found to be 
required to induce degradation of SUMOylated proteins at irrepairable 
double-strand breaks or collapsed replication forks (Nagai et al., 2008). 
Subsequently RNF4 was identified as the first human STUbL with homology 
to Slx5-Slx8. Similarly, RNF4 contains a catalytic RING domain and four N-
terminal SIM domains (Sun et al., 2007). Poly-SUMOylated PML was 
identified as the first physiological substrate of RNF4, with accumulation of 
modified PML in PML bodies upon RNF4 depletion (Tatham et al., 2008).  
RNF4 has since been demonstrated to play a role in DNA repair, being 
recruited to DSBs in a SIM dependent fashion (Galanty et al., 2012). Here 
RNF4 regulates the turnover of MDC1 and replication protein A to allow 
access for recombination factors. 
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1.5 Thesis Aims 
Previous work carried out in the Whitehouse laboratory has demonstrated 
that the Hey1 cellular repressor protein is marked for degradation by KSHV 
RTA. RTA interacts with and ubiquitinates Hey1 via its intrinsic E3 ubiquitin 
ligase activity. Furthermore, Hey1 was shown to repress the ORF50 
promoter during latency through recruitment of the mSin3 repressor 
complex. RTA-mediated degradation of Hey1 therefore allows maximal 
activation of the ORF50 promoter and entry into lytic replication. The initial 
aim of this project was to determine the mechanism by which RTA 
recognises Hey1 as a degradation target, which could potentially be 
extended to additional RTA E3 ligase substrates. Specifically it was 
investigated if RTA belonged to a class of ubiquitin ligases termed 
SUMOylation targeted ubiquitin ligases (STUbLs). Chapter 3 demonstrates 
that RTA contains putative SIM domains, which are required for STUbL 
function. Mutation of these domains diminished RTA mediated degradation 
of Hey1 and its ability to reactivate latent KSHV. Furthermore, Hey1 was 
demonstrated to be SUMOylated in cell culture and cell free assays. 
Together, these results suggest that RTA could be a STUbL, however this 
finding is complicated by the fact that RTA SIM mutations also abrogated 
RTA-mediated transactivation. 
 
The second aim of this project was to identify novel points of interaction 
between RTA and the host cell using Stable Isotope Labelling of Amino 
Acids in Cell culture (SILAC) coupled with mass spectroscopy. To this end 
two inducible cell lines were created to express either RTA (iRTA) or 
RTA
H145L
 (iH145L), an E3 ubiquitin ligase null mutant. In Chapter 4 the iRTA 
cell line was utilised to perform a SILAC-based nuclear-cytoplasmic 
fractionation experiment. Mass spectrometry data was analysed to identify 
host proteins which showed significant changes in abundance in either the 
cytoplasmic or nuclear fraction. The AT-rich interactive domain-containing 
protein 3B (ARID3B) demonstrated a significant increase in nuclear 
abundance upon RTA expression. Further analysis demonstrated a 
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moderate increase in overall ARID3B mRNA levels upon RTA expression or 
KSHV reactivation. Moreover ARID3B was shown to co-localise with RTA in 
BCBL-1 lytic replication centres.  
 
Chapter 5 utilised the iRTA and iH145L cell lines to perform SILAC 
immunoprecipitation assays. This was employed to identify potential RTA 
interaction partners or E3 ubiquitin ligase targets. The cellular co-activator, 
RNA-binding protein 14 (RBM14), was highly enriched by RTA 
immunoprecipitation and was demonstrated to alter its localisation upon RTA 
expression. The RBM14-RTA interaction could also be independently 
confirmed. However RBM14 overexpression did not affect KSHV reactivation 
or RTA transactivation function. 
 
This investigation aims to add to the current knowledge on the mechanism of 
KSHV lytic reactivation of replication. Lytic reactivation plays a critical role in 
KSHV transmission and pathogenesis.  By understanding the molecular 
mechanisms regulating lytic replication we become better placed to develop 
therapeutic strategies for treatment of KSHV associated malignancies.  
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Chapter 2 
Materials and Methods 
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2 Materials and Methods 
2.1 Materials 
 
2.1.1 Chemicals 
Chemicals were obtained from Melford, Fisher Scientific and Sigma-Aldrich
®
 
unless stated otherwise. Sterilisation of solutions was achieved by 
autoclaving (121ºC, 30 minutes, 15psi) or by passing through 0.2 μm filters 
(Millipore). 
 
2.1.2 Enzymes 
All restriction enzymes were obtained from New England BioLabs. Other 
enzymes were sourced as in  table 2.1; 
 
Enzyme Supplier 
Taq DNA polymerase 
Invitrogen
TM
 Platinum
®
 Pfx DNA polymerase 
RNase OUT
TM
 
T4 DNA ligase 
New England BioLabs Inc. 
M-MuLV Reverse Transcriptase 
Proteinase K 
Millipore 
RNase A 
DNA-free
TM
 DNase I treatment kit Ambion
®
 
DpnI Agilent Technologies 
SensiMix SYBR  Bioline 
Table 2.1 List of enzymes and their suppliers.  
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2.1.3 Antibodies 
All primary antibodies were obtained from suppliers as indicated in table 2.2. 
Secondary HRP conjugated anti-mouse and anti-rabbit were obtained from 
Dako and used at 1:1000 working concentration for Western blotting. Alexa-
Fluor
®
 conjugated anti-mouse and anti-rabbit Immunoglobulin G (IgG) 
antibodies were supplied by Invitrogen
TM
 and used for immunofluorescence 
microscopy. 
 
Antibody Origin 
Working concentration 
Supplier 
WB IF ChIP 
Anti-LaminB Mouse 1:1000 - - Calbiochem 
Anti-B23 Mouse - 1:200 - 
Santa Cruz 
biotechnology Inc. 
Anti-RNA polymerase II Rabbit - - 1:1000 Millipore 
Anti-GFP Mouse 1:5000 - - 
Clontech 
Anti-GFP  Rabbit - - 1:500 
Anti-RTA Rabbit 1:500 - - 
David Blackbourn, 
University of 
Birmingham 
Anti-Myc Mouse 1:5000 1:200 - 
Sigma-Aldrich
®
 Anti-Myc Rabbit - - 1:200 
Anti-FLAG Rabbit 1:2500 1:200 - 
Anti-GAPDH Mouse 1:5000 - - 
AbCam
®
 
Anti-ORF8 Rabbit 1:1000 - - 
Anti-Hey1 Rabbit 1:1000 - - 
Anti-ARID3B Rabbit 1:1000 1:100 1:100 
Anti-SUMO2 Rabbit 1:1000 - - 
Anti-RBM14 Rabbit 1:1000 1:100 - GeneTex 
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Anti-YBX1 Rabbit 1:1000 1:200 - 
Anti-hnRNPUL1 Rabbit 1:1000 1:200 - 
Anti-RNMT Rabbit 1:1000 - - 
Anti-hnRNPAB1 Rabbit 1:1000 - - 
Anti-AUF1 Rabbit 1:1000 1:200 - 
Anti-HP1γ Rabbit 1:1000 1:500 - 
Anti-DDX3X Rabbit 1:1000 - - 
Anti-PYCR Rabbit - 1:100 - 
Anti-TCP Rabbit 1:1000 - - 
Table 2.2 List of antibodies, their dilutions for various applications and 
suppliers. 
 
2.1.4 Cell culture reagents 
Cell culture media, selection antibiotics and transfection reagents were 
supplied as shown in table 2.3. 
 
Reagent Supplier 
Zeocin
TM
 InvivoGen 
Puromycin dihydrochloride Sigma-Aldrich
®
 
Isotope labelled DMEM  
Dundee cell products 
Dialysed foetal calf serum 
DMEM  
Lonza 
TC100 Insect Medium  
Hygromycin B 
Invitrogen
TM
 
Lipofectamine 2000
TM
 
RPMI 
foetal calf serum 
penicillin-streptomycin 
Table 2.3 List of cell culture reagents and their suppliers. 
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2.1.5 Oligonucleotides 
All primers used are shown in table 2.4 and were purchased from Sigma-
Aldrich
®
. 
 
Primer Application Sequence (5’-3’) 
SIM 1 
Site-directed 
mutagenesis 
F 
GCCCAACTCTACCAGTGTGCGGCCGCTATAAATGACG
CATACGAAACAATC 
R 
GATTGTTTCGTATGCGTCATTTATAGCGGCCGCACAC
TGGTAGAGTTGGGC 
SIM 2 
Site-directed 
mutagenesis 
F 
GCATCCCAAGGCATTATTCGGGCCGCCACGGAGAGG
ATCTTATTC   
R 
GAATAAGATCCTCTCCGTGGCGGCCCGAATAATGCCT
TGGGATGC 
SIM 3 
Site-directed 
mutagenesis 
F 
CAGTCCAGGGCCCTCTGCGCGGCGGTTTTCCAACCG
GTC 
R 
GACCGGTTGGAAAACCGCCGCGCAGAGGGCCCTGG
ACTG 
pET-21b-
Hey1 
Site-directed 
mutagenesis 
F GTGAATTCAAAGCGAGCTCACCCCGAG  
R GTAAGCTTAAAAAGCTCCGATCTCCGTCC 
RTA-
His/FLAG 
Cloning 
F 
ATCTCGAGTCACTTGTCATCGTCATCTTTATAATCATG
ATGATGATGATGATGGTCTCGGAAGTAATTACGCCA 
R 
ATCTTAAGGCCACCATGGCGCAAGATGACAAGGGTAA
G 
vIL6 qPCR (ChIP) 
F GCGAGAGAAACACGTCACAGGCAA 
R GGTCATCGGGGGTGGGAACTTGTA 
Ori-Lyt qPCR (ChIP) 
F ACGGGCCTGGAATCTCGCCTCTGG 
R ATGGGCGTAACCGTAGGACAAGCTG 
ORF45 qPCR (ChIP) 
F GGCGTCCATGGGATGGGTTAGTCAGGAT 
R ACGTCCGGAGAGTTGGAACTGTCATCGC 
Gp64 qPCR F ATGAGCAGACACGCAGCTTTT 
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R AAAAGCTGCGTGTCTGCTCAT 
GAPDH qRT-PCR  
F TGTGGTCATGAGTCCTTCCACGAT 
R AGGGTCATCATCTCTGCCCCCTC 
ARID qRT-PCR 
F TTCAGCATGGCACGGCAGCTC 
R GCAAACAGCACACCTGCATAGG 
Table 2.4 List of all primers and their applications. 
 
2.1.6 Plasmid constructs 
Plasmid constructs supplied by other laboratories are listed in table 2.5. 
 
Plasmid Source 
pHey1-Myc  Manfred Gessler, University of Wuerzburg, Germany. 
pRTA 
Gary Hayward, John Hopkins University, USA. 
pRTA
H145L
 
shUbc9 Chris Boutell, University of Glasgow, UK. 
pRBM14-FLAG Lan Ko, Medical College of Georgia, USA 
Table 2.5 List of constructs and their origin. 
 
2.2 Methods 
 
2.2.1 Molecular cloning 
 
2.2.1.1 Construction of recombinant vectors 
DNA was PCR amplified (section 2.2.1.2), gel purified (section 2.2.1.4) and 
ligated into a linearised parent vector (section 2.2.1.6). Plasmids were then 
sequenced (section 2.2.1.10) to confirm insertion of desired PCR products. 
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Table 2.6 gives a list of primers, enzymes and parent vectors used in 
creation of new constructs. 
 
Recombinant 
vector 
Parent 
vector 
Primer  
Restriction 
Enzyme 
Primer Sequence (5’-3’) 
pRTA-
His/FLAG and  
pH145L-
His/FLAG 
pcDNA5-
FRT/TO 
RTA-
His/FLAG 
(F) 
AflII 
ATCTCGAGTCACTTGTCATCG
TCATCTTTATAATCATGATGAT
GATGATGATGGTCTCGGAAG
TAATTACGCCA 
RTA-
His/FLAG 
(R) 
XhoI 
ATCTTAAGGCCACCATGGCG
CAAGATGACAAGGGTAAG 
Table 2.6 List of recombinant vectors and the primers, enzymes and parent 
vectors used in their construction. 
 
2.2.1.2 Polymerase chain reaction (PCR)  
 
2.2.1.2.1 cDNA amplification 
PCRs were performed in 0.2 ml PCR tubes (Axygen), using a TC-412 
thermal cycler (Techne
TM
). Reactions were set up as follows using Platinum
®
 
Pfx (Invitrogen
TM
): 
 
1x Reaction buffer   
1 mM MgSO4   
1-10 ng DNA template     
200 nM Reverse primer     
200 nM Forward primer     
200 µM dNTP mix  
2.5 U Platinum
®
 Pfx     
nuclease free water  up to 50µl (molecular biology grade, Sigma-Aldrich
®
) 
 
A typical PCR amplification was performed with a denaturing step at 95°C for  
2 minutes, followed by 35 cycles of denaturing at 95°C for 30 seconds, 
annealing at 55ºC for 30 seconds, extension at 68ºC for 1 minute per Kb and 
a final extension of 68ºC for 10 minutes. After PCR amplification products 
were analysed by agarose gel electrophoresis (Section 2.2.2.3). 
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2.2.1.2.2 Site-directed mutagenesis 
PCR reactions were set up as follows using the QuikChange II Site-Directed 
Mutagenesis Kit  (Agilent technologies): 
 
1x Reaction buffer     
5-50 ng DNA template     
200 nM Reverse primer     
200 nM Forward primer     
200 µM dNTP mix  
2.5 U PFU polymerase     
nuclease free water  up to 50 µl 
 
A PCR reaction was then carried out with a denaturing step at 95°C for 30 
seconds, followed by 18 cycles of denaturing at 95°C for 30 seconds, 
annealing at 55ºC for 1 minute, extension at 68ºC for 1 minute and a final 
extension of 68ºC for 20 minutes. PCR products were treated with 10 U DpnI 
for 2-4 hours at 37ºC, before transformation of XLI Blue Supercompetent 
cells (section 2.2.1.8). 
 
2.2.1.3 Agarose gel electrophoresis 
DNA samples were mixed with an appropriate volume of 10x loading buffer 
[30% (v/v) glycerol, 0.25% (w/v) Orange G] and 10 µl of each sample was 
loaded onto a 1% (w/v) agarose gel in TBE [2 mM EDTA, 80 mM boric acid, 
90 mM Tris-base] containing 0.5 µg/ml ethidium bromide, alongside a 100 bp 
or 1 kb DNA ladder (Invitrogen
TM
). Electrophoresis was performed in HE 99X 
Max horizontal electrophoresis tanks (Hoefer), in TBE buffer at 100V and 
bands were visualised under UV using the GeneGenius bio-imaging system. 
For Pulse field agarose gel electrophoresis a 1.2% (w/v) pulse field agarose 
gel was made up in 0.5x TBE. This was run for 16 hours at 6V with initial 
switch 2 seconds and final switch 16 seconds. The gel was then stained in 
0.5 µg/ml ethidium bromide solution and de-stained in distilled water (dH20). 
 
2.2.1.4 Purification of DNA from agarose gels  
DNA fragments were excised from agarose gels and extraction performed 
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using QIAquick gel extraction kit (QIAGEN), following the manufacturer ’s 
protocol. Briefly, the excised fragment was weighed and three volumes of 
buffer QG added, prior to incubation at 50°C for 10 minutes. One gel volume 
of isopropanol was added and the mixture applied to a QIAquick spin 
column.  Columns were centrifuged for 1 minute at 13,000 rpm in a 
Eppendorf 5415 R microcentrifuge and the flow-through discarded. This 
centrifugation step, with disposal of flow-through, was repeated a further 
three times with 0.5 ml buffer QG, 0.75 ml buffer PE and no buffer. The 
column was then placed into a fresh microcentrifuge tube and DNA eluted by 
addition of 50 µl buffer EB with centrifugation for 1 minute at 13,000 rpm. 
DNA was stored at -20°C. 
 
2.2.1.5 Restriction enzyme digestion 
Restriction digests were carried out following the manufacturer’s instructions 
in a total volume of 20 µl. Approximately 1 U of enzyme was added per µg of 
DNA and incubated at 37ºC for 2 hours with a compatible buffer. Double 
digests were performed simultaneously in a compatible buffer if possible, 
alternatively sequential digests were performed with enzymes in separate 
buffers. Reactions were stopped by heat inactivation for 20 minutes at 65°C.  
 
2.2.1.6 DNA ligation  
Ligation reactions were set up in of a total of 20 µl containing 1x ligase buffer 
[50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, (pH 7.5)], 1 U  T4 
DNA ligase (New England Biolabs), 100 ng of linearised vector and varying 
molar ratios of insert DNA fragments. Reactions were performed at 16ºC for 
a minimum of 1 hour. 
 
2.2.1.7 Preparation of chemically competent E.coli DH5α 
All products were cloned in Escherichia coli (E.coli) strain DH5α 
(Genotype:F
-
, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-,mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1). Liquid cultures 
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were propagated in sterile Luria broth (LB) [1% (w/v) tryptone, 0.5% (w/v) 
NaCl, 0.5% (w/v) yeast extract, (pH 7.5)], shaking at 37°C. If necessary, 
colonies were grown on LB agar (LB with 1.5% agar) at 37°C. 
Chemically competent E.coli cultures were produced via a rubidium chloride 
based method. DH5α cells were streaked onto LB agar plates and incubated 
at 37°C. A single colony was picked and used to inoculate 2 ml of LB media, 
which was then shaken at 37°C for 5-7 hours. 0.5 ml of this culture was then 
used to inoculate 50 ml LB media, with cells shaken at 37°C until they 
reached an OD600 of 0.3-0.6. Cells were pelleted by centrifugation at 5,000 
rpm for 5 minutes at 4°C. The pellet was resuspended in 40 ml sterile chilled 
TBFB1 buffer [30 mM KOAc, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 
15% (v/v) glycerol, adjusted to pH 5.8 with acetic acid] and incubated at 4°C 
for 5 minutes. The cells were pelleted at 5,000 rpm for 5 minutes at 4°C and 
resuspended gently in 2 ml ice-cold sterile TFB2 buffer [10 mM MOPS, 75 
mM CaCl2, 10 mM RbCl, 15% (v/v) glycerol, adjusted to pH6.4 with KOH], 
followed by incubation on ice for 15-60 minutes. Cells were aliquoted and 
quick-frozen on dry ice, before storage at -80°C. 
 
2.2.1.8 Transforming chemically competent bacteria  
50 µl aliquots of chemically competent bacteria (DH5α, BL21 or XLI Blue 
Supercompetent cells) were thawed on ice and incubated with approximately 
100 ng of DNA at 4°C for 30 minutes. Cells were then heat shocked at 42°C 
for 30-60 seconds and incubated on ice for a further 2 minutes. 200 µl of LB 
was then added to each transformation reaction and shaken for 1 hour at 
37°C. The bacteria were then plated onto LB agar plates, containing 
appropriate selective antibiotics (either ampicillin or kanamycin at 50 µg/ml) 
and left for 16-20 hours at 37°C. 
 
2.2.1.9 Plasmid purification 
 
2.2.1.9.1 Small scale plasmid purification  
Single colonies from LB-Agar plates were used to inoculate 3 ml LB, 
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containing an appropriate selective antibiotic, and shaken overnight at 37ºC. 
Bacteria were pelleted by centrifugation of 1.5 ml culture for 1 minute at 
13,000 rpm and the supernatant removed by aspiration. The pellet was 
resuspended in 100 µl ice-cold resuspension buffer [50 mM glucose, 25 mM 
Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 100 µg/ml RNase A], followed by 
addition of 200 µl lysis buffer [0.2 M NaOH, 1% (w/v) SDS] and 150 µl ice-
cold neutralisation buffer [30% (v/v) glacial acetic acid, 5 M potassium 
acetate], with gentle mixing. The suspension was incubated on ice for 5 
minutes before centrifugation for 10 minutes at 12,000 rpm, 4 ºC and the 
supernatant was transferred to a fresh microcentrifuge tube. An equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the 
lysate and centrifuged for 2 minutes at 12,000 rpm, 4ºC. The upper aqueous 
phase was then transferred to a fresh tube and 900 μl isopropanol added, 
vortexed and left at room temperature for 2 minutes. Samples were then 
centrifuged for 5 minutes at 12,000 rpm, 4ºC, the supernatant was discarded 
and the pellet allowed to air dry. Resulting DNA was washed twice with 1 ml 
ice-cold 70% ethanol for 5 minutes at 12,000 rpm, 4 ºC. The pellet was 
finally dissolved in 40 μl nuclease free water containing 20 μg/ml RNase A 
and stored at -20ºC.  
 
2.2.1.9.2 Large scale plasmid purification  
Large scale plasmid purification was carried out using a QIAGEN plasmid 
maxi kit and a modified version of the manufacturer’s protocol. A starter 
culture was used to inoculate 200 ml LB, containing appropriate selective 
antibiotics  and shaken for approximately 16 hours at 37°C. The bacterial 
suspension was pelleted in 50 ml aliquots for 20 minutes at 4,500 rpm, 4ºC 
using an Eppendorf 5810R centrifuge. Cells were resuspended in a total 
volume of 10 ml ice-cold buffer P1 [50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 
100 µg/ml RNase A] prior to addition of 10 ml buffer P2 [200 mM NaOH, 1% 
SDS] with mixing. Samples were incubated for 5 minutes at room 
temperature before addition of 10 ml ice-cold buffer P3 [3 M potassium 
acetate, pH 5.5] with mixing and placed on ice for 20 minutes. Lysates were 
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cleared by centrifugation for 15 minutes at 4,500 rpm, 4ºC and then applied 
to a QIAGEN-tip 500 column, pre-equilibrated with 10 ml buffer QBT [750 
mM NaCl, 50 mM MOPS (pH 7.0), 15% (v/v) isopropanol, 0.15% (v/v) Triton 
X-100]. Once the lysate had passed through the resin by gravity flow, 
columns were washed twice with 30 ml buffer QC [1 M NaCl, 50 mM MOPS 
(pH 7.0), 15% (v/v) isopropanol] before elution of DNA with 15 ml buffer QF 
[1.25 M NaCl, 50 mM Tris-HCl (pH 8.5), 15% (v/v) isopropanol]. The eluted 
DNA was mixed with 10.5 ml isopropanol and centrifuged for 30 minutes at 
4,500 rpm, 4ºC. The resulting DNA pellet was washed with 1.5 ml 70% 
ethanol for 10 minutes at 13,000 rpm, 4ºC. The ethanol wash was aspirated 
and the pellet air dried prior to resuspension in 200 μl of nuclease free water. 
The DNA concentration was determined by absorbance at 260 nm, using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) and 
stored at -20 ºC. 
 
2.2.1.9.3 Bacmid purification 
Isolation of bacmid DNA from DH10Bac (Invitrogen
TM
) was carried out using 
a modified version of plasmid maxi kit (QIAGEN) manufacturer’s protocol. A 
DH10Bac starter culture was used to inoculate 1 litre of LB and grown 
overnight on a shaker at 37ºC. Bacteria were harvested by centrifugation 
(Sorvall RC5B plus) at 6,000 rpm for 15 minutes and the pellet resuspended 
in 10 ml P1  [50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 ug/ml RNase A] 
per 500 ml of culture, followed by addition of 12 ml buffer P2 [200 mM 
NaOH, 1% SDS]. The sample was then incubated on a roller for 20 minutes 
at 4ºC, before 12 ml buffer P3 [3 M potassium acetate, pH 5.5] was added 
and rotated for a further 10 minutes. The resulting lysate was left on ice for 
30 minutes followed by centrifugation at 12,000 rpm for 30 minutes, 4ºC. 
The supernatant was then gauze filtered and further centrifuged for 15 
minutes at 5,000 rpm, 4ºC followed by addition of 15 ml isopropanol. 
Samples were incubated on ice for 30 minutes prior to harvesting of DNA 
pellet by centrifugatiion for 30 minutes at 5,000 rpm, 4ºC. DNA was then 
gently resuspended in 0.5 ml TE [10 mM Tris-HCl (pH 8.0), 1 mM EDTA] and 
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4.5 ml buffer QBT [750 mM NaCl, 50 mM MOPS (pH 7.0), 15% (v/v) 
isopropanol, 0.15% (v/v) Triton X-100]. The QIAGEN-tip 500 column was 
equilibrated with 12 ml Buffer QBT  and both samples, each from 500 ml 
culture, applied to the column. The column was then washed with two 20 ml 
aliquots of buffer QC [1 M NaCl, 50 mM MOPS (pH 7.0), 15% (v/v) 
isopropanol] before the DNA was eluted with 20 ml buffer QF [1.25 M NaCl, 
50 mM Tris-HCl (pH 8.5), 15% (v/v) isopropanol], which was pre-heated to 
65ºC. The eluate was then incubated with 30 ml isopropanol on ice for 30 
minutes and DNA harvested for 30 minutes at 5,000 rpm, 4ºC. The purified 
DNA was then washed with 1 ml 70% ethanol at 6,000 rpm, 4ºC for 10 
minutes, before allowing the pellet to air dry and resuspending in final 
volume of 100 µl TE. DNA was then stored at 4ºC.   
 
2.2.1.10 DNA sequencing 
Purified DNA was diluted to 50 ng/μl and sequenced by GATC biotech using 
either free universal primers or custom primers supplied at 10 pmol/µl. All 
sequence data was received in the form of Chromas chromatograms and the 
sequences were compared against an NCBI reference using the ClustalW 
online alignment program (Larkin et al., 2007). 
 
2.2.2 Cell culture 
 
2.2.2.1 Cell lines 
Human embryonic kidney (HEK) 293T cells were used for most transfection 
based experiments, however, for studies in the context of viral infection 
TREx BCBL-1 cells (Nakamura et al., 2003) or HEK 293T cells, harbouring 
latent recombinant rKSHV.219 (Vieira and O'Hearn, 2004), were employed. 
HeLa and SUMO2-His HeLa cell lines were used for lentivirus knockdown 
and immunoprecipitation experiments respectively. HEK 293 FlpIn cells were 
utilised for the production of inducible RTA (iRTA) and inducible 
RTA
H145L
(iH145L) cell lines required for SILAC investigations and their 
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subsequent validation. The non-mammalian Sf9 insect cell line was also 
used for the production of baculovirus. 
 
2.2.2.2 Cell maintenance 
Sf9 insect cells were grown in TC-100 medium containing 10% foetal calf 
serum (FCS) and 5 U/ml penicillin and streptomycin (complete TC-100) and 
passaged every 3-4 days. Fresh media was added to Sf9 monolayers which 
could then be resuspended by scraping and split 1:4 into fresh complete TC-
100.   
 
TREx BCBL-1 cells were propagated in RPMI medium containing 10% FCS 
and 5 U/ml penicillin and streptomycin (complete RPMI). These cells were 
grown in suspension and were split 1:4 into fresh complete RPMI containing  
10 µg/ml Hygromycin B every 3-4 days. 
 
All other cell lines were maintained in Dulbecco’s modified Eagles medium 
(DMEM) containing 10% FCS and 5 U/ml penicillin and streptomycin 
(complete DMEM), being passaged every 3-4 days. Confluent monolayers of 
293-based lines and were resuspended by a sharp force, whereas HeLa 
cells were removed by trypsinisation. These resulting suspensions were then 
split 1:20 into fresh complete DMEM. SUMO2-His HeLa and HEK 293T 
rKSHV.219 cells were maintained in complete DMEM containing 1 mg/ml 
puromycin. 293 FlpIn cells were maintained in complete DMEM containing 
10 µg/ml zeocin and iRTA and iH145L cells were maintained in complete 
DMEM containing 10 µg/ml Hygromycin B. For SILAC experiments complete 
DMEM was replaced with Dundee cell products DMEM equivalent, with 
labelled amino acids R0K0, R6K4 or R8K10 containing 10% dialysed FCS.  
 
For long-term storage, cells were resuspended at 1 x 10
6
 cells/ml in freezing 
medium [40% (v/v) cell culture medium, 50% (v/v) FCS, 10% (v/v) DMSO] 
and aliquoted into 1.8 ml CryoTubes
TM
 (NUNC
TM
). Tubes were then placed 
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in a freezing container (Nalgene
®
) at -80ºC for 24 hours, before being 
transferred to liquid nitrogen. 
 
2.2.2.3 Other cell culture 
 
2.2.2.3.1 Transient transfection 
Cell lines were set up in 6-well dishes (35mm diameter, Sigma-Aldrich
®
) 16-
20 hours prior to transfection to be at approximately 70% confluency at the 
time of transfection. Reactions were set up in two bijous, one containing 
plasmid DNA plus 250 µl DMEM (serum-free) and another containing 3 µl 
Lipofectamine 2000
TM
 per µg DNA plus 250 µl DMEM. The reactions were 
incubated at room temperature for 5 minutes before being mixed and then 
incubated for a further 20 minutes. The complete DMEM in the 6-well dishes 
was exchanged for serum free DMEM and transfection mixtures were 
pipetted gently onto the cell monolayer. Transfections were left at 37ºC for 5-
6 hours before replacing media with complete DMEM and returning cells to 
37ºC. Plasmids were expressed for 24-48 hours before harvesting of the cell 
pellet. For luciferase assays cells were seeded into 24-well plates (Sigma-
Aldrich
®
) and transfection volumes were scaled down accordingly. A 
maximum of 0.8 µg of DNA was diluted in 50 µl DMEM and 2 µl of 
Lipofectamine
TM
 2000 was diluted in a further 50 µl DMEM. The two 
solutions were mixed and added to the cells in the same way as described 
for 6-well plates.  
 
2.2.2.3.2 Production of inducible cell lines 
For creation of inducible cell lines 293 FlpIn cells, containing FRT integration 
sites, were utilised. These cells were co-transfected with pPGK/Flip/ObpA 
and either pRTA-His/FLAG or pH145L-His/FLAG at a ratio of 9:1 using 
varying amounts of DNA (section 2.2.2.3.1). At 48 hours post transfection 
cells were split into fresh 6-well dishes at 25% confluency and after 2-3 
hours 10 µg/ml Hygromycin B was added. Cells were cultured for several 
weeks replacing the selection medium every 3-4 days until visible colonies 
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had formed. Individual colonies were then gently washed from the plate and 
subjected to a 10 times serial dilution in complete DMEM in 24-well plates. 
Once cells had adhered, the lowest cell containing dilution per colony was 
selected and expanded in selection  medium into a 75 cm
3
 tissue culture 
vessel (Sigma-Aldrich
®
). Each clonal cell line was tested for gene expression 
through the addition of 2 µg/ml doxycycline hyclate (Invitrogen
TM
). Cells were 
harvested at 24 and 48 hours after induction with doxycycline and lystates 
subjected to SDS-PAGE (section 2.2.3.3) and Western blotting (section 
2.2.3.4)  
 
2.2.2.3.3 Baculovirus production 
To produce baculovirus infectious particles, purified bacmid was transfected 
into Sf9 cells (section 2.2.2.3.1) and the virus containing supernatant 
harvested after 72 hours. Cellular material was removed by centrifugation at 
1,700 rpm for 5 minutes. Baculovirus stocks were further amplified by 
infecting Sf9 cells with 1 ml virus and harvesting at 5 days post-infection. 
Viral stocks were stored at -80ºC. 
 
2.2.2.3.4 Lentivirus production 
At 16-20 hours prior to transfection 1.5 x 10
6
  HEK 293T cells were seeded 
into 60mm dishes in complete DMEM. Transfections were carried out as 
described in section 2.2.2.3.1 however, 10 µl of MISSION
®
 lentiviral 
packaging (Sigma-Aldrich
®
) was also added to the DNA mix containing 1 µg 
of shUbc9. Transfections were left at 37ºC for 5-6 hours before replacing the 
media with DMEM containing 30% FCS and 5 U/ml penicillin and 
streptomycin and returning cells to 37ºC. At 48 hours post-transfection 
media was removed, stored at 4ºC, and replaced with 4 ml DMEM containing 
30% FCS and 5 U/ml penicillin and streptomycin. At 72 hours post-
transfection media was removed, combined with that from the previous day 
and centrifuged for 5 minutes, 1,500 rpm at 4ºC. The virus containing 
supernatant was then filtered through a 0.45 µm filter and stored at -80ºC. 
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2.2.3 Preparation and Electrophoretic analysis of protein lysates 
 
2.2.3.1 Preparation of whole cell lysates 
Cells were washed in 1 ml PBS by centrifugation at 1,600 rpm for 5 mins and 
the pellet resuspended in 250 µl ice-cold RIPA buffer [50 mM Tris, 150 mM 
NaCl, 1% (v/v) NP40 (pH 7.6)] containing 1 x Complete
®
Protease Inhibitor 
EDTA free (Roche). Samples were incubated on ice for 30 minutes before 
centrifugation for 10 minutes at 12,000 rpm, 4 ºC. For SDS-PAGE analysis 
lysates were then mixed in equal volume with 2x solubilisation buffer [10 mM 
DTT, 2% (w/v) SDS, 20% (v/v) glycerol, 50 mM Tris-HCl (pH 6.8), 50 μg/ml 
bromophenol blue] and heated for 5 minutes at 95ºC. 
 
2.2.3.2 Nuclear-cytoplasmic fractionation for SILAC 
HEK 293T or iRTA cell lines were grown in appropriate SILAC media for 6 
passages, with five 175 cm
3
 tissue culture vesseles per experimental 
condition. Labelled HEK 293T cells were infected with baculovirus 
supernatant whereas iRTA cells were induced with 2 µg/ml doxycycline, for 
24 hours. Cells for each condition were then harvested and washed three 
times in PBS at 2,000 rpm for 5 minutes. The pellet was resuspended in 6 ml 
ice-cold buffer A [10 mM Hepes (pH7.9), 10 mM KCl, 1.5 mM MgCl2, 0.5 mM 
DTT] and incubated on ice for 5 minutes. The sample was then 
homogenised with a chilled Dounce homogeniser until >90% lysis was 
achieved and the pellet was collected at 1,100 rpm for 5 minutes at 4ºC. The 
cytoplasmic fraction was removed and the nuclei containing pellet was 
resuspended in 3 ml S1 [0.25 M sucrose, 10 mM MgCl2]. This was then 
carefully layered over 3 ml of solution S2 [0.35 M sucrose, 0.5 mM MgCl2] 
and centrifuged at 2,800 rpm for 5 minutes at 4ºC. The pellet was 
resuspended in 3 ml S2 prior to 15 cycles of 10 second sonication with 10 
second intervals on ice, leaving the nuclear fraction. The protein 
concentration of each sample was determined by BSA assay and fraction 
purity verified by SDS-PAGE (section 2.2.3.3) followed by Western blot 
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analysis (section 2.2.3.4). Equal amounts of protein from differentially 
labelled samples were mixed for both nuclear and cytoplasmic fractions, 
prior to resuspension in protein solubilising buffer [10 mM DTT, 2% (w/v) 
SDS, 20% (v/v) glycerol, 50 mM Tris-HCl (pH 6.8), 50 μg/ml bromophenol 
blue]. The samples were then sent to the Dundee proteomics facility where 
they were subject to SDS-PAGE prior to in-gel trypsin digestion and analysis 
by mass spectrometry. 
 
2.2.3.3 Tris-glycine SDS-PAGE 
Polyacrylamide gels were made up as in table 2.7, consisting of a resolving 
gel overlaid with a stacking gel. Protein samples boiled in solubilisation 
buffer were loaded onto an appropriate percentage polyacrylamide gel in 
addition to the BenchMark™ Pre-Stained Protein Ladder (Invitrogen
TM
). 
Electrophoresis was carried out in BioRad Mini-Protean Tetra System tanks 
containing tris-glycine running buffer [0.1% (w/v) SDS, 250 mM Tris-base, 
192 mM glycine], at 180V for approximately 45 minutes. Gels were then 
subject to Western blotting (section 2.2.3.4) or stained with Coomassie blue 
[50% (v/v) methanol, 10% (v/v) acetic acid, 0.05% (w/v) Brilliant Blue R-250] 
for 1 hour followed by destaining [50% (v/v) methanol, 10% (v/v) acetic acid]. 
 
 
 
 
Resolving Gel 
Stacking Gel 
8% 10% 12% 
dH2O 2.32ml 2.00 ml 1.65ml 1.70 ml 
30% Acrylamide 1.33ml 1.65 ml 2.00ml 0.42 ml 
1.5 M Tris-HCl (pH 8.8) 1.25 ml 1.25 ml 1.25 ml - 
1 M Tris-HCl (pH 6.8) - - - 0.32 ml 
10% (w/v) ammonium 
persulfate 
50 µl 50 µl 50 µl 25 µl 
10% (w/v) SDS 50 µl 50 µl 50 µl 25 µl 
TEMED 2 µl 2 µl 2 µl 2.5 µl 
Table 2.7  Reagents used for making various percentage SDS-polyacrylamide 
gels. 
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2.2.3.4 Western blotting 
Bio-Rad Mini-Protean 3 cell tanks were used to transfer proteins from SDS- 
polyacrylamide gels onto a Hybond-C nitrocellulose membrane (Amersham 
Biosciences) according to the manufacturer’s instructions. The 
polyacrylamide gel and nitrocellulose membrane were sandwiched together 
between four sheets of Whatman 3MM filter paper soaked in transfer buffer 
[20% (v/v) methanol, 25 mM Tris-base, 190 mM glycine] and placed in the 
Bio-Rad tank. The transfer was carried out at 100V for 1 hour in transfer 
buffer, before incubation of the membrane in 5% (w/v) dried milk in TBST 
[500 mM NaCl, 20 mM Tris, 0.1% (v/v) Tween-20] for a minimum of 1 hour. 
Blots were then incubated in primary antibody diluted in 5% (w/v) dried milk 
in TBST for a minimum of 1 hour (concentrations in table 2.2) and washed 
for three five minute intervals with TBST alone. The membrane was then 
transferred to a secondary antibody diluted 1:1000 in 5% (w/v) dried milk in 
TBST for 1 hour and again washed for three five minute intervals with TBST 
alone. All incubations were carried out on roller or rocking platform. The blots 
were then coated with EZ-ECLA and EZ-ECLB (Geneflow)  mixed at a 1:1 
ratio and incubated for 2 minutes before being visualised using Hyperfilm 
ECL™ (GE Healthcare) in a Konica SRX-101A developer. 
 
2.2.4 Analysis of protein-protein interactions 
 
2.2.4.1 His pull down assays 
The SUMO2-His HeLa cell line was transfected (section 2.2.2.3.1) with 
appropriate constructs for 24 hours before lysis in  5 ml of cell lysis buffer [6 
M Guanidinium-HCl, 10 mM Tris-HCl (pH 8.0), 100 mM sodium phosphate 
buffer (pH 8.0) ], with addition of 5 mM β-mercaptoethanol and 5 mM 
imidazole. This solution was then sonicated for 30 seconds and lysates 
centrifuged at 4,000 rpm for 15 minutes. The supernatant was then added to 
50 µl Ni-NTA beads (QIAGEN), which were pre-washed three times in 0.5 ml 
cell lysis buffer. The beads were rotated for 2 hours at 4ºC, before 
harvesting at 2,000 rpm for 2 minutes. Bead washes were carried out once 
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with 4 ml cell lysis buffer containing 5 mM β-mercaptoethanol and 0.1% (v/v) 
Triton X-100, once with 4 ml pH 8.0 wash buffer [8 M urea, 10 mM Tris-HCl, 
0.1% (v/v) Triton X-100, 5 mM β-mercaptoethanol, 100 mM sodium 
phosphate buffer (pH 8.0)] and three times with 4 ml pH 6.3 wash buffer [8 M 
urea, 10 mM Tris-HCl, 0.1% (v/v) Triton X-100, 5 mM β-mercaptoethanol, 
100 mM sodium phosphate buffer (pH 6.3)]. Finally the Ni-NTA beads were 
washed with 1.5 ml pH 6.3 wash buffer, prior to harvesting and resuspension 
in 25 µl 2x protein solubilising buffer [10 mM DTT, 2% (w/v) SDS, 20% (v/v) 
glycerol, 50 mM Tris-HCl (pH 6.8), 50 μg/ml bromophenol blue] and heated 
for 5 minutes at 95ºC. All steps were performed at room temperature unless 
stated otherwise. The precipitated polypeptides were resolved on an SDS–
polyacrylamide gel (section 2.2.3.3) and analysed  by immunoblotting 
(section 2.2.3.4). Protocol was adapted from Tatham et. al 2009 
 
2.2.4.2 FLAG pull down assays 
iRTA and 293 FlpIn cells were grow in 75 cm
3
 tissue culture flasks, with 
induction of RTA expression using  2 µg/ml doxycycline at approximately 
70% confluency. At 24 hours post induction one flask per cell line was 
washed in 10 ml PBS being centrifuged for 5 minutes at 1,600 rpm, then 
resuspended in 1 ml RIPA buffer [50 mM Tris, 150 mM NaCl, 1% (v/v) NP40 
(pH 7.6)] containing 1 x Complete
® 
Protease Inhibitor EDTA free. The 
suspensions were incubated on ice for 30 minutes prior to centrifugation for 
5 minutes at 12,000 rpm, 4°C and 40 µl input samples removed. Lysates 
were then transferred to microcentrifuge tubes containing 20 µl  anti-DDDDK 
tag antibody (Agarose) (Abcam), which were prewashed three times in 1 ml 
PBS. Samples were rotated for 1 hour at 4°C followed by centrifugation at 
1,000 x g for 5 minutes, 4 °C and removal of the supernatant. The agarose 
beads were then washed three times with 1 ml ice-cold PBS following 
centrifugation at 1,000x g for 5 minutes, 4 °C. Finally the beads and input 
samples were mixed with 40 µl 2x solubilisation buffer [10 mM DTT, 2% 
(w/v) SDS, 20% (v/v) glycerol, 50 mM Tris-HCl (pH 6.8), 50 μg/ml 
bromophenol blue] and heated for 5 minutes at 95ºC. Samples were 
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analysed by SDS-PAGE (section 2.2.3.3) followed by Western blot analysis 
(section 2.2.3.4). 
 
2.2.4.3 SILAC IP analysis 
iH145L, iRTA and 293 FlpIn cells were grown for 6 passages in R10K8, 
R6K4 and R0K0 complete DMEM, respectively. Three 75 cm
3
 tissue culture 
flasks of iRTA and iH145L cells were induced using 2 µg/ml doxycycline at 
approximately 70% confluency. At 24 hours post induction the DMEM was 
removed and the three flasks of each cell line combined in 10 ml PBS. 
Samples were centrifuged at 1,500 rpm for 5 minutes and resuspended in 10 
ml PBS before being counted in a haemocytometer. Equal numbers of cells 
from each cell line were then centrifuged at 1,500 rpm for 5 minutes prior to 
resuspension in 10 ml RIPA buffer [50 mM Tris, 150 mM NaCl, 1% (v/v) 
NP40 (pH 7.6)] containing 1 x Complete
® 
Protease Inhibitor EDTA free and 
rotated for 30 minutes at 4°C. Lysates were centrifuged for 10 minutes at 
12,000 rpm, 4°C and input samples taken. The 10 ml of cleared lysates were 
then transferred to tubes containing 60 µl anti-DDDDK tag antibody 
(Agarose) (Abcam), which were prewashed three times in 1 ml PBS. The 
samples were rotated for 1 hour at 4°C before being sedimented for 5 
minutes at 1,000 rpm, 4°C. Beads were then washed three times with 10 ml 
PBS, before being centrifuged for 5 minutes at 1,000 rpm, 4°C. The beads 
from each condition were combined in 1 ml PBS and again centrifuged for 5 
minutes at 1,000 rpm, 4°C. The washed beads were then resuspended in 60 
µl of NuPage LDS sample buffer (Invitrogen
TM
) and boiled for 5 minutes at 
95°C. Samples were centrifuged for 1 minute at 16,000 rpm and 45 µl of 
supernatant transferred to a fresh tube followed by addition of 5 µl of 10x 
NuPage sample reducing agent (Invitrogen
TM
). The sample was then sent to 
the University of Bristol where it was subject to SDS-PAGE prior to in-gel 
digestion and analysis by mass spectrometry. 
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2.2.5 In vitro SUMOylation assay 
In vitro SUMOylation assays were performed by David J. Hughes. For 
purification of recombinant proteins, BL21 cells were transformed and 
protein expression was induced in 100 ml mid-log cultures (OD600 0.6) by the 
addition of 0.1 mM IPTG followed by 5 hour incubation at 37°C. GST-
SAE1/2 was purified using Glutathione Sepharose 4B (GE Healthcare) and 
His-Ubc9, His-SUMO2-GG and Hey1-His were purified using Ni-NTA 
agarose (QIAGEN). PD MidiTrap G-25 columns (GE Healthcare) were used 
for sample clean-up and proteins were eluted in 50 mM Tris-HCl (pH 7.6), 5 
mM DTT and concentrated using Vivaspin columns (5000 MWCO; Sartorius 
Stedim Biotech). For in vitro SUMOylation assays, 10 µl reactions containing 
120 ng SAE1/2, 1 µg Ubc9, 2.5 µg SUMO2-GG, 2.5 µg substrate (Hey1 or 
IRF2), 5 mM MgCl2, 2 mM ATP, 50 mM Tris-HCl (pH 7.6) and 5 mM DTT 
were incubated for 3 hours at 37°C. For negative controls, ATP was omitted. 
Reactions were stopped by the addition of 10 µl protein solubilising buffer 
[10 mM DTT, 2% (w/v) SDS, 20% (v/v) glycerol, 50 mM Tris-HCl (pH 6.8), 50 
μg/ml bromophenol blue] and analysed by SDS-PAGE (section 2.2.3.3)  
followed by Coomassie blue staining and immunoblot analysis (section 
2.2.3.4). 
 
2.2.6 Analysis of protein-DNA interactions by Chromatin 
Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was carried out using the EZ
TM
-ChIP 
kit (Millipore) according to the manufacturer’s protocol. For ChIP using the 
HEK 293T cell line, cells were grown in 6 cm dishes (Sigma-Aldrich
®
), with 
three dishes per condition, and transfected as in section 2.2.2.3.1.  When 
using TREx BCBL-1 cells, 60 ml of suspension culture was grown in a 175 
cm
3
 tissue culture vessel (Sigma-Aldrich
®
)  and either reactivated with 2 
µg/ml doxycycline for 24 hours or left untreated.  
 
To prepare the necessary sheared chromatin, cells were treated with 1% 
formaldehyde for 10 minutes at room temperature before incubation with 1x 
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glycine for 5 minutes, to quench the reaction. Cells were then washed twice 
with 10 ml ice-cold PBS and resuspended in 1 ml PBS containing 1x 
protease inhibitor cocktail II. The cells were centrifuged for 3 minutes at 700 
rpm, 4°C and the pellet resuspended in 3.5 ml SDS lysis buffer [1% (w/v) 
SDS, 10 mM EDTA, 50 mM Tris, (pH 8.1)] containing 1x protease inhibitor 
cocktail II. The lysates were then sonicated at 4°C for a time optimised for 
each cell line  and insoluble material removed by centrifugation for 10 
minutes at 12,000 rpm, 4°C. To determine that sheared DNA was in the 
optimum size range of 200-1000 bp a 5 μl aliquot was removed and 
incubated with 90 μl of dH20 and 4 μl of 5 M NaCl for 4 hours at 65°C. 
Samples were then placed at 37°C for 30 minutes with addition of 1 μl of 
RNase A. 2 μl 0.5 M EDTA, 4 μl 1 M Tris-HCl and 1 μl Proteinase K were 
then added and samples incubated at 45°C for a further 2 hours. Chromatin 
was visualised on a 1% agarose gel under UV (section 2.2.1.3). If the 
sheared crosslinked chromatin was of the desired size range it could then be 
stored at -80°C for several months. 
 
For immunoprecipitation (IP) 100 μl of the prepared chromatin per IP was 
added to 900 μl of dilution buffer [0.01% (w/v) SDS, 1.1% Triton X-100, 1.2 
mM EDTA, 16.7 mM Tris-HCl, (pH 8.1), 167 mM NaCl.] containing 1x 
protease inhibitor cocktail II. The samples were then pre-cleared by rotation 
with 60 μl of Protein G agarose for 1 hour at 4°C. The agarose was pelleted 
by brief centrifugation for 1 minute at 4000 rpm and the supernatant 
transferred to a fresh microcentrifuge tube. A 10 μl input sample was 
removed before addition of immunoprecipitating antibodies with rotation 
overnight at 4°C. For each ChIP experiment a positive control anti-RNA 
Polymerase II and a negative control isotype matched IgG were used in 
addition to specific test antibodies (concentrations indicted in table 2.2). The 
following day 60 μl of Protein G Agarose was added to each IP and rotated 
for 1 hour at 4°C prior to brief centrifugation for 1 minute at 4000 rpm, 4°C 
and removal of the supernatant. The Protein G agarose-antibody/chromatin 
complex was washed by resuspension in 1 ml of the following ice-cold 
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buffers in order before centrifugation for 1 minute at 4000 rpm, 4°C and 
removal of the supernatant; 
 
1) 1x Low Salt Immune Complex Wash Buffer [0.1% (w/v) SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, (pH 8.1), 150 mM NaCl.] 
2) 1x High Salt Immune Complex Wash Buffer [0.1% (w/v) SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, (pH 8.1), 500 mM NaCl] 
3) 1x LiCl Immune Complex Wash Buffer [0.25 M LiCl, 1% IGEPAL 
CA630, 1% deoxycholic acid (sodium salt), 1 mM EDTA, 10 mM Tris, 
(pH 8.1)] 
4) 2x TE Buffer [10 mM Tris-HCl, pH 8.0, 1 mM EDTA] 
 
To elute the DNA/protein complexes 100 μl elution buffer [1% (w/v) SDS, 0.1 
M  NaHCO3] was added to the washed protein G and incubated at room 
temperature for 15 minutes prior to centrifugation for 1 minute at 4000 rpm, 
4°C. The supernatant was transferred to a fresh microcentrifuge tube and 
elution repeated with a further 100 μl buffer, giving a total volume of 200 μl. 
To the input tubes 200 μl of elution buffer was added directly. 
 
To free the complexed DNA from remaining protein, 8 μl of 5 M NaCl was 
added to each sample and incubated at 65°C for 4 hours, followed by 
incubation at 37°C for 30 minutes with 1 μl of RNase A. To each sample 4 μl 
0.5 M EDTA, 8 μl 1M Tris-HCl and 1 μl Proteinase K was then added and 
incubated at 45°C for a further 2 hours. To purify the DNA, 1 ml of bind 
reagent A was added to each tube and applied through a spin filter column 
in 600 μl aliquots with centrifugation for 30 seconds at 10,000 rpm. The flow-
through was discarded and 500 μl wash reagent B was applied to the 
column and centrifuged for 30 seconds at 10,000 rpm. The flow through was 
again discarded and the centrifugation step repeated prior to placing the 
column in a fresh microcentrifuge tube. Finally 50 μl of Elution Buffer C was 
placed onto the spin filter membrane and centrifuged for 30 seconds at 
10,000 rpm. The purified DNA could then be analysed by qPCR (section 
2.2.7.1.4) or stored at -20°C.  
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2.2.7 Analysis of gene expression 
 
2.2.7.1 Semi quantitative RT-PCR 
 
2.2.7.1.1 Extraction of RNA 
Cells were harvested and washed in 1 ml PBS at 1,600 rpm for 5 minutes. 
The pellet was then resuspended in 1 ml TRIzol
®
 (Invitrogen
TM
) and 
incubated at room temperature for 5 minutes, followed by the addition of 200 
µl chloroform. The suspension was vortexed for 15 seconds, incubated for a 
further 2 minutes at room temperature, and then centrifuged for 10 minutes, 
12,000 rpm at 4°C. The upper aqueous phase was transferred to a fresh 
RNase free tube (Axygen) and RNA precipitated by the addition of 500 µl 
isopropanol and incubated at room temperature for 5 minutes. Samples 
were centrifuged for 10 minutes at 12,000 rpm, 4°C and the supernatant 
aspirated. The pellet was washed with 1 ml 75% ethanol and centrifuged for 
a further 5 minutes, 7,500 rpm at 4°C. The supernatant was again aspirated 
and the pellet air dried before being resuspended in 16 µl of nuclease free 
water and dissolved at 57°C for 10 minutes. 
 
2.2.7.1.2 DNase treatment 
The Ambion DNase I kit was used to remove any contaminating DNA from 
RNA samples. Briefly, 0.1 volumes of 10x DNase buffer [100 mM Tris-HCl 
(pH 7.5), 25 mM MgCl2, 5 mM CaCl2] and 1 µl of DNase I were added to 16 
µl of RNA and incubated at 37°C for 20 minutes. 0.1 volumes of inactivation 
reagent was then added and incubated at room temperature for 2 minutes 
before centrifugation at 10,000 rpm for 90 seconds. The supernatant was 
transferred to a fresh RNase free tube and stored at -80°C. 
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2.2.7.1.3 Reverse transcription 
For reverse transcription the extracted RNA was diluted to 50 ng/µl in 
nuclease free water and each reaction was set up in duplicate as below; 
 
RNA (50 ng/µl)     10 µl 
Oligo(dT)12-18 (500 µg/ml)     1 µl                                             
dNTP mix (2.5 mM/dNTP)     1 µl     
 
The mixture was then heated to 65°C for 5 minutes before a quick chill on 
ice. The New England Biolabs M-MuLV reverse transcriptase was used for 
production of cDNA with addition of the remaining components; 
 
5x M-MuLV Reverse Transcriptase Reaction Buffer  4 µl                                                    
[50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, (pH 8.3)] 
0.1 M DTT        2 µl                                         
RNaseOUT
TM
 (40 U/µl)       1 µl                                       
 
To tube 1. M-MuLV Reverse Transcriptase    1 µl 
To tube 2. nuclease free water (negative RT control)  1 µl 
 
The reactions were then incubated at 42°C for 50 minutes prior to heat 
inactivation for 20 minutes at 65°C. cDNA could then be stored at -20°C. 
 
2.2.7.1.4 qPCR 
qPCR reactions were carried out using SensiMix™ SYBR No-ROX Kit 
(Bioline) in a Rotor-Gene 6000 Real-Time PCR machine (Corbett Life 
Science). Reactions were set up in 0.1ml strip tubes (QIAGEN) as follows; 
 
cDNA     5 µl 
5 µM Reverse primer  1 µl 
5 µM Forward primer  1 µl 
2x Sensimix     12.5 µl 
Nuclease free water  5.5 µl 
Final volume    25 µl 
 
The cycling parameters were set to 95ºC for 10 minutes, followed by 40 
cycles of: 95ºC, 15 seconds; 60ºC, 30 seconds; 72ºC, 20 seconds. The 
machine was set to acquire data during the extension step of each cycle. 
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Test primer sets were normalised to GAPDH levels and data was analysed 
using the Rotor-Gene 6000 Series Software Version 1.7 
 
2.2.7.2 Luciferase assays 
For dual luciferase assays, transfections were carried out in triplicate as 
described in section 2.2.3.1. Minimal transfection requirments included the 
vIL6 reporter construct transfected alongside 10 ng of the renilla control 
plasmid, pRL-TK. The total DNA was kept constant using appropriate 
backbone vectors. Luciferase activity was detected using the Dual-
Luciferase
®
 Reporter Assay System (Promega) according to the 
manufacturer’s protocol. Typically, at 24 hours post transfection media was 
removed from the plates and cells washed gently with 100 µl PBS, before 
addition of 100 µl 1x passive lysis buffer to the cell monolayer. Plates were 
rocked for 15 minutes at room temperature and 20 µl of each lysate was 
then transferred to one well of a 96-well plate (Greiner Bio-one Ltd). 
Luciferase measurements were carried out in a FLUOstar Optima microplate 
reader (BMG Labtech Ltd) according to the manufacturer’s protocol, with 
injectors 1 and 2 being used to dispense 50 µl of Luciferase Assay Reagent 
II and Stop & Glo
®
 Reagent respectively. For single luciferase assays 
Luciferase Assay Reagent II alone was used. 
 
2.2.7.3 Knockdown of gene expression 
 
2.2.7.3.1  siRNA transfection 
Specific and scramble siRNAs were transfected into HEK 293T based cells 
as in section 2.2.2.3.1. Varying amounts of siRNA were transfected, ranging 
from 5 to 50 pmol for SUMO2 specific siRNA (ABgene) and 1 to 25 nmol for 
ARID3B specific siRNA (Qiagen). At 24 and 48 hours post-transfection the 
cells were harvested and knockdown was analysed by SDS-PAGE (section 
2.2.3.3) followed by Western blot analysis (section 2.2.3.4). 
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2.2.7.3.2  Lentivirus transduction 
For infection with shUbc9-lentivirus, 1 x 10
6
 HeLa cells were seeded into 60 
mm dishes, 16-20 hours before infection. Cells were infected with 1 ml virus 
supernatant per dish plus 1 ug/ml  polybrene for 1 hour with periodic shaking 
before addition of a further 3 ml of virus. At 24 hours post infection the media 
was replaced with complete DMEM and at 30 hours post infection 2 µg/ml 
puromycin selection was added. Selection media was then replaced every 3-
4 days. 
 
2.2.8 Immunofluorescence microscopy 
 
2.2.8.1 Analysis of protein localisation 
Coverslips were washed in 100% ethanol and air dried in 6-well dishes for 5 
minutes prior to a 5 minute incubation with poly-L-lysine (Sigma-Aldrich
®
). 
The poly-L-lysine was then removed, the coverslips washed with PBS and 
air dried for a minimum of 3 hours. Cells were seeded onto poly-L-lysine-
treated coverslips 16-20 hours before transfection or induction. Once cells 
were ready for staining they were fixed in 4% (v/v) paraformaldehyde and 
permeabilized in 1% (v/v) Triton X-100 for 15 minutes each, with three PBS 
washes after each incubation. Bovine serum albumin (BSA) made up to 1% 
in PBS was used as a blocking agent and incubated with the cells at 37°C 
for 1 hour. The coverslips were then transferred to a humidity chamber (a 
Petri dish lined with parafilm, containing soaked filter paper to prevent cells 
drying out) and incubated with a primary antibody in 1% BSA  (concentrations 
indicated in table 2.2) for 1 hour at 37°C, followed by five PBS washes. A 
secondary Alexa Flour
® antibody was diluted 1:500 in 1% BSA and incubated 
with the cells for 1 hour at 37°C, again followed by five PBS washes. 
Coverslips were mounted in VECTASHIELD® DAPI containing mounting 
medium (Vector Laboratories), and staining was visualized on an Upright 
LSM 510 META Axioplan 2 confocal microscope (Zeiss) using LSM imaging 
software (Zeiss). For GFP expressing cells only, the protocol was carried out 
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without the primary and secondary antibody incubation steps. All steps were 
carried out at room temperature unless otherwise stated. 
 
2.2.8.2 EdU assay 
Cells were labelled and stained using the Click-iT® EdU Alexa Fluor® 647 
Imaging Kit (Invitrogen
TM
) according to the manufacturer’s instructions. TREx 
BCBL-1 cells were seeded onto poly-L-lysine treated coverslips (prepared as 
in section 2.2.8.1) prior to induction with 2 µg/ml doxycycline and incubated 
at 37°C for 16 hours. At 45 minutes prior to fixation 10 µM EdU (5-ethynyl-2´-
deoxyuridine) was added to each well. At 16 hours cells were then fixed in 
4% (v/v) paraformaldehyde and permeabilized in 0.5% (v/v) Triton
 
X-100 for 
15 minutes each, with three washes using 3% BSA in PBS after each 
incubation. The Click-iT® reaction cocktail was then made up as below and 
0.5 ml placed on each coverslip for 30 minutes, protected from light 
exposure; 
 
1x Click-iT® reaction buffer   430 µl 
CuSO4 (100 mM)    20 µl 
Alexa Flour® azide     1.2 µl 
Reaction buffer additive    50 µl 
 
The coverslips were washed once with 3% BSA before being transferred to a 
humidity chamber and incubated with a primary antibody in 1% BSA  
(concentrations indicated in table 2.2) for 1 hour at 37°C. Coverslips were 
then washed  five times in PBS before incubation with a secondary Alexa 
Fluor
® antibody, diluted 1:500 in 1% BSA for 1 hour at 37°C. This was again 
followed by five PBS washes, before coverslips were stained with 5 μg/mL of 
Hoechst 33342 for 30 minutes. Coverslips
 
were mounted in 
VECTASHIELD® mounting medium (Vector Laboratories),
 
and staining was 
visualized on an Upright LSM 510 META Axioplan 2 confocal microscope 
(Zeiss) using LSM imaging software (Zeiss). All coverslip incubations  
following permeabilization were performed protected from the light. 
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2.2.9 Analysis of KSHV reactivation 
 
2.2.9.1 Flow cytometry 
HEK 293T rKSHV.219 cells were seeded into 6-well dishes and 16-20 hours 
later were transfected with appropriate constructs (section 2.2.2.3.1). At 30 
hours post-transfection cells were collected in 1ml PBS, pelleted by 
centrifugation at 500 rpm and resuspended in 600 µl PBS. Cells were sorted 
using a BD-LSRFortessa flow-cytometer (BD Biosciences). 
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Chapter 3 
Investigating the possible SUMOylation Targeted Ubiquitin 
Ligase activity of RTA 
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3 Investigating the possible SUMOylation Targeted 
Ubiquitin Ligase activity of RTA  
 
3.1 Introduction 
The virally encoded RTA protein is necessary for the induction of KSHV lytic 
replication. RTA promotes reactivation by functioning as a transcriptional 
activator, binding to lytic gene promoters to upregulate gene expression. 
RTA can induce gene expression through both direct or indirect promoter 
binding, in conjunction with cellular factors. Additionally, RTA acts as an E3 
ubiquitin ligase, targeting transcriptional repressors for degradation by the 
proteasome. This function was first demonstrated against the cellular protein 
IRF7, which binds to and represses the ORF57 promoter (Yu et al., 2005). 
This ubiquitin ligase activity was attributed to a non-canonical Cys plus His-
rich region within RTA, unlike any previously described ubiquitin ligase 
domains. Moreover, point mutations within this region abolished RTA-
mediated degradation of IRF7.  Additional targets of RTA E3 ubiquitin ligase 
activity were identified as the cellular repressor proteins K-RBP (Yang et al., 
2008) and Hey1 (Gould et al., 2009). Moreover, RTA has been shown to 
downregulate Toll-interleukin-1 receptor domain-containing adaptor-inducing 
β-interferon (TRIF) (Ahmad et al., 2011), LANA and K-bZIP (Yang et al., 
2008) in a proteasome dependant manner. Thus RTA is able to promote exit 
from latency by transactivation of viral genes in a repressive environment. 
 
SUMOylation targeted ubiquitin ligases (STUbLs) represent a point of 
crosstalk between the SUMO and ubiquitin post-translational modification 
systems. These E3 ubiquitin ligases interact with SUMOylated target 
substrates via internal SUMO interaction motifs (SIMs) (Geoffroy and Hay, 
2009). SIM domains have the consensus sequence (V/I/L)-X-(V/I/L)-(V/I/L) 
(where V; valine, L; leucine, I; isoleucine) and interact non-covalently with 
substrate SUMO moieties (Song et al., 2004). This interaction assists target 
recognition, ubiquitin transfer and subsequent degradation. This chapter 
describes experiments to determine if RTA functions as a STUbL. To this 
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end potential SIM domains within RTA were identified by bioinformatic 
analysis and subjected to site-directed mutagenesis. The ability of these SIM 
mutants to degrade the Hey1 repressor was then assessed. The 
SUMOylation status of Hey1 was also investigated in both cell-based and 
cell free assays. Furthermore, the effects of SIM mutations upon other RTA 
functions, including lytic induction, transcriptional activation and DNA binding 
were characterised.  
 
3.2 Bioinformatic analysis reveals putative SIM domains 
within RTA 
To establish if RTA could have STUbL activity, the RTA amino acid 
sequence was examined for putative SUMO interaction motifs. The 
bioinformatics tool ScanProsite (de Castro et al., 2006) was used to identify 
hxhh and hhxh motifs (where h is valine, isoleucine or leucine and x is any 
amino acid). From this analysis three N-terminal SIM domains were selected 
for validation, the sequence and amino acid position of which are given in 
figure 3.1a. Each putative SIM domain was subjected to site-directed 
mutagenesis, substituting two or three SIM residues for alanine in a GFP-
RTA construct. Positive clones were subjected to small scale plasmid 
purification and digestion of recovered plasmid with PstI and BglII confirmed 
the presence of RTA (figure3.1b). Incorporation of the desired mutations was 
verified by DNA sequencing analysis. As STUbL substrates can be subject 
to poly-SUMOylation, it is likely that multiple SIM domains have an additive 
effect on substrate binding affinity. The SIM1/3 and SIM 2/3 double mutant 
combinations were therefore constructed by digestion of single mutants and 
ligation of a SIM 3 fragment with SIM 1 or SIM 2 vectors. Plasmid digestion 
with PstI and BglII confirmed the presence of RTA and DNA sequencing 
verified the inclusion of two mutant domains (figure3.1b). 
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a) 
 
 
Domain Amino acid 
position 
Wild Type Mutant 
SIM 1 99 VLLI AAAI 
SIM 2 111 IRIL IRAA 
SIM 3 196 LCLL LCAA 
b)  
 
Figure 3.1 Mutagenesis of three putative SIM domains within RTA.  
(a) The RTA peptide sequence was scanned for putative SIMs with the 
consensus motif hxhh or hhxh, where h is valine, leucine or isoleucine and x is 
any amino acid. The amino acid position in the table refers to the first amino 
acid of the given sequence. Three N-terminal SIM domains were subjected to 
site-directed mutagenesis, altering two or three motif residues as indicated. (b) 
SIM mutant plasmids were purified from transformed bacteria and digested with 
PstI and BglII. Agarose gel electrophoresis was used to visualise the excised 
RTA fragment (2.1 Kb) and pEGFP vector (4.7kb). Mutations were confirmed by 
DNA sequencing. 
 
Western blotting and immunofluorescence microscopy were then employed 
to determine if the generated SIM mutants expressed protein of the correct 
size and demonstrated the same cellular localisation as wild type RTA.  
293T cells were transfected with GFP, GFP-RTA or GFP-SIMs for 24 hours 
prior to cell lysis. Samples were analysed by SDS-PAGE followed by 
immunoblotting using a GFP specific antibody (figure 3.2a). All five SIM 
mutants were found to be expressed at the same molecular weight as wild 
type RTA. 293T cells were also seeded onto poly-L-lysine treated coverslips 
prior to transfection with GFP, GFP-RTA or GFP-SIMs. After 24 hours the 
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cells were fixed and GFP visualised by direct immunofluorescence. Figure 
3.2b demonstrates that RTA, the three single and two double SIM mutants 
localised to the nucleus and were all excluded from the nucleolus.  
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                      a) 
 
 
Figure 3.2 Expression of RTA and SIM mutants.  
(a) HEK 293T cells were transfected with GFP, GFP-RTA or GFP-SIMs for 24 
hours prior to cell lysis. Samples were analysed by Western blotting using a GFP-
specific antibody. (b) HEK 293T cells were seeded onto coverslips that were pre-
treated with Poly-L-lysine and transfected with GFP, GFP-RTA or GFP-SIMs. 
Nuclear heterochromatin was stained using DAPI (Blue), visualisation of GFP, GFP-
RTA and GFP-SIMs was via direct GFP fluorescence and shown in green. Scale 
bars represent a width of 10 µm. 
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3.3 RTA SIM mutants display reduced ubiquitin ligase 
activity against Hey1 
To investigate whether the selected SIM domains had any role in RTA 
ubiquitin ligase activity, SIM mutants were tested for their ability to degrade 
the Hey1 repressor protein. Previous work in the Whitehouse laboratory has 
demonstrated that Hey1 is targeted for proteasomal degradation by RTA, to 
remove repression from the ORF50 promoter (Gould et al., 2009). To assess 
SIM mutant activity, GFP, GFP-RTA or GFP-SIMs were co-transfected with 
Hey1-Myc into 293T cells. At 24 hours post-transfection the cells were 
harvested and resulting lysates subjected to SDS-PAGE followed by 
immunoblotting with GFP and Myc specific antibodies. A GAPDH specific 
antibody was also used to demonstrate equal loading. As shown in figure 
3.3a, levels of Hey1-Myc are dramatically reduced when transfected with 
RTA compared to the GFP control, suggesting RTA targets Hey1 for 
degradation. Mutation of the SIM 3 single mutant and both the SIM1/3 and 
SIM2/3 double mutants appeared to reduce the degradation capacity of RTA 
to variable extents, as highlighted by an increase in Hey1 protein levels.   
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To demonstrate the reproducibility of this effect, the degradation assay was 
repeated a further three times and quantified by densitometry. Image J 
software was used to quantify the levels of Hey1 with each mutant compared 
 
 
  
Figure 3.3 RTA SIM mutants show a reduced ability to degrade Hey-1.  
(a) HEK 293T cells were co-transfected with Hey1-Myc and either GFP, GFP-RTA 
or each GFP-SIM mutant. At 24 hours post-transfection cell lysates were harvested 
and analysed by immunoblotting, with levels of Hey1-Myc detected using a Myc-
specific antibody and levels of RTA or SIM mutants with a GFP-specific antibody. A 
GAPDH-specific antibody was used as a loading control. (b) The fold change in 
Hey1 levels was calculated for each SIM mutant when compared with wild type 
RTA.  Immunoblots were analysed using Image J software, an average was taken 
over four Western blots and standard deviation calculated. P values were 
determined for each SIM mutant compared to wild type RTA.  
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
RTA SIM 1 SIM 2 SIM 3 SIM 1/3 SIM 2/3
R
a
ti
o
 o
f 
H
e
y
1
 S
IM
 /
 H
e
y
1
 R
T
A
p=0.003 p=0.002 p=0.786 p=0.027 p=0.031 
- 100 - 
with wild type RTA and the average and standard deviation was calculated 
(figure 3.3b). From this data it appears that all of the SIM mutants except for 
SIM3, have a significant effect upon the ability of RTA to degrade Hey1. On 
average levels of Hey1 were 2.5-3.5 fold higher in the presence of  SIM1/3 
and SIM 2/3 double mutants compared with wild type RTA. This is consistent 
with these domains having a functional role in the ubiquitin ligase activity of 
RTA. As cellular proteins are often poly-SUMOylated, it is not surprising that 
mutation of multiple SIMs would have an additive phenotypic effect. It is 
feasible that each motif interacts with an individual SUMO chain moiety, 
acting in concert to increase substrate binding affinity. Interestingly, SIM 1 
and SIM 2 mutations increased the degradation of Hey1, although this effect 
remains to be explored. 
 
3.4 RTA SIM mutants reduce viral reactivation 
As SIM mutations appear to affect the ability of RTA to target Hey1 for 
proteasomal degradation, it was next determined if these mutations could 
affect RTA-mediated induction of lytic replication. In this study rKSHV.219 
HEK 293T cells were utilised, which contain the latent KSHV genome with 
an RFP reporter gene under control of the PAN promoter. Transfection of 
RTA into these cells is sufficient to induce lytic reactivation and the full 
cascade of viral gene expression (Vieira and O'Hearn, 2004). The ubiquitin 
ligase activity of RTA has previously been attributed to an internal Cys plus 
His-rich region (Yu et al., 2005). Point mutants within this region, including 
RTA
C131S
, RTA
C141S
 and RTA
H145L
, have been proven to prevent degradation 
of several RTA targets including IRF7 and Hey1 (Gould et al., 2009). The 
RTA
H145L
 mutant was therefore used to demonstrate the effect of an E3 
ubiquitin null phenotype in this assay.  
 
To assess reactivation capabilities the GFP-RTA, GFP-SIM and untagged 
H145L, plasmids were transfected into rKSHV.219 HEK 293T cells and left 
at 37°C for 30 hours. Different amounts of GFP-SIM plasmids were 
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transfected in an attempt to generate equal expression levels for a direct 
comparison. For SIM 1 and SIM 2, 2 µg of DNA was used compared with 4 
µg for SIM 3, 1/3 and 2/3. The amount of GFP-RTA transfected ranged from 
0.25 to 3 µg. The samples were then harvested and analysed by 
immunoblotting with GFP, gB and GAPDH specific antibodies. As gB is a 
KSHV late gene product, any reduction in levels of gB is indicative of 
reduced reactivation. Figure 3.4a demonstrates that increasing amounts of 
transfected RTA leads to increased levels of gB expression. Moreover the 
H145L mutant does not induce gB expression, illustrating the importance of 
RTA ubiquitin ligase function in viral reactivation.  As previously, mutation of 
SIM 1 does not affect RTA function, with levels of gB equal to that of wild 
type transfection. However SIM 2, SIM 3, SIM 1/3 and SIM 2/3 mutants show 
reduced levels of the gB protein, with this effect being more pronounced for 
the double mutants.   
 
To support this data, the effect of SIM mutants upon reactivation was also 
studied using the rKSHV.219 HEK 293T RFP reporter. Cells were 
transfected in the same manner as above and at 30 hours post-transfection 
cells were harvested and subjected to analysis by flow cytometry. The 
percentage of RFP expressing cells, and thus the lytic population, was 
recorded for each sample. This was repeated a further two times and the 
average percentage of RFP expressing cells and corresponding standard 
deviations were calculated. Similar to the immunoblot analysis, figure 3.4b 
demonstrates that RTA transfection can induce lytic replication but the 
H145L mutant is incapable of inducing viral gene expression. Mutation of 
SIM3, either singly or in combination with SIMs 1 or 2, reduced the ability of 
RTA to induce lytic reactivation. The SIM 3 single mutant reduced RFP 
levels by approximately 50% whereas transfection of double mutants 
produced negligible RFP signal. Taken together this suggests a functional, 
co-operative role for SIM domains 1-3 in RTA function.   
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Figure 3.4 SIM mutants show reduced ability to reactivate latent KSHV. 
(a) rKSHV.219 HEK 293T were transfected with either an untagged RTA ubiquitin 
ligase null mutant, RTA
H145L
, varying amounts of GFP-RTA or GFP-SIM mutants. 
For SIM 1 and SIM 2, 2 µg of DNA was transfected whereas for SIM 3, 1/3 and 2/3, 
4 µg of plasmid DNA was used. At 30 hours post transfection cells were harvested 
and analysed by Western blotting using GFP-specific and a gB-specific antibodies. 
Equal loading was judged using a GAPDH-specific antibody. (b) rKSHV.219 HEK 
293T were transfected as in (a) and after 30 hours were harvested and subject to 
flow cytometry analysis. The average percentage of RFP expressing cells was 
determined for each condition and standard deviation calculated. 
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3.5 Hey1 can be SUMO2 modified 
For Hey1 to represent a valid STUbL target it must be permissive for SUMO 
modification. Interestingly, the other targets of RTA-mediated degradation, 
IRF7 and K-bZIP, have been shown to be SUMOylated, but to date this has 
not been investigated for Hey1 (Izumiya et al., 2005; Kubota et al., 2008).  
To determine if Hey1 is SUMOylated in cell culture, HeLa cells which stably 
express a His tagged SUMO-2 were utilised. The Hey1-Myc and the 
negative control ORF57-Myc constructs were transfected into SUMO2-His 
HeLa cells and left at 37°C for 24 hours. The cells were then lysed and 
nickel beads used to pull-down His-SUMO2 and any associated proteins. 
The precipitated proteins were subject to SDS-PAGE followed by 
immunoblotting with a Myc specific antibody. As seen in figure 3.5a ORF57 
and Hey1 protein expression can be detected in the input transfected cells 
however only Hey1 is visible after nickel bead pull-down. As Hey-1 co-
precipitates with His-SUMO2, this suggests that Hey1 is likely to be SUMO2 
modified in HeLa cells. However, this assay could be repeated with further 
controls, incubating cell lysates with plain agarose beads in addition to nickel 
beads. This would verify that Hey1-Myc alone does not bind to the resin.  
 
To support this result, in vitro SUMOylation assays were performed using 
purified Hey1 and IRF2 as substrates. IRF2 is a transcription factor, the 
activity of which is known to be regulated by SUMO1 modification (Han et al., 
2008). IRF2 is also recommended as a substrate for in vitro SUMOylation 
reactions. The purified substrate, E1 enzyme (SAE1/2), E2 enzyme (Ubc9) 
and SUMO2 reaction components were mixed and incubated for three hours 
at 37°C. This was performed in both the presence and absence of ATP and 
resulting samples analysed by SDS-PAGE followed by Coomassie blue 
staining or Western blotting. Figure 3.5b  illustrates that in the presence of 
ATP, IRF2 is polySUMOylated as indicated by a high molecular weight 
smear upon Coomassie staining (assays performed by David Hughes). 
Although Hey1 SUMO2 modification cannot be seen clearly by Coomassie 
staining, immunoblotting with a Hey1 specific antibody visualises a ladder of 
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Hey1 polySUMOylated species. This discrete banding pattern is consistent 
with progressive addition of 12 kDa conjugates. Thus Hey1 represents a 
valid STUbL target, being SUMO2 modified in cell culture and 
polySUMOylated by in vitro SUMOylation assays.  
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Figure 3.5 Hey-1 is poly-SUMO2 modified.  
(a) HeLa cells which stably express SUMO2-His were transfected with either Hey1-
Myc or ORF57-Myc. SUMO2 conjugated proteins were precipitated using Nickel 
beads and analysed by immunoblotting with a Myc-specific antibody. (b) For in vitro 
SUMOylation assays, the labelled purified reaction components were incubated for 
3 h at 37°C. For negative controls, ATP was omitted. Reactions were stopped by 
the addition of 10 µl Laemmli sample buffer and analysed by SDS-PAGE followed 
by Coomassie blue staining and immunoblot analysis with a Hey1-specific antibody 
(Note- assays in panel b were performed by David Hughes). 
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3.6 Hey1 is not SUMO2 modified at consensus acceptor 
sites 
As Hey1 was found to be SUMO2 modified in both in vitro and cell culture 
based assays, the next step was to determine if RTA-mediated degradation 
of Hey1 is SUMO dependant. To investigate this possibility, Hey1 
degradation assays would need to be performed in the absence of any 
SUMO modification. SUMO conjugation frequently occurs at consensus 
acceptor sites with the amino acid sequence ΨKxE (in which Ψ is an 
aliphatic branched amino acid and x is any amino acid) but also occasionally 
at non-consensus acceptor lysines (Rodriguez et al., 2001). The Hey1 
peptide sequence was scanned for SUMO acceptor sites using the SUMOsp 
2.0 prediction tool (Ren et al., 2009). This analysis provided two overlapping 
putative SUMO acceptor sites, with one consensus and one non-consensus 
site (figure 3.6a).  To characterise these SUMO acceptor sites Hey1 was 
subjected to site-directed mutagenesis, mutating both potentially modified 
lysine residues to arginine.  
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a) 
 
 
 
Figure 3.6 Mutation of Hey1 predicted SUMO acceptor sites does not prevent 
SUMO2 modification.  
(a) The SUMOsp 2.0 prediction software was used to identify two overlapping 
putative SUMO acceptor sites within Hey1. The amino acid sequences of the 
predicted sites are indicated and key lysine residues were subject to site-directed 
mutagenesis. (b) 293T cells were co-transfected with wild-type or mutant Hey1-Myc 
and GFP or GFP-RTA. At 24  hours post-transfection cells were harvested and 
lysates subject to SDS-PAGE followed by immunoblotting with GFP, Myc and 
GAPDH specific antibodies. (c)  SUMO2-His HeLa cells were transfected with wild-
type or mutant Hey1-Myc and nickel beads used to pull-down any His associated 
cellular components. Precipitates were analysed by Western blotting with a Myc 
specific antibody.  
 
To determine if these mutations had any effect upon proteasomal targeting 
of Hey1, degradation assays were repeated as previously described with the 
generated mutant. The Hey1-Myc mutant or wild type Hey1-Myc plasmids 
were co-transfected with GFP or GFP-RTA into 293T cells. At 24 hours post-
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transfection cells were lysed and examined by immunoblotting with GFP, 
Myc and GAPDH specific antibodies. As expected, levels of Hey1-Myc were 
again severely reduced when co-transfected with RTA compared with the 
GFP control. However, mutation of the Hey1 predicted SUMO acceptor sites 
did not alter this outcome (figure 3.6b). If RTA possessed STUbL activity, it 
would be expected that proteasomal targeting of substrate proteins would be 
dependent upon their SUMO modification. Therefore to clarify if the Hey1 
mutant lacked SUMO modifications, the SUMO2-His HeLa cells were again 
utilised. The Hey1-Myc mutant or wild type Hey1-Myc plasmids were 
transfected into these cells and after 24 hours, lysates were incubated with 
nickel beads. The subsequent precipitated SUMO2-His proteins were 
analysed by Western blotting with a Myc specific antibody. Figure 3.6c 
demonstrates that both wild type and mutant Hey1 are pulled down by the 
nickel resin, suggesting they are both SUMO2 conjugated. However, as with 
figure 3.5a, this assay could be repeated with an additional negative control, 
incubating lysates with plain agarose beads to check for non-specific 
binding. Hey1 is therefore not exclusively modified at these SUMOsp 2.0 
predicted sites. It may be that these lysine residues are not SUMOylated or 
that additional Hey1 SUMO acceptor sites are sufficient to maintain 
detectable levels of the Hey1-SUMO species.  
 
3.7 SUMO2 knockdown is insufficient to prevent RTA 
mediated Hey-1 degradation 
To determine if the RTA-mediated degradation of Hey1 is SUMO dependant, 
putative SUMO acceptor sites within Hey1 were mutated. However, these 
sites were found not to be exclusive SUMO2 acceptors of Hey1. Another 
method to prevent Hey1 modification was therefore explored using SUMO2 
directed siRNA. Knockdown of global SUMO2 transcript levels would prevent 
modification of all cellular proteins, including Hey1. To test the efficacy of 
siRNA-mediated SUMO2 specific knockdown, 293T cells were transfected 
with 5, 25 or 50 picomoles of siRNA and incubated for either 24 or 48 hours. 
At the appropriate time-point, samples were harvested and lysates analysed 
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by Western blotting using SUMO2 and GAPDH specific antibodies (figure 
3.7a). Partial knockdown of SUMO2 levels was seen for all concentrations of 
siRNA at 24 and 48 hours. The Hey1 degradation assay was then repeated 
in the presence of 25 picomoles of SUMO2 siRNA. 293T cells were 
transfected with scramble or SUMO2 siRNA, and incubated at 37°C for eight 
hours, before being transfected again with Hey1-Myc and RTA-FLAG or 
Hey1-Myc and a control vector for an additional 24 hours. Cells were then 
harvested, lysed and analysed by SDS-PAGE followed by immunoblotting 
with Myc, FLAG, SUMO2 and GAPDH specific antibodies. The vector control 
samples marked with an asterisk are negative for RTA-FLAG expression but 
show non-specific bands. As seen in figure 3.7b, RTA-mediated degradation 
of Hey1 is not affected by SUMO2 knockdown. Levels of Hey1-Myc were 
unchanged in the presence of SUMO2 siRNA compared with a scramble 
control. However, it must be noted that  complete knockdown of SUMO2 
could not be achieved in this assay. 
 
Figure 3.7 SUMO2 knockdown does not affect Hey1 degradation.  
(a) 293T cells were transfected with 5, 25 or 50 picomoles of siRNA for 24 or 48 
hours. Cells were lysed and knockdown was evaluated by immunoblotting using a 
SUMO2 and a GAPDH specific antibodies. (b) 293T cells were transfected with 25 
picomoles of scramble or SUMO2 siRNA for eight hours before being transfected 
again with Hey1-Myc and RTA-FLAG or Hey1-Myc and a control vector for a further 
24 hours. Samples were harvested and analysed by Western blotting using a 
FLAG, Myc, SUMO2 and GAPDH specific antibody. Lanes marked with an asterisk 
are negative for RTA-FLAG expression but have non-specific bands of a similar 
size to RTA. 
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Although SUMO2 siRNA did not affect RTA-mediated targeting of Hey1 for 
proteasomal degradation, this may be due to the fact that only partial 
SUMO2 knockdown was achieved. Moreover, as SUMO2 and SUMO3 are 
highly redundant, SUMO-3 may compensate in the event of SUMO2 
depletion. An alternative knockdown strategy would therefore need to be a 
component of the SUMOylation conjugation machinery, such as the E2 
enzyme Ubc9. As Ubc9 is solely responsible for conjuation of all SUMO 
isoforms, knockdown of this enzyme would prevent any cellular SUMOylation 
and SUMO-mediated processes. For this purpose a shUbc9 expressing 
lentivirus was generated, also containing a puromycin resistance gene. HeLa 
cells were infected with the shUbc9 lentivirus and at 30 hours post-
transduction selection media was added. As only those cells expressing the 
shUbc9 expression cassette could survive puromycin selection, a stable 
Ubc9 knockout cell line would result. However, no viable cells could be 
generated using this system (figure 3.8). This suggests that Ubc9 is an 
essential gene for HeLa survival.  
 
 
Figure 3.8 Stable Ubc9 knockdown HeLa cells are not viable. 
shUbc9 containing lentiviruses were generated using the MISSION® lentiviral 
packaging mix (Sigma-Aldrich®). HeLa cells were infected with shUbc9 lentivirus 
and 30 hours later were subjected to selection with puromycin. Selection media was 
replaced every 3-4 days and cell growth monitored.  
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3.8 RTA SIM mutation reduces activation of the RTA 
responsive  vIL6 promoter  
Mutation of putative SIM domains within RTA was shown to diminish both 
RTA-mediated degradation of Hey1 and reactivation of latent KSHV 
episomes. The SIM 2 and SIM 3 single mutants demonstrated moderate 
disruption of RTA function however, this effect was more evident using SIM 
2/3 and SIM 1/3 combination mutants. If these motifs represent specific 
modulators of RTA STUbL function, SIM mutants would be expected to 
retain wild type function of unrelated roles of RTA. To investigate this 
hypothesis, a vIL6 reporter construct was employed to examine the 
transactivation capacity of the SIM mutants. This reporter construct consists 
of the vIL6 RTA response element containing promoter fragment, upstream 
of a luciferase gene. 293T cells were transfected in triplicate with the vIL6 
reporter plasmid and either GFP, GFP-RTA or each GFP-SIM mutant. At 24 
hours post-transfection cells were subject to passive lysis and the luciferase 
activity of each sample measured. The relative light unit averages and 
standard deviations were then calculated from triplicate transfections (figure 
3.9). As expected, co-transfection of GFP-RTA increased the vIL6 promoter 
activity by approximately 5-fold compared to the GFP control. However, co-
transfection of the vIL6 reporter with SIM 2, SIM 3, SIM1/3 and SIM 2/3 
mutants resulted in luciferase activity equivalent to, or less than the GFP 
control. Disruption of these SIM domains therefore has a detrimental effect 
upon RTA-mediated transcriptional activation of vIL6.  
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Figure 3.9 RTA SIM mutants do not activate a vIL6 luciferase reporter plasmid.  
GFP, GFP-RTA or GFP-SIM mutants were co-transfected with the vIL6 reporter 
plasmid in triplicate into 293T cells. After 24 hours the cells were lysed and 
luciferase activity measured using the Promega Luciferase Assay Reagent II and a 
FLUOstar Optima microplate reader. Replicates were used to calculate average 
measurements and corresponding standard deviations.  
 
3.9 RTA SIM mutation reduces binding to the RTA 
responsive vIL6 promoter 
SIM mutants demonstrated a decreased ability to transactivate the RTA 
responsive vIL6 promoter in luciferase reporter assays. This result could be 
indicative of a general dysfunction of the SIM mutants, not specific to RTA 
target recognition. However, as SIM domains are mediators of general 
protein-protein interactions, not just effectors of proteasomal targeting, it is 
possible that they may be required for the interaction of RTA with additional 
transcriptional components. If this were the case, SIM mutants should still 
retain their ability to directly bind to promoter DNA. As RTA has been shown 
to directly bind to a RRE within the vIL6 promoter (Deng et al., 2002), this 
DNA should be enriched by chromatin immunoprecipitation (ChIP) of RTA. 
Therefore ChIP assays were performed to assess the DNA binding ability, 
comparing wild type and SIM RTA mutants. 293T cells were co-transfected 
with GFP, GFP-RTA or GFP-SIMs in the presence of the vIL6 reporter 
construct. At 24 hours post-transfection these cells were fixed, lysed and 
chromatin disrupted by sonication. Each condition was then subject to 
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immunoprecipitation with polymerase II and GFP specific antibodies and a 
non-specific, isotype matched IgG. Proteins were then removed from the 
purified complexes and resulting DNA was used as a qPCR template using 
vIL6 specific primers. Raw Ct values were obtained from the generated PCR 
curves and adjusted Ct values were then determined by subtracting the IgG 
Ct from all Ct values for each sample. These values could then be used to 
calculate fold changes compared with the negative control IgG (figure 3.10). 
 
Chromatin immunoprecipitation of RTA enriched vIL6 promoter specific DNA 
by 2-fold over a non-specific IgG. This level of binding is particularly low, only 
slightly above the 1.5 fold enrichment of GFP transfection. Of the five SIM 
mutants SIM3, SIM 1/3 and SIM 2/3 demonstrated binding below the level of 
the GFP transfected control (dashed line). These SIM 3 containing mutants 
correspond to those which demonstrated disruption of RTA E3 ligase, 
reactivation and transactivation functions. This could suggest that the effect 
of mutating these SIM domains is non-specific. However, due to low binding, 
results from this assay are inconclusive and therefore must be repeated. 
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Figure 3.10 Assessing SIM mutant binding to the vIL6 RRE.  
293T cells were co-transfected with the vIL6 promoter construct and either GFP, 
GFP-RTA or GFP-SIM for 24 hours. Samples were fixed and DNA was sheared 
prior to immunoprecipitation with polymerase II and GFP specific IgGs and a non-
specific IgG. The precipitated complexes were washed and the associated DNA 
was purified. qPCR was performed using vIL6 specific primers and SensiMix™ 
SYBR No-ROX Kit in a Rotor-Gene 6000 Real-Time PCR. Ct values were used to 
calculate the fold change in GFP associated DNA compared with the internal IgG 
control. The dotted line represents the level of background GFP binding.   
 
3.10  Discussion 
RTA promotes lytic reactivation of KSHV through its functions as a 
transcriptional activator and an E3 ubiquitin ligase. The E3 ligase activity of 
RTA was initially characterised against the cellular transcription factor IRF7, 
with identification of  a non-canonical Cys plus His-rich catalytic domain (Yu 
et al., 2005). Subsequently, Hey1 (Gould et al., 2009) and K-RBP (Yang et 
al., 2008) were identified as genuine RTA substrates, with LANA, K-bZIP 
and TRIF (Ahmad et al., 2011) representing additional potential targets. 
However, the mechanism by which RTA recognises its E3 ligase targets has 
not been elucidated. In this chapter we investigated the possibility that RTA 
belongs to a class of ubiquitin ligases termed SUMOylation targeted ubiquitin 
ligases (STUbLs) which specifically recognise SUMOylated substrates for 
ubiquitination.  
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STUbL enzymes contain internal SUMO interaction motifs (SIMs) which 
interact non-covalently with substrate conjugated SUMO moieties. The RTA 
peptide sequence was scanned for putative SIM domains and three N-
terminal SIM domains were chosen for validation. These SIM1-3 domains 
were mutated by site-directed mutagenesis and SIM 1/3 and SIM 2/3 double 
mutants were than sub-cloned. All five mutants demonstrated similar 
expression levels to wild-type RTA and immunofluorescence confirmed their 
nuclear localisation. Once these SIM mutants had been generated they were 
tested for their ability to degrade the known RTA target, Hey1. In this assay 
the SIM 1/3 and SIM 2/3 double mutants demonstrated a reduction in Hey1 
proteasomal targeting, with 2-3 fold higher levels of Hey1 compared with wild 
type RTA. Given that these mutants decreased the degradation capacity of 
RTA, the effect of these mutations upon viral reactivation was tested. Whilst 
wild type RTA could induce detectable levels of reactivation, induction with 
the H145L ubiquitin ligase null mutant was negligible. The SIM 3, SIM1/3 
and SIM 2/3 mutations decreased the ability of RTA to induce lytic 
reactivation. This was most evident for the SIM double mutants, congruent 
with the observations from the Hey1 degradation assay. From these assays 
the putative SIM domains appear to be co-operatively involved in RTA 
function, consistent with STUbL activity. 
 
For RTA to be a STUbL, the proteins which it degrades must be subject to 
SUMOylation. SUMO modification has a wide range of cellular functions but 
has been shown to play a prominent role in transcriptional repression 
(Garcia-Dominguez and Reyes, 2009). This is compatible with the currently 
identified targets of RTA mediated degradation being repressors of lytic 
promoters. Moreover both IRF7 and K-bZIP have been shown to be 
SUMOylated (Izumiya et al., 2005; Kubota et al., 2008). To determine if 
Hey1 is SUMO2 modified, HeLa cells containing a stable His tagged SUMO2 
were utilised and modified proteins pulled down on a nickel resin. 
Immunoblotting identified Hey1 as being SUMO2 modified and this result 
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was confirmed using in vitro poly-SUMOylation assays.  The individual 
moieties of Hey1 conjugated poly-SUMO2 chains could potentially mediate 
interactions with tandem SIM domains.  
 
SUMO modification of substrates often occurs at consensus modification 
sites (Xu et al., 2008). The Hey1 peptide sequence was scanned for 
potential acceptor sequences, identifying two potentially modified Lysine 
residues. To determine if RTA mediated degradation of Hey1 is SUMO 
dependant, these acceptor residues were subjected to site-directed 
mutagenesis. However, the generated mutant was still SUMO2 modified. 
Thus these sites are either not true sites of modification or are modified in 
conjunction with additional unidentified sites, which are sufficient to 
compensate for these mutations. As this approach could not prevent Hey1 
modification, SUMO2 siRNA was used in an attempt to knockdown cellular 
SUMO2. The Hey1 degradation assay was repeated in the presence of 
SUMO2 siRNA, however this had no effect upon RTA E3 ligase efficiency. 
This result can be explained by the fact that only partial knockdown was 
achieved. Finally, knockdown of the E2 SUMO conjugating enzyme, Ubc9, 
was attempted. As Ubc9 represents the sole E2 enzyme in the SUMOylation 
system, knockdown would globally prevent protein modification with any of 
the three SUMO paralogues. HeLa cells were infected with a shUbc9 
containing lentivirus, and transduced cells were subject to antibiotic 
selection. However cells expressing shUbc9 could not be expanded, 
suggesting that this gene is essential for cellular function.  
 
To determine if the SIM mutant phenotype was specific to disruption of E3 
ligase function, transcriptional activity of the SIM mutants was tested. A vIL6 
reporter construct was used for this assay, as it is known to be activated by 
direct binding of RTA to a promoter response element (Deng et al., 2002). 
Activation of the vIL6 promoter was found to be diminished with four of the 
five SIM mutants, compared to wild type RTA. To determine if this was due 
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to decreased DNA binding, chromatin immunoprecipitation of RTA and SIM 
mutants was carried out using a GFP specific antibody. Enrichment of vIL6 
promoter DNA for SIM3, SIM1/3 and SIM2/3 mutants was found to be below 
the level of the GFP control, suggesting reduced binding capacity. However, 
due to low levels of precipitated DNA, results from this assay were 
inconclusive.  
 
In summary, experiments presented herein show that RTA contains putative 
SIM domains which are required for RTA function. Moreover, the Hey1 
degradation target was shown to be SUMO2 modified. This data is 
consistent with the possibility of RTA having intrinsic STUbL function. 
However, these results are complicated by the fact that SIM mutation also 
affects other RTA functions. Further investigation is therefore required to 
make any definitive conclusions. 
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Chapter 4 
Using SILAC based quantitative proteomics to identify novel 
RTA modulated host proteins 
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4 Chapter 4 
Using SILAC based quantitative proteomics to identify 
novel RTA modulated host proteins 
 
4.1 Introduction 
The previous chapter explored a potential mechanism by which RTA 
recognises target proteins for proteasomal degradation. However, the 
remainder of this investigation concentrates upon identifying novel points of 
interaction between RTA and the host cell. These studies were not limited to 
one aspect of RTA function but designed to look globally at the effect of RTA 
across the cellular proteome. While chapter 5 focuses upon identifying direct 
interaction partners of RTA, this chapter quantifies changes in protein 
abundance in response to RTA expression.  To this end SILAC (stable 
isotope labelling with amino acids in cell culture) experiments were carried 
out coupled with mass spectrometry analysis. For this approach, cells are 
grown in either standard growth medium or medium containing stable heavy 
isotopes. The differentially labelled cells are subjected to different conditions, 
such as the absence or presence of RTA, before being separated into 
nuclear and cytoplasmic fractions and mixed in equal ratios. Samples are 
then analysed by mass spectrometry, where mass differences conferred by 
the alternative isotopes can be used to identify the sample origin of a given 
peptide.  A catalogue of all the detected proteins is then constructed, with 
protein abundance being quantified as a ratio between two conditions. 
  
To carry out SILAC-based quantitative proteomics, a large number of cells 
are required to ensure sufficient material for the final analysis. The large 
scale nature of this protocol therefore makes transfection of an RTA plasmid 
unfeasible. A baculovirus RTA expression vector was therefore initially 
explored as a suitable alternative. Baculovirus stocks were expanded in Sf9 
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insect cells and infection of mammalian cells resulted in detectable levels of 
RTA expression. SILAC-based proteomics was carried out upon infection 
with this virus in addition to uninfected and empty vector controls. However, 
data analysis proved this approach to be unsuitable and so the use of an 
inducible RTA expression system was explored. SILAC-based proteomics 
was repeated using this cell line, with abundance of several hundred 
proteins being altered upon RTA expression by more than two-fold. The 
cellular protein ARID3B is one such factor found to be upregulated by over 
seven-fold in the nuclear fraction. The latter half of this chapter describes 
attempts to validate and further describe a functional relationship between 
RTA and the putative target ARID3B. 
 
4.2 Production of recombinant baculovirus expressing RTA 
for infection of HEK 293T 
The baculoviral expression system represents an efficient method for large-
scale protein expression.  Moreover, recombinant baculoviruses can be 
amplified in Sf9 insect cells, producing high titre stocks for transduction of 
mammalian cells (Hofmann et al., 1995). An RTA expressing recombinant 
baculovirus was therefore obtained from Dr D.Lukac and used for SILAC-
based analysis (Lukac et al., 2001). To firstly confirm baculoviral infection 
could produce detectable levels of RTA protein in mammalian cells, 293T 
cells were seeded into 6-well dishes prior to infection with varying amounts 
of the recombinant virus. At 24 hours post-infection, cells were harvested 
and lysates analysed by Western blotting using RTA- and GAPDH-specific 
antibodies (Figure 4.1). RTA expression was detected in all infected 
samples, with expression levels correlating with the amount of input virus.  
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Figure 4.1 RTA expression using a recombinant baculovirus in 293T cells. 
293T cells were infected with various numbers of RTA-Baculovirus particles and 
incubated for 24 hours in DMEM containing 5% FCS. Cells were harvested and 
lysates subject to SDS-PAGE followed by immunoblotting using RTA and GAPDH 
specific antibodies.  
 
In addition to the RTA-Baculovirus, an “empty” baculovirus control was also 
required for the SILAC investigation as an appropriate infection control. In 
order to create this “empty” virus, bacmid DNA was isolated from DH10Bac 
cells. To confirm the presence of purified bacmid, DNA was digested with 
AscI prior to analysis by pulse field gel electrophoresis (figure 4.2a). As 
predicted, restriction digest resulted in the excision of a 4Kb fragment from 
the baculovirus genome. To produce sufficient infectious virus for the SILAC 
experiment, the empty bacmid was then transfected into Sf9 cells and the 
supernatant harvested after 72 hours. In the absence of a suitable 
expression cassette, the presence of control “empty” baculovirus particles 
was confirmed by qPCR using primers against gp64 coat protein gene. 
Moreover, this also gave an indication of the titre of the various virus stocks 
(Hitchman et al., 2007). 293T cells were infected with either RTA-
baculovirus, empty baculovirus or left uninfected prior to extraction of 
episomal DNA. qPCR verified the presence of gp64 template DNA in both 
infected samples but not in the uninfected control as demonstrated by the Ct 
values in figure 4.2b. This analysis confirmed similar levels of infectivity of 
the two baculovirus stocks. Plaque assays were also performed using both 
viruses but attempts to determine titres from these assays were 
unsuccessful.  
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Figure 4.2 Creation of an “empty” baculovirus vector. 
(a) Purified bacmid DNA was digested using the AscI restriction enzyme which cuts 
at two points in the baculovirus genome. DNA was analysed by pulse field gel 
electrophoresis with an arrow highlighting the expected 4Kb restriction fragment. (b) 
293T cells were infected with either RTA containing or “empty” baculovirus in 
triplicate or left uninfected, prior to episome rescue. The resulting DNA was subject 
to qPCR using gp64 specific primers and Ct values determined.  
 
4.3 SILAC-based quantitative proteomics of baculovirus 
infected cells 
Following amplification of the RTA-expressing and wild type baculoviruses 
by serial passaging in Sf9 cells, 293T cells were transferred into the 
appropriate SILAC medium. Cells were maintained in light (R0K0), medium 
(R6K8) or heavy (R10K8) complete DMEM for a minimum of 5 passages, to 
allow full incorporation of labelled amino acids. Medium and heavy labelled 
cultures were then infected with wild type and RTA-expressing baculovirus 
respectively, whilst the light control remained uninfected. At 24 hours post-
infection samples were harvested and subjected to separate nuclear 
cytoplasmic fractionation. A protein assay was then performed to determine 
sample concentrations and equal masses of each fraction were loaded onto 
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SDS-PAGE gels. SDS-PAGE was followed by Coomassie staining (figure 
4.3a) or immunoblotting with RTA, GAPDH and Lamin B specific antibodies 
(figure 4.3b). The GAPDH cytoplasmic marker and Lamin B nuclear marker 
illustrate both fraction purity and equal loading, with RTA expression being 
detected in the heavy fractions. Equal amounts of protein from the three 
samples of each fraction were mixed, before being analysed by mass 
spectrometry by Dundee cell proteomics. 
 
Figure 4.3 Nuclear- cytoplasmic fractions of Baculovirus infected cells. 
Cytoplasmic and nuclear fractions from R0K0, R6K4 and R10K8 conditions were 
subject to SDS-PAGE followed by (a) Coomassie staining or (b) Western blotting. 
GAPDH and lamin B specific antibodies were used as cytoplasmic and nuclear 
markers respectively. An RTA specific antibody confirmed protein expression in 
R10K8 labelled cells.  
 
Mass spectrometry analysis of nuclear and cytoplasmic fractions detected 
the presence hundreds of proteins. Abundance of each protein was 
determined for the RTA-expressing condition compared with each control 
(i.e. heavy/medium or heavy/light). However, despite the large numbers of 
proteins quantified, very few demonstrated any noticeable change upon RTA 
expression. Table 4.1 summarises the data comparing RTA baculovirus 
infected cells with the “empty” baculovirus infected control. Employing a 2-
fold change cut-off, less than 50 proteins showed significant change in 
abundance. Moreover, none of the significantly altered proteins were found 
to relocalise between the nuclear and cytoplasmic compartments. This initial 
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approach was therefore concluded as unsuitable for further investigation. 
One explanation for this result is that although RTA could be detected at 
significant levels by Western blotting, this could be due to high levels of 
expression in a small sub-population of cells. In this instance protein levels 
from the majority of non-RTA expressing cells would mask any significant 
RTA induced changes.  
Nuclear Cytoplasmic
Identified 610 1034
> 2-fold increase 11 27
Common increases 0
> 2-fold Decrease 2 5
Common decreases 0
 
Table 4.1 Summary of RTA expressing/control infected baculovirus SILAC 
results. 
 
4.4 Production of an inducible RTA expressing cell line 
In order to repeat the SILAC experiment, an alternative method to reliably 
express RTA in the majority of the cell population was required. Inducible 
cell lines represent one such system, where expression of a gene of interest 
can be induced in every cell of a monoclonal population upon addition of a 
specific drug. To create an inducible cell line, 293 FlpIn cells were utilised 
which contain a single stably integrated FRT recombination site, selected 
through a Zeocin resistance gene. An RTA-His/FLAG PCR product was 
cloned into the pcDNA5/FRT/TO vector which contains a tetracycline 
responsive hybrid CMV/TetO2 promoter. In addition, the pcDNA5 vector 
contains a single FRT site for recombination and a Hygromycin resistance 
gene for selection. Therefore to produce an RTA inducible cell line the 
pCDNA5/FRT/TO/RTA-FLAG/His construct was co-transfected with a flip 
recombinase containing plasmid into 293 FlpIn cells, promoting 
recombination of the two FRT sites and insertion of RTA into the genome. 
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RTA positive clones were then selected using Hygromycin and monoclonal 
populations of cells were amplified (figure 4.4). 
 
 
Figure 4.4 Creating an inducible cell line.  
The inducible RTA vector and flip recombinase containing plasmid were co-
transfected into the 293 FlpIn cell line. Recombination between FRT sites within the 
pcDNA5/FRT/TO vector and 293 FlpIn cells facilitated insertion of the RTA 
expression cassette. Recombinant clones were selected using Hygromycin and 
monoclonal populations of cells expanded. RTA expression could then be induced 
upon treatment with doxycycline.  
 
Once Hygromycin resistant clones were expanded, inducible expression of 
RTA was tested. Ten iRTA clones were either left untreated or induced with 
doxycycline for 24 or 48 hours. Lysates were analysed by Western blotting 
using a FLAG-specific antibody (figure 4.5a). All clones demonstrated 
inducible RTA expression at 24 and 48 hours at varying levels and clone 10 
was chosen for further validation. To check that RTA expression 
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demonstrated the same nuclear expression pattern as shown previously, 
clone 10 cells were seeded onto poly-L-lysine treated coverslips prior to 
addition of doxycycline. At 24 hours post-induction cells were fixed and 
permeabilised before being stained with a FLAG specific antibody. Figure 
4.5b compares images of iRTA expressing cells with RTA-GFP transfected 
293T cells. In both cases RTA co-localises with the nuclear DAPI stain and 
is excluded from the nucleolus.  
 
Figure 4.5 Testing RTA expression of inducible cell lines.  
a) Monoclonal populations of iRTA cells were left untreated or incubated with 
doxycycline for 24 or 48 hours. Cells were then harvested and lysed prior to 
analysis by SDS-PAGE and immunoblotting with a FLAG specific antibody. b) Clone 
10 iRTA cells and 293T cells were seeded onto coverslips, iRTA cells were then 
induced with doxycycline while 293T cells were transfected with GFP-RTA. After 24 
hours cells were fixed and permeabilised, iRTA cells were stained with a FLAG 
specific antibody and a red secondary antibody. RTA-GFP was visualised directly 
(green) and nuclear heterochromatin was stained using DAPI. Scale bars represent 
a width of 10 µm. 
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To further demonstrate that RTA expression from the inducible cell line 
produced a functional protein, a luciferase promoter assay was carried out. 
iRTA cells were transfected with the RTA responsive vIL6 promoter in 
triplicate and at six hours post-transfection half of the samples were treated 
with doxycycline. At 24 hours post-induction cells were subject to passive 
lysis and luciferase activity measured. The experiment was carried out three 
times and average luciferase activity and standard deviations calculated 
(figure 4.6). Induction of RTA expression increased vIL6 promoter activity by 
approximately 4-fold, consistent with previous results using transfected GFP-
RTA (figure 3.9).  
 
Figure 4.6 The vIL6 reporter construct is activated by iRTA induction.  
iRTA cells were seeded into 24 well plates prior to transfection with the vIL6 
luciferase construct in triplicate. After six hours, half of the samples were induced 
with doxycycline for a further 24 hours. Cells were then lysed using passive lysis 
buffer prior to being transferred to a 96 well plate. Luciferase activity was detected 
using the Promega Luciferase Assay Reagent II and a FLUOstar Optima microplate 
reader. Average relative light units and standard deviations were calculated from 
three independent experiments.  
 
4.5 SILAC-based quantitative proteomics using the iRTA cell 
line 
Following generation of an inducible cell line, iRTA cells were grown in either 
light (R0K0) or heavy (R10K8) labelled complete DMEM. Cells were cultured 
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in this medium for a minimum of 5 passages prior to induction of the heavy 
labelled cells with doxycycline for 24 hours. A small proportion of cells, which 
had been seeded onto coverslips prior to induction, were used to check 
levels of RTA expression by immunofluorescence. These samples were 
fixed and permeabilised followed by incubation with a FLAG-specific primary 
antibody and a fluorescent green secondary antibody. Figure 4.7a 
demonstrates that while no RTA protein could be detected in the uninduced, 
light labelled cells, RTA was strongly expressed in the induced, heavy 
labelled cells. The remainder of the labelled cells were harvested and 
subjected to nuclear-cytoplasmic fractionation. Fraction purity was assessed 
by Western blotting with antibodies to the cytoplasmic marker, GAPDH and 
the nuclear marker, Lamin B (figure 4.7b). Following confirmation of fraction 
integrity, sample protein concentrations were determined and equal amounts 
of each fraction combined. The nuclear and cytoplasmic fractions were then 
analysed by mass spectrometry by the Dundee cell proteomics service. 
 
Figure 4.7 Analysis of SILAC iRTA cells. 
Heavy labelled iRTA cells were induced with doxycycline for 24 hours whilst light 
labelled cells were left untreated. (a) Cells which had been seeded onto coverslips 
were fixed and permeabilised prior to staining with a FLAG-specific antibody (green) 
Nuclear heterochromatin was stained using DAPI (blue) and scale bars represent a 
width of 10 µm. (b) The remaining cells were subject to nuclear-cytoplasmic 
fractionation and lysates analysed by SDS-PAGE and immunoblotting using 
GAPDH, Lamin B and FLAG-specific antibodies. 
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Mass spectrometry analysis detected the presence of several thousand 
proteins in both nuclear and cytoplasmic fractions. Protein abundance was 
quantified as a ratio of induced over uninduced samples for each fraction. 
For this analysis, a 2-fold change in protein level was used as a cut-off and 
subsequently over 600 proteins were found to be significantly altered (table 
4.2).  Furthermore, 20 proteins showed a significant change in abundance 
which was conserved across both nuclear and cytoplasmic fractions. Table 
4.3 lists the top 15 proteins with increased nuclear and cytoplasmic 
abundance. To explore the large number of RTA induced changes, results 
were inputted into the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) software (Huang et al., 2009). This programme can be 
used to identify the cellular pathways or processes enriched within a large 
data set. Table 4.4 lists cellular pathways from the KEGG database which 
were found to be over-represented in the nuclear data set. From this 
analysis RNA processing, DNA replication and repair are highly represented. 
The two most significantly identified networks, the spliceosome and 
nucleotide excision repair, are illustrated in figures 4.8 and 4.9.   
.  
Nuclear Cytoplasmic
Identified 1398 1951
> 2-fold increase 504 103
Common increases 18
> 2-fold Decrease 23 18
Common decreases 2
 
Table 4.2 Summary of SILAC data from iRTA nuclear and cytoplasmic 
fractions. 
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Top 15 upregulated nuclear proteins 
Ratio 
induced/uninduced 
ATPase family AAA domain-containing protein 3B 53.4 
Condensin complex subunit 3 21.4 
Zinc finger CCHC domain-containing protein 12 17.5 
Cell division cycle-associated 7-like protein 15.5 
Protein DBF4 homolog B 15.0 
TSPYL protein 13.7 
Transmembrane protein 43 11.9 
Kinesin-like protein KIF11 11.7 
BAT2 domain-containing protein 1 10.8 
Centrosomal protein of 170 kDa 9.6 
Uncharacterized protein KIAA1671 9.3 
upstream of NRAS isoform 3 9.1 
Putative uncharacterized protein WDR1 7.8 
AT-rich interactive domain-containing protein 3B 7.5 
General transcription factor 3C polypeptide 2 7.5 
Top 15 upregulated cytoplasmic proteins   
Small subunit processome component 20 homolog 16.9 
Melanoma-associated antigen D2 12.7 
Mediator of DNA damage checkpoint protein 1 10.6 
Protein strawberry notch homolog 1 9.2 
Protein CASC3 6.5 
Putative uncharacterized protein 
ENSP00000411935 6.5 
hypothetical protein XP_002346735 5.0 
Cadherin-2 4.9 
Methionine synthase 4.9 
Lysine-specific demethylase 5C 4.7 
alanyl-tRNA synthetase domain containing 1  4.7 
Integrator complex subunit 3 4.3 
Asparagine synthetase [glutamine-hydrolyzing] 4.1 
Isoform 1 of Tuberin 3.9 
Putative uncharacterized protein TMX2 3.9 
 
Table 4.3 Top 15 upregulated proteins in the nuclear and cytoplasmic 
fractions.  
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Term Count % P-Value
Spliceosome 20 4.1 2.10E-10
Nucleotide excision repair 10 2.1 1.10E-06
RNA degradation 11 2.3 1.20E-06
DNA replication 9 1.9 2.30E-06
Cell cycle 14 2.9 1.30E-05
Base excision repair 7 1.4 2.10E-04
Ribosome 10 2.1 3.20E-04
Aminoacyl-tRNA
biosynthesis
7 1.4 5.10E-04
Ubiquitin mediated 
proteolysis (Cullin family)
11 2.3 2.30E-03
Tight junction 10 2.1 6.60E-03
Pathogenic Escherichia coli 
infection
6 1.2 1.40E-02
Mismatch repair 4 0.8 1.90E-02
Adherens junction 6 1.2 4.50E-02
 
Table 4.4 Pathways enriched within the upregulated nuclear proteins. 
 
 
Figure 4.8 SILAC identified spliceosome components. 
Diagram illustrating the KEGG spliceosome pathway, proteins identified 
within the SILAC data set are highlighted with a red star. 
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Global genomic repair 
(GGR)
Transcription-coupled 
repair (TCR)
 
Figure 4.9 SILAC identified nucleotide excision repair components. 
Diagram illustrating the KEGG nucleotide excision repair pathway, proteins 
identified within the SILAC data set are highlighted with a red star. 
 
4.6 Levels of the SILAC identified target ARID3B are 
increased upon RTA expression  
One approach to validating the iRTA SILAC data was to investigate the 
proteins which demonstrated the greatest changes in abundance. A 
selection of targets from table 4.3 were therefore originally screened for 
changes upon RTA expression. One example of these proteins is the AT-rich 
interactive domain-containing protein 3B (ARID3B), the nuclear abundance 
of which increased over 7.5-fold upon expression of RTA. It was decided to 
focus on this protein in more detail as little is known about its function. As an 
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initial examination, the whole cell levels of ARID3B were investigated in the 
absence or presence of RTA. In addition to the iRTA cell line, BCBL-1 TREx 
cells were also utilised for this investigation. These cells are latently infected 
with KSHV but can be reactivated using doxycycline, which induces 
expression of RTA-Myc. iRTA and BCBL-1 TREx cells were either left 
untreated or induced with doxycycline for 24 hours.  In figure 4.10a cells 
were lysed and analysed by Western blotting using RTA, GAPDH and 
ARID3B specific antibodies. RTA was successfully induced in both samples 
and GAPDH illustrates equal loading. From this result there was no clear 
change in ARID3B protein levels upon induction of RTA. However, it should 
be noted that these samples were from whole cell lysates compared to 
SILAC data which was from the nuclear fraction. ARID3B mRNA levels were 
also investigated using qPCR, a more sensitive and quantitative approach. In 
figure 4.10b cells were subjected to RNA extraction followed by reverse 
transcription. The resulting cDNA was used to setup qPCR reactions with 
GAPDH and ARID3B specific primers. The fold change in ARID3B mRNA 
samples was determined from resulting Ct values, normalised to the GAPDH 
control. Levels of ARID3B mRNA were found to be moderately but 
consistently increased upon induction of both iRTA and BCBL1 TREx cell 
lines.  
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Figure 4.10 ARID3B mRNA levels are moderately increased upon RTA 
expression. 
BCBL-1 TREx and iRTA cells were either left untreated or induced with doxycycline 
for 24 hours. (a) Cells were then harvested and lysates analysed by SDS-PAGE 
followed by immunoblotting with RTA, GAPDH and ARID3B specific antibodies. (b) 
RNA extractions were performed in triplicate for each condition and cDNA 
generated by reverse transcription. qPCR reactions were carried out using 
SensiMix™ SYBR No-ROX Kit with ARID3B and GAPDH specific primers in a 
Rotor-Gene 6000 Real-Time PCR machine. Ct values were used to calculate the 
fold change in ARID3B levels normalised to GAPDH. The graph shows the average 
fold change and standard deviations from a combination of three independent 
experiments.  
 
4.7 ARID3B localises to replication compartments in 
reactivated TREx BCBL-1 cells 
ARID3B is a cellular DNA binding protein belonging to the AT-rich interactive 
domain family of proteins. Proteins of the ARID family have roles in a variety 
of processes including chromatin remodelling, transcriptional regulation, 
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differentiation, development and cell cycle regulation (Wilsker et al., 2005).  
ARID3B was first identified through its ability to interact with pRB (Numata et 
al., 1999) and its expression has been associated with ovarian cancer (Dahl 
et al., 2009) and stage IV neuroblastoma (Kobayashi et al., 2006). Although 
the cellular function of ARID3B is not well characterised, it has also been 
shown to play an essential role in embryogenesis (Casanova et al., 2011) 
and has been implicated in the induction of death receptor mediated 
apoptosis (Joseph et al., 2012). As cellular mRNA levels of ARID3B were 
increased upon RTA expression, subcellular localisation of ARIB3B was 
investigated by immunofluorescence in the presence of RTA alone and in 
the context of KSHV lytic reactivation. BCBL-1 TREx and iRTA cells were 
seeded onto coverslips and induced with doxycycline for 16 and 24 hours 
respectively. Cells were then fixed and permeabilised before being incubated 
with an ARID3B specific antibody (green) and either a FLAG (iRTA) or Myc 
(BCBL-1 TREx) specific antibody for RTA detection (Red).  Figure 4.11 
demonstrates that ARID3B is distributed across the entire cell in both 
uninduced and induced iRTA cells. In the uninduced BCBL-1 TREx cells 
ARID3B shows a general nuclear localisation, however, in lytically induced 
cells it becomes redistributed to sub-nuclear compartments. Moreover, RTA 
co-localised with ARID3B to these globular structures. 
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Figure 4.11 ARID3B subcellular distribution. 
iRTA and BCBL-1 TREx cells were seeded onto coverslips and induced with 
doxycycline for 24 and 16 hours respectively. Following fixation and 
permeabilisation iRTA cells were stained with an ARID3B (green) specific antibody 
and a FLAG (red) specific antibody for visualisation of RTA. BCBL-1 TREx cells 
were incubated with an ARID3B (green) specific antibody and a Myc (red) specific 
antibody for visualisation of RTA. Nuclear heterochromatin was visualised using 
DAPI (blue). Scale bars represent a width of 10 µm. 
 
Lytic replication of KSHV is initiated from the ori-Lyt region which contains an 
RTA responsive element (Wang et al., 2004c). This RRE is essential to the 
formation of a replication initiation complex and RTA has been demonstrated 
to associate with the six core viral replication proteins (Wang et al., 2006). 
Upon lytic reactivation these origin associated proteins localise to globular, 
sub-nuclear structures, known as replication centres (Wu et al., 2001a). Due 
to the striking co-localisation of RTA and ARID3B to sub-nuclear domains in 
lytic BCBL-1 TREx cells, it was hypothesised that these may represent 
KSHV replication centres. To investigate this possibility, EdU 
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immunofluorescence assays were performed to visualise areas of active 
DNA synthesis. TREx BCBL-1 cells were seeded onto poly-L-lysine treated 
coverslips prior to induction of lytic replication for 16 hours. At 45 minutes 
prior to fixation EdU (5-ethynyl-2´-deoxyuridine), which incorporates into 
actively replicating DNA, was added to cultures. At 16 hours cells were fixed 
and permeabilised before staining of ARID3B (green), Myc (red) and Edu 
(far red) (figure 4.12). Consistent with previous results ARID3B and RTA 
demonstrated co-localisation, with enrichment in sub-nuclear domains. 
Furthermore, these domains co-localised with Edu staining and thus regions 
of DNA synthesis, which are likely to represent viral replication centres. This 
suggests that the RTA-dependent nuclear enrichment of ARID3B could be 
linked to KSHV lytic replication.  
 
Figure 4.12 ARID3B co-localises with viral replication compartments. 
BCBL-1 TREx cells were seeded onto poly-L-lysine treated coverslips prior to 
induction with doxycycline for 16 hours. For the final 45 minutes of lytic induction 
cells were incubated with 10 µM Edu. Cells were fixed and permeabilised prior to 
staining of Edu (far red), Myc (red) and ARID3B (green). Cellular DNA was 
visualised using Hoechst 33342. Scale bars represent a width of 10 µm. 
 
To investigate if ARID3B plays a role in lytic replication, an ARID3B specific 
siRNA was employed. Given that BCBL-1 TREx cells demonstrate poor 
transfection efficiency, ARID3B knockdown was tested in the HEK 293T 
rKSHV.219 cell line. As these cells also contain the latent KSHV genome, 
the effect of ARID3B knockdown upon KSHV genome replication and virus 
production could be assayed. HEK 293T rKSHV.219 cells were transfected 
with either 0,1,10 or 25 nmol of ARID siRNA in duplicate and incubated for 
24 or 48 hours. At the appropriate time point samples were harvested and 
lysates analysed by Western blotting using ARID3B and GAPDH specific 
antibodies (figure 4.13).  However, ARID3B knockdown could not be 
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achieved for any siRNA concentration at 24 or 48 hours. It must be noted 
that the ARID3B-specific antibody, whilst excellent in immunofluorescence, 
highlights a variety of non-specific bands in immunoblotting. Nevertheless, 
this result was also confirmed by qRT-PCR using ARID3B specific primers. 
 
 
Figure 4.13 Transfection of ARID3B siRNA into HEK 293T rKSHV.219 cells. 
HEK 293T rKSHV.219 cells were transfected with either 0,1,10 or 25 nmol of 
ARID directed siRNA in duplicate. At 24 or 48 hours post-transfection cells 
were lysed and analysed by SDS-PAGE followed by immunoblotting using 
ARID3B and GAPDH specific antibodies. 
    
4.8 ChIP analysis suggests ARID3B does not bind to the 
KSHV ori-Lyt 
As ARID3B appeared to co-localise with viral replication centres, it was 
postulated that it could be directly involved in KSHV replication. During lytic 
reactivation, replication of the viral genome is initiated from the ori-Lyt 
region. Due to insufficient knockdown in siRNA-mediated depletion 
experiments, as an attractive assay to investigate this potential role of 
ARID3B in KSHV replication, chromatin immunoprecipitation (ChIP) was 
performed to determine if it could bind to the ori-Lyt region. BCBL-1 TREx 
cells were either left untreated or reactivated with doxycycline for 16 hours 
prior to formaldehyde crosslinking and sonication. Four separate 
immunoprecipitations (IPs) were performed for both conditions using a 
positive control RNA-polymerase II specific antibody, a negative control 
isotype matched IgG, an ARID3B specific antibody and a Myc specific 
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antibody to target Myc-RTA. Protein was then removed from precipitated 
complexes and the remaining DNA purified. Samples were analysed by 
qPCR using non-specific and ori-Lyt directed primers. Ct values were used 
to calculate a fold change enrichment compared to the negative control IgG 
(figure 4.14).  The polymerase II positive control demonstrated moderate 
binding to the ori-Lyt in uninduced cells which was dramatically increased 
upon lytic reactivation. Moreover, ori-Lyt DNA was enriched over ten-fold 
upon RTA IP from reactivated cells, consistent with the presence of an RTA 
binding element. These results confirm the validity of this assay for 
identifying ori-Lyt binding proteins. However, there was no enrichment of ori-
Lyt DNA from ARID3B IP samples, suggesting that ARID3B does not bind 
directly to the origin complex. Nevertheless, at present we have no proof that 
the ARID3B specific antibody is able to function in ChIP assays. Therefore, 
ChIP assays could be repeated using a tagged ARID expression vector and 
a validated ChIP grade antibody. 
 
Figure 4.14 ARID3B does not bind to the KSHV lytic replication origin. 
BCBL-1 TREx cells were either left untreated or induced with doxycycline for 16 
hours. Samples were fixed and DNA was sheared prior to immunoprecipitation with 
polymerase II, Myc and ARID3B specific antibodies in addition to a non-specific 
IgG. The precipitated complexes were washed and the associated DNA was 
purified. qPCR was performed using ori-Lyt specific or control non-specific primers 
and SensiMix™ SYBR No-ROX Kit in a Rotor-Gene 6000 Real-Time PCR machine. 
Ct values were used to calculate the fold enrichment of ori-Lyt DNA compared with 
the internal IgG control and associated standard deviations.  
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4.9 Discussion 
The aim of this chapter was to identify novel RTA induced changes in the 
cellular proteome. For this investigation, SILAC-based quantitative 
proteomics was performed coupled with mass spectrometry using nuclear 
and cytoplasmic fractions. This highly sensitive approach can identify 
thousands of proteins from a given sample and quantify changes in protein 
abundance between two conditions. In order to carry out this experiment, a 
method to reliably express RTA in a large population of cells was required. 
An RTA expressing baculovirus was initially utilised, being easily expanded 
in insect cells for subsequent transduction of mammalian cells. However, this 
approach could not successfully identify RTA induced changes, with one 
possible explanation being low transduction efficiency. Therefore, the use of 
an inducible RTA cell line was explored.  An RTA-His/FLAG tagged gene 
was placed under control of a tetracycline inducible promoter and inserted 
into the 293 genome by Flp-FRT recombination. Recombinant cells were 
then selected and monoclonal populations expanded.  Addition of 
doxycycline to these clones could successfully induce a high level of RTA 
expression in the entire population. Furthermore, the RTA protein produced 
from these cells demonstrated the expected nuclear localisation and could 
activate the RTA responsive promoter, vIL6. This expression system was 
thus considered as more appropriate for SILAC-based experiments. 
 
Prior to processing of SILAC samples, iRTA cells were grown in light (R0K0) 
or heavy (R10K8) SILAC media for several weeks. RTA expression was then 
induced in the heavy labelled cells for 24 hours while the light cells remained 
untreated. Nuclear and cytoplasmic fractions were separated and fractions 
from the two conditions mixed in equal amounts. Mass spectrometry analysis 
of these samples identified a total of around 2000 proteins from each 
fraction. Of these proteins, more than 600 demonstrated a change in 
abundance upon RTA expression equal to or greater than two-fold. The 
- 140 - 
majority of these changes were attributed to increases in nuclear 
abundance. However, this is not surprising, given that RTA functions are 
related to its nuclear localisation. Pathway analysis of this data highlighted 
enriched cellular networks, with RNA processing and DNA replication and 
repair being heavily represented. Although RTA has no known function in 
RNA processing, manipulation of host DNA replication and repair could be 
linked to the role of RTA in lytic genome replication. Investigation of these 
cellular processes in relation to lytic reactivation therefore provides scope for 
extensive future investigation. However rather than concentrating upon over-
represented pathways, subsequent analysis was focussed upon proteins 
with the most dramatic changes in abundance.  
 
As the majority of RTA induced changes were linked to increased nuclear 
abundance, targets for validation were selected from this group. The cellular 
AT-rich interactive domain-containing protein 3B (ARID3B) is one such 
target, the nuclear abundance of which increased 7.5 fold upon RTA 
expression. A preliminary experiment demonstrated that ARID3B mRNA 
levels were increased by two-fold upon induction of iRTA. Although levels of 
ARID3B are increased to a greater extent in the nuclear SILAC data, as 
mRNA is a  measure of whole cell transcripts, it should not necessarily 
reflect changes in nuclear abundance. Moreover, this increase was also 
seen in KSHV positive BCBL-1 TREx cells undergoing lytic replication. 
Although little is known about ARID3B itself, members of the ARID family of 
DNA binding proteins have been implicated in many cellular processes, 
including chromatin remodelling and transcriptional regulation (Wilsker et al., 
2005). Thus ARID3B presented an interesting target for further validation. 
 
To assess changes in the subcellular localisation of ARID3B, 
immunofluorescence was performed in iRTA and BCBL-1 TREx cell lines. In 
the iRTA cell line, ARID3B was distributed across the entire cell, with no 
obvious differences between uninduced and induced conditions. However, in 
- 141 - 
BCBL-1 TREx cells a marked change in localisation was observed, from 
general nuclear staining in latent cells to defined sub-nuclear domains in lytic 
cells. RTA was also found to localise to these ARID3B-rich regions. These 
globular structures were consistent with the presence of viral replication 
centres, which represent defined sites of active DNA synthesis for genome 
replication. These structures contain the viral and cellular proteins required 
for KSHV genome production, including RTA (Wang et al., 2006). An Edu 
assay was therefore performed to visualise sites of active DNA synthesis. 
ARID3B and RTA were found to be highly enriched in areas of DNA 
replication, corresponding to replication compartments.  
 
Following this observation, it was investigated if ARID3B could bind directly 
to the KSHV origin of lytic replication, ori-Lyt. Chromatin immunoprecipitation 
confirmed the presence of RTA upon the ori-Lyt in lytic BCBL-1 TREx cells. 
ARID3B did not appear to bind to this region, however, it may be that the 
ARID3B specific antibody used was not suitable for this application. 
Therefore, although ARID3B localises to KSHV replication centres upon lytic 
induction, it may not bind directly to the replication origin. Further studies are 
thus required to fully characterise the role of ARID3B in KSHV infection. An 
attractive experiment would be to optimise ARID3B knockdown in lytic 
BCBL-1 TREx cells. The formation of viral replication compartments and 
KSHV genome replication could then be assessed upon reduction of 
ARID3B protein levels.  
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proteins which interact with RTA 
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5 Chapter 5 
Using SILAC immunoprecipitation to identify novel host 
proteins which interact with RTA 
 
5.1 Introduction 
RTA interacts with numerous cellular proteins to aid in its function as a 
transcriptional activator. Transcriptional regulators such as Rbp-Jκ (Liang et 
al., 2002), C/EBPα (Wang et al., 2003b), and AP-1 (Wang et al., 2004a) all 
co-operate with RTA to upregulate lytic gene expression.  Once these 
activating factors have bound to target promoters, RTA can recruit chromatin 
remodelling complexes, such as the CBP/p300 (Gwack et al., 2001) and 
SWI/SNF (Gwack et al., 2003a). Furthermore, RTA also interacts with 
cellular repressor proteins, acting as an E3 ubiquitin ligase to mediate their 
degradation. These include IRF7 (Yu et al., 2005), Hey1 (Gould et al., 2009) 
and K-RBP (Yang et al., 2008). These multitude of interactions between 
RTA and cellular components are fundamental to its role as the KSHV 
latent-lytic switch protein. The aim of this chapter was to identify novel 
cellular interaction partners or degradation targets of RTA. To this end 
SILAC immunoprecipitations (IPs) were carried out comparing an inducible 
RTA-FLAG (iRTA) and inducible RTA
H145L
-FLAG cell line (iH145L) (figure 
5.1). The coupling of immunoprecipitation with mass spectroscopy provides 
a sensitive method of detecting co-immunoprecipitated proteins. The 
RTA
H145L
 ubiquitin ligase null mutant was used in the hope of identifying 
targets of RTA mediated degradation. Any proteins found to be enriched in 
the H145L condition compared with wild type RTA, would represent plausible 
E3 ubiquitin ligase substrates. 
 
To this end, iRTA and iH145L cell lines, plus a 293 FLAG control, were 
grown in R0K0 (light), R6K4 (medium) or R10K8 (heavy) isotope labelled 
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medium, before induction of protein expression for 24 hours. Equal numbers 
of cells from each condition were subjected to FLAG immunoprecipitation 
and samples analysed by mass spectroscopy. In addition to these results, 
data from RTA immunoprecipitation in BCBL-1 TREx cells was also made 
available (D.Hughes unpublished data). As the BCBL-1 TREx cells also 
contain the KSHV genome, this provided complementary information in both 
the context of viral infection and an alternative cell type. These two data sets 
were compared to look for shared interaction partners or proteins with 
functional commonalities. From these data sets ten putative targets were 
chosen for validation using antibodies specific to each endogenous protein. 
After an initial screen one such target, RNA binding protein 14 (RBM14), was 
selected for more detailed investigation. Following confirmation of the RTA-
RBM14 interaction, the effect of RBM14 upon RTA-mediated transactivation 
and KSHV reactivation functions was further analysed.  
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Figure 5.1 Using SILAC immunoprecipitation to identify novel cellular 
interaction partners of RTA. 
An inducible RTA-FLAG, inducible H145L-FLAG and control FLAG cell line were 
grown in differentially labelled media before a 24 hour induction period with 
doxycycline. Equal numbers of cells were lysed and immunoprecipitated using 
FLAG-affinity beads prior to mixing of the three samples. Mass spectrometry 
analysis detected enriched proteins and differences in abundance between the 
conditions were determined through amino acid mass differences.  
 
 
5.2 Production of an inducible RTAH145L expressing cell line 
Before SILAC IPs could be carried out, an inducible RTA
H145L
-FLAG cell line 
was created (iH145L), in a similar manner to the wild type inducible RTA cell 
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line (section 4.4). This mutation in the Cys plus His-rich catalytic region of 
RTA abolishes its E3 ubiquitin ligase activity. Using an iH145L cell line 
therefore provides an alternative to performing RTA immunoprecipitation in 
the presence of a proteasome inhibitor, which could be associated with 
many off-target effects. The pH145L-His/FLAG construct was created by 
PCR from the untagged pRTA
H145L
 template and ligated into the pcDNA5-
FRT/TO inducible vector. Resulting colonies were screened for the H145L-
His/FLAG insert and sequence integrity verified by DNA sequencing. 
 
To create an inducible cell line, 293 FlpIn cells, containing FRT integration 
sites, were co-transfected with pH145L-His/FLAG and the Flip recombinase 
containing plasmid, pPGK/Flip/ObpA. Recombination events then occur at 
FRT sites, inserting the H145L-His/FLAG expression cassette into the 
cellular genome. These recombinants were selected using Hygromycin 
resistance and monoclonal populations of cells generated. Eight monoclonal 
colonies were then expanded and inducible expression of the inserted gene 
was tested by the addition of 2 µg/ml doxycycline. At 24 and 48 hours post 
induction cells were harvested and analysed by Western blotting using a 
FLAG-specific antibody (figure 5.2a). All clones exhibited H145L expression 
at both 24 and 48 hours, although some also demonstrated leaky expression 
in the uninduced samples, such as clones 2 and 3. In contrast clone 1 cells 
exhibited strong expression at 24 hours with no uninduced expression and 
was therefore selected for use in further studies. To confirm H145L nuclear 
localisation, clone 1 cells were seeded onto coverslips prior to induction with 
doxycycline for 24hours. H145L expression was visualised using a FLAG 
specific antibody and a Texas red secondary. As can be seen in figure 5.2b 
the expected nuclear localisation was demonstrated, which is identical to 
wild type localisation (figure 4.5) 
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Figure 5.2 Testing expression of iH145L cell lines.  
(a) The pH145L-His/FLAG vector was co-transfected with a flip recombinase 
encoding plasmid into 293 FlpIns and subsequent recombination events allowed 
selection for inducible clones.  Expanded monoclonal populations were tested for 
protein expression after 24 and 48 hour inductions with 2µg/ml doxycycline. Cell 
lysates were analysed by immunoblotting, with levels of H145L detected using a 
FLAG-specific antibody (b) Clone 1 iH145L cells were induced for 24 hours with 
doxycycline on coverslips which were pre-treated with Poly-L lysine. A FLAG 
specific antibody was used for H145L staining (red) and nuclear heterochromatin 
was stained using DAPI (Blue). Scale bars represent a width of 10 µm. 
 
A 293 FLAG cell line, which had previously been generated in our laboratory, 
was used as a negative control. This cell line was produced by transfection 
of 293 FlpIn cells with a pcDNA3.1-FLAG vector followed by selection with 
Geneticin. Monoclonal populations of cells were selected as with iRTA and 
iH145L cell lines. 
 
 
5.3 SILAC immunoprecipitation of inducible RTA and 
RTAH145L expressing cell lines 
In order to perform SILAC IPs, the 293 FLAG, iH145L and iRTA cell lines 
were grown in R0K0, R6K4 and R10K8 complete DMEM, respectively. Cells 
were maintained in this medium for a minimum of five passages to allow full 
incorporation of heavy isotopes into cellular proteins. The two inducible cell 
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lines were then treated with doxycycline for 24 hours. Equal numbers of cells 
from each condition were subjected to a separate FLAG IP before the beads 
were washed and combined. Samples from input lysates, the unbound 
fraction and final IP were analysed by immunoblotting using a FLAG-specific 
antibody and a GAPDH-specific antibody to illustrate equal input levels 
(figure 5.3).  Inducible protein expression could be detected in all samples, 
indicating sufficient protein expression for bead saturation. Upon verification 
of successful IPs, samples were sent for analysis at the University of Bristol. 
There proteins were separated by SDS-PAGE, gels cut into three slices and 
in gel digestion performed before analysis by mass spectrometry.  
 
 
Figure 5.3 SILAC immunoprecipitation. 
Equal numbers of differentially labelled 293 FLAG, iH145L and iRTA cells were 
lysed and rotated with FLAG-affinity agarose at 4 °C for 2 hours. Input samples 
were taken before the addition of beads and unbound samples removed prior to 
bead washes. The three bead sets were then mixed and boiled in protein 
solubilising buffer. Input, unbound and IP samples were subject to SDS-PAGE 
followed by Western blotting with FLAG and GAPDH specific antibodies. The IP 
sample was stored at -20 °C, before being sent to the University of Bristol for 
analysis by mass spectrometry.  
 
Mass spectrometry results were presented as ratios comparing peptide 
enrichment in the test vs. control conditions (i.e. iRTA/293 FLAG and 
iH145L/293 FLAG). A significance cut-off was set at 1.5 fold enrichment and 
proteins above this threshold were selected for further analysis. Table 5.1 
summarises the total number of proteins identified for RTA and H145L 
conditions and the number of proteins above the 1.5-fold threshold. There 
were substantially more enriched proteins from the iH145L cell line 
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compared with iRTA, and all 11 of the significant iRTA interaction partners 
were also present in the iH145L sample. This increased IP efficiency is likely 
due to the enhanced stability of the H145L mutant. As RTA has been shown 
to auto-ubiquitinate, mutation of the E3 ubiquitin ligase domain prevents 
RTA-mediated self-degradation, in addition to degradation of cellular 
proteins (Yu et al., 2005). As all of the detected RTA interaction partners 
were encompassed within the H145L data set, subsequent analysis was 
focused upon the iH145L significant proteins.  
 
 
Table 5.1 Summary of SILAC FLAG immunoprecipitation results. 
 
 
A parallel SILAC experiment was also performed in the Whitehouse 
laboratory, immunoprecipitating RTA from BCBL-1 TREx cells (D.Hughes 
unpublished data).  This provided an independent data set for comparison of 
enriched proteins.  Table 5.2 summarises the number of protein ratios 
identified in the BCBL-1 TREx and iH145L cell line with 6 commonly 
enriched proteins being detected. From these SILAC IP data sets ten 
putative interaction partners were chosen for further validation. Table 5.3 
lists the selected proteins, their fold change and a brief functional 
description. Choices were rationalised on the basis of high enrichment, 
relevant annotated functions or the identification of multiple complex 
subunits. For example RNA binding protein 14 (RBM14) was chosen due to 
its high enrichment in both data sets whereas subunit 4 of the chaperonin 
containing TCP1 (TCP) was selected due to enrichment of several 
chaperonin family members. 
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Table 5.2 Comparison of SILAC immunoprecipitation in iH145L and BCBL-1 
TREx cell lines. 
 
 
 
Table 5.3 Ten putative RTA interaction partners chosen for validation.  
Ten cellular target proteins were selected for further study from across the iH145L 
and BCBL-1 TREx data sets. The name, abbreviation and uniprot protein 
description are listed. Additionally the fold change of each protein and origin data 
set are shown (note: where the protein appears in both data sets the highest fold 
change is shown). 
 
5.4 Assessing endogenous levels of SILAC IP targets upon 
RTA expression 
Following analysis of the SILAC IP data, endogenous antibodies were 
obtained for ten putative RTA interacting proteins. To perform an initial 
screen, levels of endogenous proteins were assessed for changes in the 
presence of RTA across the iRTA, iH145L and BCBL-1 TREx cell lines. Cells 
were grown in 75cm
3 
tissue culture flasks and either left uninduced or 
induced with doxycycline for 24 hours prior to cell lysis. Samples were 
analysed by SDS-PAGE followed by immunoblotting with antibodies specific 
to RTA and the ten target proteins. Equal loading was confirmed using a 
GAPDH-specific antibody (Figure 5.4). With the exception of PYCR, 
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endogenous proteins could be detected in all samples. Although minor 
variations in protein levels could be seen between uninduced and induced 
conditions for some targets, these results could not be consistently 
reproduced. This suggests that although these cellular proteins may interact 
with RTA, they are not likely to be ubiquitin-mediated degradation targets of 
the RTA protein.  
 
As Western blotting could not detect reproducible differences in target 
protein levels, the ten targets were further analysed by immunofluorescence 
microscopy. Visualisation of individual cells allowed for observation of more 
subtle changes in subcellular localisation caused by RTA expression. iRTA 
cells were plated onto coverslips pre-treated with poly-L-lysine and either left 
uninduced or induced for 24 hours with doxycycline. Samples were fixed and 
permeabilised, before staining with both a FLAG specific antibody and one 
of the ten cellular target protein specific antibodies (figure 5.5). Six of the ten 
antibodies produced specific staining as shown in green, with RTA induction 
 
Figure 5.4 Western blot analysis of ten SILAC target protens. 
iRTA, iH145L and BCBL-1 TREx cells either left uninduced or induced for 24 hours 
with doxycycline. Cells were then harvested and lysed prior to Western blotting with 
the ten target specific antibodies, an RTA specific antibody and a GAPDH specific 
antibody to assess equal loading.  
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being visualised in red. Although the majority of the target proteins appeared 
unaffected by RTA expression, RBM14 displayed a change in localisation. 
Although predominantly nuclear in both conditions, induction of RTA 
appeared to alter the sub-nuclear localisation of RBM14, where RBM14 
appears to form nuclear aggregates, potentially in the nucleolus. 
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Figure 5.5 Immunofluorescence analysis of ten target proteins. 
iRTA cells were plated onto poly-L-lysine treated coverslips and half of the cells 
induced with doxycycline for 24 hours. Fixed samples were incubated with a FLAG 
monoclonal antibody (red) and one of the ten test antibodies (green) followed by 
staining with secondary Alexa Fluor
® 
antibodies. Heterochromatin was visualised 
using DAPI and images taken by confocal microscopy. Scale bars represent a 
width of 10 µm. 
- 154 - 
5.5 The SILAC identified target RBM14 demonstrates altered 
localisation upon RTA expression  
RBM14 (also known as coactivator activator; CoAA) is an hnRNP-like 
protein which has been shown to be overexpressed in numerous cancers 
(Sui et al., 2007). A transcriptional co-activation function of RBM14 was 
initially characterised by the potent activation of the TRBP coactivator 
(thyroid-hormone receptor-binding protein) (Iwasaki et al., 2001).  RBM14 
contains two RNA recognition motifs (RRMs) involved in mRNA splicing and 
a central YQ domain required for transcriptional activation (Perani et al., 
2005). The presence of these two domains also facilitates transcription 
coupled mRNA splicing, as demonstrated for the interaction with TRBP 
(Auboeuf et al., 2004). Following its initial description, RBM14 has also been 
shown to augment the activity of several other transcription factors, including 
SYT (synovial sarcoma translocation protein) (Perani et al., 2005) and PEA3 
(polyoma enhancer activator 3) group members (Verreman et al., 2011). 
Due to its role as a transcriptional co-activator, it was speculated that the 
RBM14 interaction with RTA could enhance transactivation of lytic 
promoters. From the ten original targets, RBM14 was therefore selected for 
further investigation. 
 
From initial immunofluorescence studies RBM14 appeared to aggregate in 
nuclear foci, perhaps the nucleolus, upon RTA expression (figure 5.5). To 
confirm this observation iRTA cells were seeded onto poly-L-lysine treated 
coverslips prior to induction of half of the cells with doxycycline for 24 hours. 
Cells were fixed and permeabilised prior to incubation with RBM14 and B23 
specific antibodies for one hour. Coverslips were stained with the 
appropriate secondary Alexa-Fluor
® 
antibodies and confocal microscopy was 
used to visualise the nucleolar marker, B23 (red) and RBM14 (green) 
(Figure 5.6a). As previously, RBM14 localisation was altered upon RTA 
expression, with B23 staining confirming movement into the nucleolar 
compartment. To determine if the equivalent localisation was seen in KSHV 
lytic cells, identical staining was repeated using the BCBL-1 TREx cell line. 
However, as shown in figure 5.6b, RBM14 was localised to the nucleolus in 
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both uninduced, latent cells and induced, lytic cells. Thus this pattern of 
altered localisation appears to be cell type specific. 
 
Figure 5.6 RBM14 co-localises with the nucleolar marker B23. 
(a) iRTA or (b) BCBL-1 TREx cells were seeded onto poly-L-lysine treated coverslips 
before induction of duplicate wells with doxycycline for 24 hours. Following fixation and 
permeabilisation, cells were incubated with B23 and RBM14 specific antibodies prior 
to staining with appropriate secondary antibodies. Nuclear heterochromatin was 
visualised using DAPI (blue), with RBM14 being shown in green and B23 in red. Scale 
bars represent a width of 10 µm.    
 
In addition to the role of RTA in transcriptional activation and proteasomal 
targeting, RTA is also required for KSHV genome replication. RTA binds to 
the ori-Lyt DNA sequence and recruits factors required for initiation of 
replication (Wang et al., 2006). During lytic replication RTA localises to viral 
replication centres which are active sites of DNA synthesis, containing the 
necessary enzymatic components. As RBM14 co-immunoprecipitated with 
RTA in lytically replicating BCBL-1 TREx cells, it was investigated if RBM14 
also co-localised to these replication centres. BCBL-1 TREx cells were 
seeded onto coverslips and induced with doxycycline for 16 hours. At 45 
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minutes prior to fixation cells were incubated with 5-ethynyl-2´-deoxyuridine 
(Edu) containing media, which incorporates into actively replicating DNA.  
Following fixation and permeabilisation, EdU was stained using the Click-iT® 
EdU Alexa Fluor® 647 Imaging Kit. RTA was visualised using a Myc specific 
antibody (red), in addition to endogenous RBM14 staining (green) (Figure 
5.7). The sub-nuclear replication centres (RC) were visualised by Edu 
staining (far-red) in cells undergoing lytic replication. As expected, RTA was 
shown to co-localise with these structures, however RBM14 was largely 
excluded from these areas of the nucleus. It is therefore unlikely that RBM14 
is involved in KSHV lytic DNA replication.  
 
 
Figure 5.7 RBM14 does not co-localise with KSHV replication centres.  
BCBL-1 TREx cells were seeded onto coverslips which were pre-treated with poly-
L-lysine. Lytic replication was induced for 16 hours using doxycycline and EdU 
containing media was added at 45 minutes prior to sample processing. EdU 
incorporation was stained using the Click-iT® EdU Alexa Fluor® 647 Imaging Kit 
(far-red). A Myc specific antibody was used to visualise RTA (red), with RBM14 
specific staining being shown in green. Hoechst 33342 was utilised as an overall 
DNA stain. Scale bars represent a width of 10 µm. 
 
5.6 RBM14 co-immunoprecipitates with RTA 
As expression of RTA led to a change in localisation of cellular RBM14, a 
functional relationship between these two proteins was investigated. To 
confirm the interaction between RTA and RBM14, an independent FLAG IP 
was therefore performed. iRTA cells were induced with doxycycline for 24 
hours while 293 FlpIn cells were left untreated prior to being harvested. Cells 
were lysed and input samples taken before being pre-cleared with 
unconjugated beads for 1 hour. The unbound fraction was then incubated 
with FLAG affinity agarose beads for an additional 2 hours before being 
washed with PBS. The input and precipitated proteins were analysed by 
SDS-PAGE followed by immunoblotting using FLAG-specific and RBM14-
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specific antibodies (Figure 5.8). Endogenous RBM14 can be seen in the two 
input samples and RTA-FLAG was detected in the iRTA cell line. In the 
iRTA IP sample, RTA-FLAG is highly enriched and low levels of endogenous 
RBM14 were detected. As RBM14 is not present in the 293 FLAG IP this 
confirms a weak interaction between RTA and RBM14, as predicted from 
the two SILAC data sets. 
 
 
Figure 5.8 RBM14 co-immunoprecipitates with RTA.  
293 FlpIn and induced iRTA cells were harvested and lysed prior to rotation with 
protein A beads for 1hour at 4°C. The pre-cleared lysates were then incubated with 
FLAG-affinity agarose for an additional 2 hours at 4°C. Beads were boiled in 
Laemmli buffer and precipitated proteins subject to Western blotting with FLAG and 
RBM14 specific antibodies.  
 
5.7 RBM14 overexpression reduces activation of the RTA 
responsive promoter vIL6 
 After verification of the RTA-RBM14 interaction, the next step was to 
determine if RBM14 enhanced RTA function. As RBM14 acts as a cellular 
transcriptional co-activator one logical purpose would be to enhance the 
transactivation function of RTA. To investigate this possibility an RBM14-
FLAG containing plasmid was obtained. To check expression from this 
plasmid, iRTA cells were either left untransfected or transfected with 
pRBM14-FLAG. Cells were harvested at 24 hours post-transfection and  
immunoblotting with a FLAG-specific antibody confirmed RBM14 
overexpression.  
 
Following verification of RBM14-FLAG expression, luciferase assays using 
the RTA responsive promoter, vIL6, were performed in the presence of 
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increasing amounts of RBM14. iRTA cells were co-transfected with the vIL6-
reporter construct and either 0, 0.2, 0.4 or 0.6µg pRBM14-FLAG with the 
total DNA maintained at constant levels using an empty vector. 
Transfections were performed in triplicate for both uninduced and induced 
conditions with RTA expression being induced with doxycycline for 24 hours.  
Cells were then washed and lysed in situ before transferral of lysates to a 
96-well plate. Relative light units were recorded and used to calculate an 
average fold change in promoter activity of induced over uninduced 
conditions (figure 5.9). The vIL6 promoter was activated fivefold upon 
induction of RTA, however RBM14 overexpression did not enhance this 
activation. Surprisingly, there was a slight but significant decrease in vIL6 
activation in the presence of pRBM14-FLAG, although this effect was not 
dose dependent. 
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Figure 5.9 RBM14 does not affect RTA-mediated activation of the vIL6 
promoter. 
(a) iRTA cells were either left untransfected or transfected with pRBM14-FLAG for 
24 hours prior to cell lysis. Samples were analysed by Western blotting with GAPDH 
and FLAG-specific antibodies. (b) iRTA cells were transfected with the vIL6 
luciferase construct and either 0, 0.2, 0.4 or 0.6µg of pRBM14-FLAG. All 
transfections were performed in triplicate for each condition and DNA kept at a 
constant level using empty vector as required. Cells were subject to passive lysis 
and luciferase activity measured using the Promega Luciferase Assay Reagent II 
and a FLUOstar Optima microplate reader. Readings were used to determine the 
fold change in promoter activity upon RTA expression and triplicate averages and 
standard deviations calculated. 
 
5.8 RBM14 overexpression does not affect viral reactivation 
Overexpression of RBM14 did not enhance RTA dependant activation of the 
vIL6 promoter. In fact, a slight reduction in transactivation was observed. 
However, several cellular factors, such as CEBPα and RBP-jκ, synergise 
with RTA to activate expression in a promoter specific manner. It is therefore 
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possible RBM14 could function co-operatively at alternative lytic gene 
promoters.  The effect of RBM14 overexpression upon overall RTA-
mediated reactivation was therefore assessed. For this investigation 
rKSHV.219 HEK 293T cells were utilised, which contain the latent KSHV 
genome with an RFP reporter gene under control of the PAN promoter. RTA 
expression in this cell line is sufficient to induce lytic reactivation as 
measured by the percentage of RFP expressing cells. rKSHV.219 HEK 
293T cells were transfected with either RBM14, RTA or RBM14 and RTA 
and left at 37°C for 30 hours. Cells were harvested and flow cytometry used 
to quantify the percentage of RFP expressing cells as a measure of 
reactivation. This was repeated a further two times and the average 
percentage of RFP expressing cells and corresponding standard deviations 
were calculated (figure 5.10). Upon transfection of RTA alone 4-5% of cells 
entered the lytic replication cycle however this was neither enhanced nor 
repressed upon overexpression of RBM14. Any effect of RBM14 
overexpression upon promoter activation was therefore insufficient to affect 
overall lytic reactivation.  
 
 
Figure 5.10 RBM14 overexpresion does not affect lytic reactivation. 
rKSHV.219 HEK 293T were left untransfected or transfected with either RBM14, 
RTA or RBM14 and RTA. At 30 hours post-transfection cells were harvested and 
subject to live cell FACS analysis. The average percentage of RFP expressing cells 
was determined for each condition and standard deviations calculated. 
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5.9 Discussion 
RTA has been demonstrated to interact with many cellular factors to aid 
transcriptional activation of lytic genes and for proteasomal degradation 
targeting. The aim of this chapter was to identify novel cellular RTA 
interaction partners using SILAC-based immunoprecipitation. Using an 
inducible RTA-FLAG cell line, detection of potential transcriptional co-
activators is straightforward, however to identify novel E3 ligase targets, their 
degradation must be prevented. The RTA
H145L 
ubiquitin ligase null mutant 
was therefore utilised to create an inducible RTA
H145L
-FLAG cell line. These 
two inducible cell lines and a control 293 FLAG cell line were grown in 
differentially isotope labelled DMEM. FLAG IPs were performed on equal 
numbers of cells for the three conditions before the samples were mixed 
and analysed by mass spectrometry. The resulting SILAC IP data provided 
approximately 300 protein ratios for each test condition compared with the 
293 FLAG control. Setting a significance threshold of 1.5 fold, iRTA and 
iH145L IPs identified 11 and 54 putative interaction partners, respectively. 
However all 11 RTA binders were found within the iH145L significant data 
set, most likely due to the increased stability of the H145L mutant. 
 
A complementary SILAC RTA IP was performed in parallel using the latently 
infected BCBL-1 TREx cell line (D.Hughes unpublished data). Comparison 
of this additional data set, with that from the iH145L cell line, identified 6 
common proteins, providing an independent validation of the experimental 
approach. From these two data sets, ten target proteins were selected for 
further validation. Choices were rationalised by relevant target function, 
highly significant fold enrichment or the detection of several complex 
components. These ten targets were initially screened by Western blotting 
and immunofluorescence, looking for changes in abundance or localisation 
upon RTA expression. From this initial examination the cellular RNA binding 
motif protein 14 (RBM14) appeared to demonstrate a change in localisation 
in the presence of RTA. RBM14 had been identified in both iH145L and 
TREx data sets with a 16.6- and 13.7- fold enrichment, respectively. Co-
localisation with B23 confirmed that the relocalisation of RBM14 was 
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consistent with movement into the nucleolus in the iRTA cell line. However 
immunofluorescence using the BCBL-1 TREx cell line demonstrated that 
RBM14 was nucleolar in both latent and lytic replication phases, indicative of 
cell type variations. Previous studies using transfected YFP-RBM14 have 
demonstrated a diffuse nuclear staining with accumulation within 
paraspeckles (Fox et al., 2002). Paraspeckles represent dynamic structures, 
containing proteins that can cycle to and from nucleoli. Furthermore, upon 
inhibition of transcription with Actinomycin D, RBM14 was shown to 
relocalise to perinucleolar cap structures. However, the function of these cap 
structures remains unclear. 
 
RBM14 has been demonstrated to activate numerous cellular transcription 
factors including TRBP (Iwasaki et al., 2001), SYT (Perani et al., 2005) and 
several PEA3 (Verreman et al., 2011) family members. As the RBM14 
interaction with RTA could plausibly enhance lytic promoter transactivation 
RBM14 was chosen for further investigation. The interaction between RTA 
and RBM14 was first independently verified by RTA-FLAG IP and 
immunoblotting with an antibody that detected endogenous RBM14.  
Following this verification, it was tested if RBM14 overexpression could 
enhance RTA dependant activation of the vIL6 reporter construct via its co-
activator function. Contrary to expectations, overexpression of RBM14 
appeared to have a slight but significant inhibitory effect upon RTA-mediated 
promoter activation. Although RBM14 has predominantly been characterised 
as a transcriptional co-activator, it has been shown to repress one cellular 
protein, Runx2 (Li et al., 2009). In this case RBM14 binds to Runx2 and 
inhibits its interaction with DNA. However such activity against RTA appears 
unlikely to be advantageous to KSHV reactivation. In addition the effect of 
RBM14 overexpression upon RTA-mediated KSHV reactivation was tested. 
However no effect was seen upon overall reactivation as evaluated by the 
PAN-RFP reporter element.  
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In summary SILAC RTA IPs detected numerous enriched proteins, several 
of which could be confirmed in an independent study. The cellular RBM14 
protein demonstrated a change in localisation upon RTA expression. 
Moreover, RBM14 overexpression could repress transactivation of an RTA 
responsive promoter. Further studies are thus required to elucidate the 
exact role of RBM14 in KSHV replication. 
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Final discussion and future perspectives 
 
The Herpesviridae represent a large family of dsDNA viruses encompassing 
numerous significant human pathogens.  A defining feature of these viruses 
is their ability to establish long-term latent infections. During latency only a 
small subset of viral genes are expressed, to promote genome maintenance 
and immune evasion. However, to sustain this persistent infection and for 
transmission to a new host, the virus must enter periodic rounds of lytic 
replication. This switch between lytic and latent replication is stringently 
controlled to maintain the balance between immune avoidance and viral 
transmission. The human gamma-2-herpesvirus KSHV, is the etiological 
agent of KS and establishes latent infection in host B-cells. B-cell maturation 
represents one cellular stimulus responsible for KSHV reactivation, which is 
physiologically relevant to viral transmission (Wilson et al., 2007). However, 
irrespective of the inducing stimuli, lytic replication is initiated by the 
expression of the KSHV replication and transcription activator protein, RTA. 
RTA binds to lytic gene promoters, either directly or in association with 
cellular transcription factors, to activate gene expression. Furthermore, RTA 
promotes reactivation via its function as an E3 ubiquitin ligase. Numerous 
cellular transcriptional repressor proteins have been shown to bind to viral 
gene promoters, dampening their expression. RTA-mediated ubiquitination 
of such repressor proteins, targets them for degradation by the proteasome, 
relieving associated repression. This activity is therefore essential to 
facilitate lytic replication in a repressive cellular environment.  
 
Experiments presented herein can be split into two major objectives. The 
first was to investigate the mechanism by which RTA recognises the 
proteins which it targets for proteasomal degradation. Specifically, to 
determine if RTA represents a class of E3 ligases termed SUMOylation 
targeted ubiquitin ligases (STUbLs). The second aim was to identify novel 
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points of interaction between RTA and the host cell using proteomic-based 
approaches.  
 
The ubiquitin ligase function of RTA was first characterised via its ability to 
downregulate cellular IRF7 in a proteasome-dependant manner (Yu et al., 
2005). This activity was attributed a Cys plus His-rich catalytic region within 
RTA, unlike any other identified E3 ligase domains. Since this initial report, 
the cellular proteins Hey1 (Gould et al., 2009) and K-RBP (Yang et al., 
2008) have been shown to be additional targets for RTA-mediated 
degradation. However, the mechanism by which RTA recognises these 
targets had not been investigated. STUbLs are a class of ubiquitin ligases 
which contain internal SUMO interaction motifs (SIMs), required for 
interaction with SUMOylated substrates. STUbLs therefore represent a point 
of cross-talk between two major post-translational modification pathways. 
Although only a small number of STUbL proteins have been identified, the 
HSV-1 ICP0 protein, which is also involved in lytic replication, has been 
shown to have STUbL-like properties (Boutell et al., 2011). In addition, as 
two of the RTA substrates IRF7 (Kubota et al., 2008) and K-bZIP (Izumiya et 
al., 2005) have been shown to be SUMOylated, it was hypothesised that 
RTA could also display STUbL functions. 
 
To determine if RTA could represent a STUbL, putative SIM domains were 
identified by bioinformatic analysis. Three of these putative domains were 
then subjected to site directed mutagenesis either singly or in combination. 
The SIM 1/3 and SIM 2/3 double mutants, attenuated RTA-dependent 
degradation of Hey1. Levels of Hey1 were increased by approximately 3-
fold, indicating a functional role for these domains. As SUMO2/3 can often 
form chains upon target substrates, SIM domains are likely to function co-
operatively, each binding to individual moieties of a poly-SUMO chain. 
Furthermore, viral reactivation was dramatically reduced with these 
mutations compared with wild type RTA. This was demonstrated by 
assessing levels of the late protein gB and RTA-mediated activation of the 
PAN promoter in the HEK 293T rKSHV.219 cell line. Levels of reactivation 
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by these mutants were similar to those seen with the ubiquitin ligase null 
mutant, RTA
H145L
, which has a mutation in the catalytic Cys plus His-rich 
region of RTA. The E3 ligase function of RTA is therefore critical for lytic 
replication.  
 
These preliminary results suggest that RTA functions as a STUbL. However, 
for RTA to represent a true STUbL, the proteins which it targets for 
degradation must be SUMO modified. Both IRF7 (Kubota et al., 2008) and 
K-bZIP (Izumiya et al., 2005) have previously been shown to be 
SUMOylated, however, this had not been investigated for Hey1. 
Immunoprecipitation of SUMO2 modified proteins from HeLa cells 
highlighted the presence of a SUMO2 modified Hey1 species. This was 
confirmed by in vitro SUMOylation assays, where Hey1 was a substrate for 
conjugation of poly-SUMO2 chains. It would be interesting to further 
investigate the cellular role of Hey1 SUMOylation. One common function of 
transcription factor SUMOylation is the recruitment of downstream effectors 
of repression (Garcia-Dominguez and Reyes, 2009). Hey1 is a notch 
inducible protein belonging to a family of basic helix-loop-helix (bHLH) 
transcriptional repressor proteins (Fischer and Gessler, 2007). Hey proteins 
have been shown to recruit corepressors such as histone deacetylases 
(HDACs), nuclear receptor corepressor (NCoR), and mSin3A (Iso et al., 
2001). It can therefore be speculated that Hey1 SUMOylation could play a 
role in the formation of repressive complexes on target promoters, such as 
the RTA promoter itself. An additional noteworthy point of investigation 
would be the role of the KSHV protein K-bZIP.  K-bZIP is another IE gene 
product, which functions antagonistically to RTA  (Izumiya et al., 2003). As 
K-bZIP was recently shown to have intrinsic E3 SUMO ligase activity, this 
could be interesting point of crosstalk whereby K-bZIP marks substrates for 
RTA-mediated degradation (Chang et al., 2010) 
 
To determine if Hey1 SUMOylation is required for RTA-mediated 
degradation, a method to prevent Hey1 SUMO modification was 
investigated. A consensus SUMO acceptor sequence, with the sequence 
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ΨKxE (in which Ψ is an aliphatic branched amino acid and x is any amino 
acid), has previously been characterised from known SUMOylated proteins 
(Xu et al., 2008). Two putative acceptor sites were found within the Hey1 
peptide sequence and subjected to site-directed mutagenesis. However, 
substitution of key lysine residues did not prevent Hey1 SUMOylation, 
indicating the presence of alternative acceptor sites. SUMOylation at non-
consensus sites has been shown for many proteins such as PCNA, which is 
both ubiquitinated and SUMOylated at lysine K164 in a mutually exclusive 
manner (Papouli et al., 2005). There are a high number of lysine residues 
within Hey1, although it was beyond the scope of this project to perform 
mutational analysis on all of them.   
 
An alternative approach to preventing Hey1 SUMOylation was to knockdown 
global SUMO2 levels using siRNA. However, the presence of SUMO2 
siRNA did not affect degradation of Hey1. This was likely due to the fact that 
only incomplete knockdown of SUMO2 could be achieved and thus a 
SUMOylated pool of Hey1 was still present. Moreover SUMO2 and SUMO3 
are highly redundant, sharing 97% sequence homology. Thus even in the 
event of complete SUMO2 knockdown, polySUMO3 chains could potentially 
be conjugated to Hey1. As the E2 SUMO conjugating enzyme Ubc9 is 
involved in conjugation of all forms of SUMO, knockdown of this enzyme 
would avoid this issue of redundancy. However cells stably expressing an 
shUbc9 construct were found to be non-viable. Therefore the best way to 
prevent Hey1 SUMOylation would be to return to the original strategy, 
precisely mapping acceptor lysines using progressive Hey1 deletions or 
mass spectrometry analysis.   
 
The findings discussed thus far support the hypothesis that RTA functions 
as a STUbL. For this to be the case, the SIM mutant phenotype should also 
be specific to RTA E3 ligase function. In reporter assays using the RTA-
responsive vIL6 promoter, SIM mutations greatly reduced promoter activity. 
This could indicate that ablation of SIM domains has a detrimental, but non-
specific, effect upon RTA functions. Nonetheless, there are several potential 
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explanations for this, such as the presence of unknown repressors binding 
to the vIL6 promoter. To investigate this possibility, reporter assays could be 
performed with wild type RTA in the presence of a proteasome inhibitor, 
such as MG132. If such repressors were present, inhibition of the 
proteasome could also abrogate promoter activation. Furthermore, SIM-
SUMO interactions have been shown to mediate many functions unrelated 
to degradation. Mutation of RTA SIMs could therefore prevent binding to 
general transcription factors. In either instance, SIM mutants should retain 
the capacity to bind directly to RTA response elements. Chromatin 
immunoprecipitation was therefore performed using the vIL6 promoter, to 
determine if SIM mutants retained their DNA binding capacity. However, due 
to low levels of immunoprecipitated DNA, results from this assay were 
inconclusive.  Future work should therefore focus on repeating this, or a 
similar assay, such as EMSAs.  
 
During the writing of this discussion a study by Izumiya et. al has 
demonstrated STUbL-like activity of RTA (Izumiya et al., 2013). Here, RTA 
was demonstrated to bind and degrade SUMO, which could be significantly 
impaired upon mutation of two key SIM domains. These SIMs were 
identified between 270-320aa, as opposed to the domains characterised in 
chapter 3 between 90-200aa. In addition, mutation of the k-bZIP SUMO 
acceptor site demonstrated preferential targeting of SUMO modified 
substrates for RTA-mediated degradation. Similar to results in chapter 3, the 
SIM mutations used in this study severely reduced the transactivation of 
RTA responsive promoters. Moreover, these mutants greatly decreased the 
reactivation capabilities of RTA, as measured by lytic gene expression and 
viral copy number. However, this investigation did not assess the question 
as to whether SIM mutants retain their DNA binding capacity.  
 
In summary, results presented in chapter 3 are consistent with RTA 
functioning as a STUbL, containing functional SIM domains to target 
SUMOylated substrates such as Hey1. However, to draw a definitive 
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conclusion further investigation is required to determine why SIM mutation 
reduces the transactivation function of RTA.   
 
SILAC-based quantitative proteomics represents an unbiased strategy to 
determine how a test condition affects the distribution of cellular proteins. 
This high throughput global analysis utilises mass spectrometry to identify 
and quantify thousands of proteins from a single sample. To investigate 
changes in the cellular proteome in response to RTA expression, an 
inducible RTA cell line was generated. The RTA protein produced from this 
expression system was functionally active, being able to activate 
transcription from an RTA responsive promoter. Moreover, 
immunofluorescence detected expression of RTA at significant levels in 
virtually every cell of an induced population. SILAC-based quantitative 
proteomics was therefore performed for uninduced vs. induced iRTA cells 
and cytoplasmic and nuclear fraction samples analysed by the Dundee cell 
proteomics service. Mass spectrometry generated quantitative data for 
approximately 2000 proteins from each of the nuclear and cytoplasmic 
fractions. Of these proteins around 600 demonstrated a change in 
abundance equal to, or greater than 2-fold, upon RTA expression. A large 
proportion of these 600 proteins were found to be involved in RNA 
processing, DNA repair, DNA replication and the cell cycle. The expression 
of RTA itself was also confirmed, being enriched 80-fold over the uninduced 
control.  
 
The cellular protein, ARID3B, was found to increase in nuclear abundance 
by over 7-fold upon RTA expression and was thus chosen as an initial 
validation target. ARIB3B transcript levels were found to be moderately 
increased upon induction of RTA expression in 293 cells or lytic replication 
of BCBL1 TREx cells. This preliminary observation thus supported the 
notion of a link between RTA expression and ARID3B levels. ARID3B 
belongs to the AT-rich interactive domain-containing family of proteins, of 
which there are 15 members encoded by the human genome (Wilsker et al., 
2005). These 15 family members are grouped into seven sub-families based 
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upon sequence homology.  ARID proteins are diverse in function, with roles 
in gene expression, development and cell cycle regulation and can bind 
DNA in a specific or non-specific manner. However, very little is known 
about ARID3B-specific functions. Interestingly, ARID1A, ARID1B and ARID2 
were also enriched within the nuclear fraction between two and three fold. 
These proteins, which are the only members of subfamilies 1 and 2, are 
conditional subunits of the SWI/SNF chromatin remodelling complex (Wang 
et al., 2004b; Yan et al., 2005). This up-regulation could thus be related to 
the known interaction between RTA and the SWI/SNF subunit, Brg1 (Gwack 
et al., 2003a). 
 
Following preliminary experiments, the subcellular localisation of ARID3B 
was investigated by immunofluorescence in the BCBL-1 TREx cell line. 
During latency, ARID3B demonstrated a diffuse nuclear localisation; 
however, upon lytic reactivation ARID3B and RTA became enriched within 
sub-nuclear domains. These globular structures were reminiscent of viral 
replication centres, which are sites of viral genome synthesis. Edu assays 
strengthened this hypothesis, confirming co-localisation of ARID3B and RTA 
with areas of active DNA synthesis. This co-localisation also indicated a 
potential role for ARID3B in KSHV lytic replication. RTA and K-bZIP are viral 
origin binding proteins essential to the formation of a replication initiation 
complex upon the ori-Lyt. RTA binds directly to an RRE within the ori-Lyt 
core region and also associates with the six core viral replication proteins 
(Wang et al., 2004c; Wang et al., 2006).  A study by Wang et al. highlights 
the role for host factors in ori-Lyt dependent DNA replication (Wang et al., 
2008). Several cellular replication, repair, and recombination factors, were 
found to be associated with the ori-Lyt and viral replication compartments. 
Recruitment of cellular factors is therefore necessary for KSHV replication. 
Subsequently, inhibition of the cellular ori-Lyt binding protein, topoisomerase 
II, was shown to reduce virion production with minimal effect upon host cell 
function (Gonzalez-Molleda et al., 2012). These findings highlight the 
potential therapeutic implications of identifying cellular factors required for 
lytic DNA replication. Interestingly, one of the proteins identified in this study, 
Msh2, was upregulated 3-fold in the iRTA SILAC nuclear fraction. Msh2 is a 
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DNA repair protein specifically involved in mismatch repair. Many viruses 
have been demonstrated to manipulate host cell repair enzymes for viral 
replication. For example, in HCMV infected cells nucleotide excision repair is 
directed almost exclusively at the viral genome to the detriment of the 
cellular genome (O'Dowd et al., 2012). Several DNA repair pathways, 
including mismatch repair, nucleotide excision repair and base excision 
repair, were over-represented within the SILAC data. The contribution of 
host DNA repair factors to KSHV lytic replication could therefore provide an 
interesting avenue for further study.  
 
To establish whether ARID3B could bind to the KSHV ori-Lyt, chromatin 
immunoprecipitation was performed in BCBL-1 TREx cell lines. Although 
RTA was found to bind to this region, ori-Lyt DNA was not enriched upon 
ARID3B immunoprecipitation. However, it may be that the ARID3B antibody 
used herein is not appropriate for use in ChIP assays, therefore, despite this 
result, ARID3B could still play a functional role in KSHV lytic replication. To 
further investigate this point, KSHV replication assays could be performed 
upon ARID3B knockdown or overexpression. In such assays, levels of the 
KSHV genome are normalised to cellular DNA and the fold increase 
calculated over an induction time-course. If ARID3B is required for lytic 
replication, alteration in cellular levels would be expected to affect replication 
efficiency. As little is known about ARID3B, it would also be informative to 
further characterise its cellular function. Since ARID3B belongs to a family of 
DNA-binding proteins, techniques such as ChIP-sequencing could be 
performed in uninfected or lytically infected BCBL-1 TREx. Furthermore, 
ARID3B interacting proteins could be investigated using techniques such as 
SILAC immunoprecipitation or yeast two hybrid screening. Identification of 
novel target promoters and binding partners from such analyses could 
provide valuable insight into ARID3B regulated processes.  
 
In this chapter, one protein target was selected for validation based upon its 
considerable nuclear increase in the presence of RTA. However, a wealth of 
proteomic data remains to be explored and the investigation of enriched 
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functional networks and pathways represents a broader validation strategy. 
As described in figure 4.8, pathway analysis identified both predicted and 
unexpected over-represented functions. Surprisingly, many proteins involved 
in RNA processing were found to be upregulated, with the spliceosome 
being the most significantly enriched pathway from the KEGG database. As 
RTA has no characterised roles in RNA processing, it would be interesting to 
investigate the validity of this finding further. Numerous cellular factors 
involved in DNA replication and the cell cycle were also significantly 
increased in nuclear abundance. As RTA is vital to KSHV lytic replication, it 
seems reasonable that RTA would manipulate host replication machinery to 
aid this process. KSHV encodes several proteins which influence the cell 
cycle and also contribute to tumourigenesis, such as the latent gene 
products LANA and v-cyclin (Moore, 2007). Although manipulation of cell 
cycle checkpoint proteins by lytic gene products is unlikely to participate in 
transformation, it would be advantageous for reactivation where large 
amounts of viral DNA must be synthesised. Several structural and regulatory 
components of the DNA replication machinery were found to be increased 
over 5-fold in the nuclear compartment. For instance, abundance of subunit 
3 of the condensin complex was found to be increased over 20-fold. 
Intriguingly, condensin subunit 2 was also one of a handful of proteins to be 
significantly increased in the original baculovirus SILAC data. Thus, 
investigation of a link between RTA expression and host DNA replication 
could be the subject of future work. 
 
SILAC based proteomics can also be coupled with immunoprecipitation to 
provide a highly sensitive method for detection of novel binding partners. 
RTA interacts with numerous cellular proteins in its role as a transcriptional 
activator and E3 ubiquitin ligase. In addition to the iRTA-FLAG cell line, an 
inducible RTA
H145L
-FLAG cell line was created to perform SILAC FLAG 
immunoprecipitations. As the RTA
H145L
 mutant lacks E3 ubiquitin ligase 
activity, this presents a method for identifying putative targets of RTA-
mediated degradation. Any proteins which are enriched in the iH145L 
condition but not with iRTA, would represent putative RTA E3 ligase 
substrates. In parallel to this investigation, SILAC RTA immunoprecipitations 
- 174 - 
were also carried out in the BCBL-1 TREx cell line. This provided 
complementary information in the context of viral infection and allowed for 
detection of RTA complexes involving additional KSHV-encoded factors.   
 
Mass spectrometry analysis of these two experiments identified hundreds of 
enriched proteins and a 1.5-fold significance threshold was therefore 
imposed. Results from iRTA and iH145L cell lines identified 11 and 54 
significantly enriched proteins, respectively. All 11 enriched proteins from the 
iRTA cell line were identified within the 54 iH145L hits. In fact, the interaction 
profile for iH145L was extremely similar to iRTA but the abundance of 
interacting proteins was roughly doubled. This could reflect increased 
stability of RTA
H145L
, as this mutation also prevents RTA auto-ubiquitination 
and proteasomal degradation.  These results made it more difficult to 
identify E3 ligase targets through comparison of iRTA and iH145L conditions 
and thus analysis was focused solely upon the iH145L data set. 
Immunoprecipitation from the BCBL-1 TREx cell line identified 42 
significantly enriched proteins, six of which were also common to the iH145L 
significant data set. Within these 42 proteins were several known RTA 
interaction partners including k-bZIP (Izumiya et al., 2003) and ORF59 
(Rossetto et al., 2011), providing validation of this approach. Known binding 
partners of RTA, such as Brg1 (Gwack et al., 2003a) and PARP-1 (Gwack et 
al., 2003b), were also enriched in the iH145L data set. However, these 
proteins were found to be below the 1.5 fold significance threshold, 
indicating the cut-off stringency could be lowered further.  
 
From these SILAC data sets, ten putative interaction partners were chosen 
for validation. Initial studies demonstrated that endogenous levels of these 
proteins were not significantly altered upon RTA expression. Thus none of 
these proteins were likely to represent E3 ubiquitin ligase targets of RTA. 
Following this observation, immunofluorescence was performed in the iRTA 
cell line, to assess subcellular localisation of the selected proteins. SIx of the 
ten endogenous proteins could be successfully visualised, five of which 
could be seen within the nuclear compartment. As RTA is almost exclusively 
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nuclear, these proteins (hnRNPUL1, AUF1, HP1γ, hnRNPAB and RBM14) 
are more likely to represent valid RTA binding proteins. One such protein, 
RBM14, demonstrated a modest change in subcellular localisation upon 
RTA expression. This change in localisation appeared to correlate with a 
movement into the nucleolus upon RTA expression, which was confirmed by 
use of the nucleolar marker, B23. RBM14 has previously been identified as 
a paraspeckle component, which represents the most recently identified 
sub-nuclear structure (Fox et al., 2002; Fox and Lamond, 2010). 
Paraspeckles are composed of numerous protein and RNA species and 
have been implicated in the regulation of gene expression (Prasanth et al., 
2005). However, upon inhibition of polymerase II transcription, paraspeckle 
proteins, including RBM14, relocalise to nucleolar cap structures (Fox et al., 
2002).  The dissolution of paraspeckles is likely due to reduction in levels of 
the nucleating RNA, NEAT1 (Clemson et al., 2009). However, the 
physiological relevance of these caps is unknown, making it is difficult to 
speculate upon a function of this RTA- induced change in localisation. 
 
As RBM14 localisation was altered upon induction of RTA, this protein was 
selected for further study. The RTA-RBM14 interaction was independently 
confirmed, supporting the original SILAC data. The next step was therefore 
to identify a functional role for this interaction. The best characterised 
cellular role of RBM14 is as a transcriptional co-activator. RBM14 has been 
demonstrated to enhance transcription of several co-activators such as 
TRBP (thyroid-hormone receptor-binding protein), in addition to promoting 
transcription coupled mRNA splicing (Iwasaki et al., 2001). Given this fact, it 
seems reasonable that RBM14 could be enhancing the transcriptional 
activation capacity of RTA. However, over-expression of RBM14 had a slight 
but significant repressive effect upon RTA transactivation of the vIL6 
promoter. Although RBM14 has principally been considered as a 
transcriptional co-activator, one study has demonstrated a repressive role of 
RBM14 against the Runx2 protein (Li et al., 2009). Although an inhibitory 
interaction with RTA would not be advantageous for lytic reactivation.  
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Finally, the effect of RBM14 overexpresssion upon viral reactivation was 
assessed. RBM14 overexpression did not appear to have any effect upon 
lytic replication as measured by PAN promoter activity. The repressive effect 
of RBM14 upon the vIL6 promoter was therefore insufficient to impact upon 
the reactivation function of RTA. Overall, from the results presented in 
chapter 5, no functional role can yet be attributed to the RBM14-RTA 
interaction. To investigate this point further the effect of RBM14 knockdown 
upon viral reactivation and promoter activation could be investigated. 
Moreover, in this study only the vIL6 RTA responsive promoter was utilised, 
which could be expanded to other lytic genes to look for promoter specific 
effects.  In addition, future work could return to the remaining original 
validation targets. As hnRNPUL1, AUF1, HP1γ, hnRNPAB were all found 
within the nuclear compartment, independent immunoprecipitations could be 
optimised to confirm RTA binding prior to in depth investigation. The best 
characterised roles of hnRNPAB (Lau et al., 1997) and AUF1 (White et al., 
2013) are in RNA processing whilst hnRNPUL1 (Kzhyshkowska et al., 2003) 
and HP1γ (Vakoc et al., 2005) function as transcriptional regulators. 
Considering the main function of RTA is transcriptional activation and as 
RNA processing was highly enriched in the SILAC data sets,  these proteins 
represent appropriate validation targets.  
 
In summary, results presented herein expand our current understanding of 
the KSHV latent-lytic switch. The cellular protein ARID3B was demonstrated 
to co-localise with viral replication centres, while RBM14 was identified as a 
novel RTA-interacting protein. The implications of these findings are likely to 
be the subject of further study. Furthermore, a wealth of proteomic data has 
been generated for future investigations, in the hope of developing 
therapeutics for the treatment of KS-associated malignancies.  
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